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Abstract 
 
South Asians residing in the UK are known to be significantly different in terms of 
socio-economic and cultural influences from the UK population in general. They 
are at substantially higher risk of developing oral cancer (OSCC) and the 
potentially malignant disorder (PMD) oral submucous fibrosis (OSF). To overcome 
barriers to conventional health service use, a mobile dental unit was the base for 
screening within the South Asian community. Bilingual advocates ensured cultural 
acceptability and actively recruited high-risk individuals for screening as well as 
being involved at the secondary referral centre to facilitate attendance for definitive 
diagnosis of positive screened individuals.  
 
In total 1596 high-risk individuals were screened and 5.4% referred with 
suspicious lesions. No OSCC was detected in any positive screened individuals 
but PMDs were confirmed in 29%, with dysplasia (15%) and OSF (9%) the 
commonest lesions referred. Due to the complex presentation of OSCC the most 
appropriate gold standard screening outcome is the detection of individuals who 
cannot be discharged from long-term follow-up at the secondary referral centre. 
On this basis screening specificity was 99% and Positive Predictive Value (PPV) 
79%. The low PPV was attributed to the high prevalence of complex oral mucosal 
lesions (46%) that cannot be definitively diagnosed as benign by visual 
examination alone, which indicates diagnostic aids are required for screening this 
high-risk population. 
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Compliance with referral for positive screened individuals was only 76% and 
immediate incisional biopsy of positive screened individuals would be needed to 
improve this. In addition to histological detection of dysplasia, molecular markers 
of disease could readily be investigated by immunohistochemistry and the 
expression of keratins are ideal candidates due to their responsiveness to 
pathological signalling and abnormal expression in oral (pre)cancer. Analysis of 28 
fresh frozen OSF samples and 6 site-matched controls, using a panel of 22 
monoclonal antibodies, revealed changes in keratin 17 expression which 
correlated with disease severity. 
 
A mobile dental unit staffed by suitably experienced dentists and cultural 
advocates and equipped for immediate histological diagnosis of positive screened 
individuals is required in order to undertake effective and ethical oral cancer 
screening in high-risk UK based South Asian populations.   
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Chapter 1 
 
 
Screening for Oral Cancer in South Asian Populations 
 
 
 
Oral cancer should be an ideal target for a screening because unlike the majority 
of other cancers, almost all oral cancers develop as visible lesions. Therefore, oral 
cancers should easily be detected early when treatment is simple, particularly 
because dentists are experts in detecting abnormalities of the oral cavity. Yet in 
2012, oral cancer still presents a significant burden on the healthcare system and 
individuals still suffer immense morbidity from radical treatment and mortality rates 
still aren’t improving because the majority of oral cancers are detected at a late 
stage. 
 
1-1.01  What is Cancer? 
Cancers or malignant neoplasms are a group of diseases characterised by 
unregulated cell growth. Cancer cells replicate and grow uncontrollably allowing 
them to invade adjacent tissues and spread to distant sites. The causes of cancer 
are multifactorial but usually result in damage to genes or actions in combination 
with existing genetic faults within cells. There are over 200 different cancers that 
affect humans, each with their own specific clinical, aetiological and pathological 
features 26. Cancer is usually treated by destroying the malignant cells with 
cytotoxic drugs or radiation or removing them by surgical means. The chances of 
survival vary greatly by the type and location of the cancer and the extent of 
disease at the start of treatment. In 2007, cancer caused approximately 13% of all 
human deaths worldwide (7.9 million people) 27. 
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1-1.02  Definitions of Oral Cancer 
There is no standard definition of ‘oral cancer’ in the literature. The broadest 
descriptions include any cancerous tissue located in the oral cavity which may 
arise as a primary lesion originating in any of the oral tissues or by metastasis 
from a distant site or by extension from neighbouring anatomic structures. Oral 
cancer as a sub-group of head and neck cancer is also often used synonymously 
with mouth cancer in the literature. Further confusion arises from the salivary 
gland neoplasms that maybe included in some definitions whilst others relate only 
to oral squamous cell carcinomas (OSCC), originating in the squamous epithelium 
that lines the mouth and lips.  The definition used by organisations such as Cancer 
Research UK is “cancers of the lip, tongue, oral cavity, oropharynx, hypopharynx 
and piriform sinus” (www.cancerresearchuk.org). This definition has the advantage 
of directly relating to the World Health Organisation International Statistical 
Classification of Diseases and Related Health Problems (ICD) 28 codes ICD-10 
C00 (lip), C01 (base of tongue), C02 (other and unspecified parts of the tongue), 
C03 (gum), C04 (floor of mouth), C05 (palate), C06 (other and unspecified parts of 
the mouth), C09 (tonsil) and C10 (oropharynx). These sites are also those that 
would be most accessible to direct visualisation on examination of the oral cavity 
and therefore most applicable to a screening programme. 
 
1-1.03  The Clinical Presentation of Oral Cancer 
In textbooks the lower lip is often cited as the most frequent site for OSCC around 
the oral cavity, due to direct actinic damage 8. In the oral cavity the single most 
common site for lesions is the ventrolateral tongue and 70% of OSCCs develop in 
the ‘gutter area’ (Figure 1-01) formed by the ventrolateral border of the tongue, the 
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floor of mouth and the lingual mucosa, extending posteriorly towards the 
oropharynx. This is despite the ‘gutter area’ accounting for just 20% of the total 
mucosal surface area of the oral cavity and is likely to be due to carcinogens 
pooling and becoming concentrated in this area before being swallowed. For the 
same reason the dorsum of the tongue and hard palate are very rare sites for 
OSCC 8. 
 
Figure 1-01: Conventionally the areas at highest risk of developing OSCC in the oral cavity are the 
ventral tongue, floor of mouth and lingual mucosa making up the ‘gutter area’. 
 
 
A radically different pattern of OSCC development is seen in lesions where 
carcinogens are habitually placed against the mucosa. This is typical of areca nut 
extract usage where lesions appear at the site of placement of the areca nut 
compound and therefore most commonly occur on the buccal mucosa and in the 
lower buccal sulcus. This pattern of OSCC is particularly relevant to South Asian 
populations because of their inclination to areca nut extract usage. 
 
Early OSCC lesions usually appear as painless red, speckled or white patches 
(Figure 1-02) with only a minority being ulcerated.  
 30 
 
 
Figure 1-02: Early OSCC presenting as a mucosal white patch (Left - from 
www.oralhealthnet.co.uk) and speckled patch (Right – from https://healthinessbox.wordpress.com) 
 
As the OSCC enlarges it may develop into a raised nodule or become ulcerated 
(Figure 1-03). The classical presentation of an indurated ulcer with rolled border 
indicates an advanced lesion. Pain is not a typical symptom used in the diagnosis 
of OSCC but ulceration can be associated with soreness or stinging when eating8. 
 
  
Figure 1-03: Advanced OSCC presenting as a raised nodular lesion (Left – from http://cancer-
caregiver-treatment.com/Oral_Cancer.html) and an ulcerated lesion (Right – from 
http://www.deardoctor.com/articles/oral-cancer/page2.php).  
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1-1.04  Risk Factors for Oral Cancer 
It has not been possible to prove conclusively a causative association between 
specific aetiological factors and OSCC, suggesting that the causes are 
multifactorial. Causative factors operate over a long period and malignant change 
must occur so slowly that there is a substantial lag period before it is clinically 
evident. The suggested risk factors for OSCC are: 8 
 Carcinogens – tobacco, alcohol, areca nut. 
 Sunlight (lip lesions only). 
 Infections – syphilis, candida, viruses (e.g. HPV 16). 
 Mucosal disease – epithelial dysplasia, LP, OSF 
 Genetic disorders – dyskeratosis congenita, Fanconi’s anaemia. 
 
The effects of tobacco on the oral mucosa depend on the way it is consumed. In 
the UK cigarette smoking predominates and is believed to be the major 
aetiological factor for OSCC in synergistic combination with alcohol. Whereas, in 
South Asian countries tobacco chewing as well as smoking is a common habit and 
is frequently also associated with areca nut extract usage. Combinations of a quid 
of areca nut, lime, tobacco and spices wrapped in betel leaf as ‘paan’ (Figure 1-
04) are held in the sulcus and this site is often where OSCC develops in these 
individuals. Areca nut releases the potent carcinogen arecolin which acts in 
addition to the multitude of carcinogens in tobacco. Areca nut extract usage is also 
the prime aetiological factor in the development of the potentially malignant 
disorder Oral Submucous Fibrosis (OSF). 
 32 
 
Figure 1-04:  ‘Paan’ comprising areca nut quid, lime, tobacco and spices wrapped in betel leaf. 
(From: Avon (2004) 7) 
 
 
1-1.05  Potentially Malignant Disorders of the Oral Cavity 
Potentially malignant disorders (PMDs) are defined as “all clinical presentations 
that carry a risk of cancer” 15. They are also variously referred to as precancer or 
premalignancy in the literature but the term PMD is preferred as it conveys that not 
all transform into cancer. The proportion of PMDs that change into oral cancer 
varies greatly, based on the characteristics of the disorder and its site in the oral 
cavity, the patient’s age and gender 29, and the patient’s behaviours 15.  
 
Much of the literature on PMDs focuses on leukoplakia which is defined as “white 
plaques of questionable risk having excluded (other) known diseases or disorders 
that carry no increased risk for cancer” 15. Leukoplakia is a clinical term with no 
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specific histological presentation and can present with or without the histological 
finding of epithelial dysplasia. Overall malignant transformation rate for leukoplakia 
is estimated at around 1% per year 30 or between 6.2 and 29.1 OSCCs per 
100,000 population 31. Some forms of non-homogenous leukoplakia are known to 
have a higher rate of transformation than clinically homogenous leukoplakia and 
these mixed white and red plaque like lesions are termed erythroleukoplakia.  
Erythroplakia is considered the PMD with greatest potential for malignant change 
and is defined as “a fiery red patch that cannot be characterized clinically 
or pathologically as any other definable disease.” 15 It is reported that between 75 
and 90% of erythroplakia will undergo malignant transformation 32. 
 
Dysplastic change is believed to be the best predictor of future malignancy in 
PMDs and the more severe the dysplasia the greater the likelihood of malignant 
transformation 33. Barnes (2001) 34 suggests that the risk of developing OSCC in 
white patches with mild, moderate, and severe dysplasia is approximately 6%, 
23%, and 28% respectively. Other estimates suggest that around 50% of all 
patients with dysplasia may go on to develop oral cancer 29. Clinically leukoplakia 
and erythroplakia appear very similar to early OSCC (Figure 1-02) because of the 
fundamental underlying processes of epithelial keratinisation and dysplasia 8. The 
natural history of OSCC is only partly understood but it is evident that OSCC is 
preceded by changes in the oral mucosa although the nature of these changes is 
still unclear. Nevertheless, it is believed that the majority of OSCCs are preceded 
by a detectable preclinical phase presenting as a PMD 29. Management of these 
PMDs conventionally involves monitoring if not dysplastic or only mildly atypical. 
Dysplastic lesions are usually removed surgically or laser ablated although the 
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effect of this on risk of malignant change is not clear 35. The suggestion is that a 
dysplastic lesion is merely a discrete manifestation of the fundamentally damaged 
mucosa affected by field change 36.  
 
1-1.06  Oral Epithelial Dysplasia 
Epithelial dysplasia is a disorder of differentiation of epithelial cells that may 
regress, remain stable or progress to carcinoma. The histomorphological changes 
indicative of keratinocyte maturation disturbances that are diagnostic findings in 
dysplasia, according to the World Health Organisation, are shown in Table 1-01: 
 
Table 1-01: World Health Organisation histomorphological criteria for grading epithelial dysplasia. 
(From: Barnes et. al. (2006) 21)  
 
Architecture criteria Cytology criteria 
1. Irregular epithelial stratification 1. Abnormal variation in nuclear size 
2. Loss of polarity of basal cells 2. Abnormal variation in nuclear shape 
3. Drop-shaped rete ridges 3. Abnormal variation in cell size 
4. Increased number of mitotic figures 4. Abnormal variation in cell shape 
5. Abnormally superficial mitoses 5. Increased nuclear–cytoplasmic ratio 
6. Premature keratinisation in single cells 6. Increased nuclear size 
7. Keratin pearls within rete ridges 7. Atypical mitotic figures 
  8. Increased number and size of nucleoli 
  9. Hyperchromatism 
 
 
Dysplastic lesions are conventionally graded as ‘mild’, ‘moderate’ or ‘severe’ 
according to the extent of aggregate histomorphological abnormalities noted in 
tissue sections (Figure 1-05). However, the realisation that no truly reproducible 
criteria exist to precisely divide the spectrum of changes has resulted in proposed 
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simpler binary ‘low’ and ‘high’ risk classifications 37. A diagnosis of carcinoma-in-
situ is made when dysplastic features involve all surface epithelial strata (i.e. “top-
to-bottom”). A diagnosis of SCC is made when there is evidence that nests of 
epithelial cells have invaded the underlying lamina propria and deeper 
submucosa. 
 
Figure 1-05: Histomorphological atypia in mild (left), moderate (centre) and severe (right) oral 
epithelial dysplasia.(From: Cawson and Odell (2002) 8)  
 
1-1.07  Oral Submucous Fibrosis 
Apart from dysplasia the transformation rate of other PMDs is harder to quantify, 
ranging from 0.13% to 2.2% for all PMDs combined 29. Of specific relevance to 
South Asian populations, where areca nut extract usage is prevalent, is Oral 
Submucous Fibrosis (OSF). OSF was first described in the 1950’s as a chronic 
debilitating premalignant condition which affects millions of individuals worldwide 
38
. Incidence varies between countries but it is most commonly seen on the Asian 
subcontinent and amongst migrants from these regions 9. OSF studies frequently 
originate from countries such as India, Sri Lanka, Taiwan and China. Malignancy 
develops in 7-26% of OSF lesions 39 and these contribute to oral cancer being the 
6th most common cancer worldwide 40. 
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1-1.08  OSF Aetiology 
There is a direct relationship between the use of areca nut extract and 
development of OSCC in OSF, prompting the World Health Organisation to 
classify areca nut as a group I carcinogen 41. Areca is a natural substance chewed 
for its psychostimulating effects. The nut of the areca palm (Areca catechu) is 
often combined with the leaf of the betel piper (Piper betle) and lime (calcium 
hydroxide). Additionally, tobacco products maybe added as well as other spices 
based on regional variations and customs. OSF pathogenesis is likely to be multi-
factorial as only a small proportion of areca nut users actually suffer from this 
condition and consequently other genetic and nutritional factors have been 
implicated 39. In India the number of OSF affected individuals is rising rapidly as a 
result of the relatively recent introduction of gutkha (paan masala) an areca-nut 
and tobacco mixture. Gutkha users have higher rates of OSF development than 
other areca preparations therefore it is viewed as especially ominous because of 
the youth appeal, the ease of procurement, low expense, convenient packaging, 
and the lack of social stigma 42. 
 
1-1.09  OSF Clinical Presentation 
Diagnosis of OSF is by its distinctive orofacial presentation in a patient with a 
history of areca nut use. OSF is characterised by progressive loss of elasticity of 
the oropharyngeal mucosa and atrophy of the oral epithelium and commonly 
results in restricted mouth opening, reduced tongue mobility and sensitivity to 
spicy food (Figure 1-06). Complications include conductive deafness from 
functional stenosis of the Eustachian tubes when the paratubal muscles are 
involved 43, dysphagia due to oesophageal involvement, vocal nasality and altered 
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salivary flow from salivary gland fibrosis. The associated morbidity includes 
nutritional deficiencies, as a result of a dietary limitations and rampant caries and 
periodontal disease, from the inability to maintain oral hygiene, as well as the 
psychological impact of a chronic progressive debilitating disorder with a 
significant risk of malignant conversion. 
 
Figure 1-06: The clinical presentation of OSF in a 31 year old Indian woman with a 17 year history 
of guthka usage. Right and left buccal mucosa shows blanching, fibrous raphe and mucosal 
pigmentation combined with trismus and a shrunken uvula is characteristic of OSF. (From Reichart 
and Philipsen, 2006 9)   
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1-1.10  OSF Clinical Classification 
Pindborg (1989) 44 divided OSF progression into 3 phases based on the clinical 
presentation: 
 Stage 1:  Stomatitis: including erythematous mucosa, vesicles, mucosal ulcers, melanotic mucosal 
pigmentation, and mucosal petechia. 
 
 Stage 2:  Fibrosis occurring in ruptured vesicles and ulcers during healing: 
- Early lesions demonstrate blanching of the oral mucosa.  
- Older lesions include vertical and circular palpable fibrous bands in the  
      buccal mucosa and around the mouth opening or lips.  
- Specific findings include the following:  
 Trismus   
Stiff and small tongue 
Blanched and leathery floor of the mouth.  
Fibrotic and depigmented gingiva  
Rubbery immobile soft palate  
Blanched and atrophic tonsils  
Shrunken uvula  
Sinking of the cheeks, not commensurate with age or nutritional status  
 
 Stage 3:  Sequelae:  
                         - dysplastic lesions and malignancy  
                         - speech and hearing defects. 
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Khanna and Andrade (1995) 45 developed a classification of OSF associated 
trismus to aid clinical staging: 
Group I:  The earliest stage and is not associated with mouth opening limitations (interincisal 
distance of >35 mm.) 
Group II:  Interincisal distance of 26-35 mm. 
Group III:  Moderately advanced cases. Interincisal distance of 15-26 mm with fibrotic bands 
visible in the soft palate, pterygomandibular raphe and anterior pillars of fauces. 
Group IVA:  Advanced OSF with severe trismus (interincisal distance of less than 15 mm) and 
extensive fibrosis of all the oral mucosa. 
Group IVB:  Severe trismus with interincisal opening of less than 15 mm, extensive fibrosis of 
the oral mucosa and (pre)malignant lesions. 
 
 
1-1.11  OSF Management 
If detected early OSF can be managed by education concerning the use of areca 
nut compounds and cessation of the habit is sufficient to prevent the disease 
progressing 39. Unfortunately, most patients present when OSF is already severe 
and irreversibly limiting oral function. Treatment is then symptomatic and aimed at 
reducing further deterioration of mouth opening. A variety of topical and 
intralesional pharmacotherapeutic compounds (steroids, hyaluronidase 46, 
placental extracts 47, interferon γ 48 have been advocated but evidence of clinical 
effectiveness appears unreliable 49. Mouth-opening physiotherapy exercises 
maybe just as helpful in preventing further limitation of mouth movements. Surgical 
management is indicated when severe trismus is prohibitive to feeding and 
communication. Surgery involves extensive split-thickness skin grafting or 
nasiolabial or lingual pedicle flaps as simple excision of the fibrous bands often 
results in contracture and exacerbation of the condition. Surgical management is 
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further complicated by the difficulties of laryngoscopy and intubation of the trachea 
50
. The potential healthcare burden of OSF is hugely increased by late detection 
and the substantial risk of malignant transformation necessitating frequent biopsy 
and long term follow-up. Therefore, as with OSCC, there are substantial 
advantages to the early detection of OSF. 
 
1-1.12  Referral Guidelines for Suspected Oral Cancer 
OSCC develops in the superficial epithelium lining the oral cavity and is therefore 
relatively open to visual assessment although histological examination is the gold 
standard required to confirm the diagnosis. The National Institute of Health and 
Clinical Excellence (NICE) has issued referral guidelines for suspected cancer 10 
to be used by primary care practitioners (e.g. general dental and medical 
practitioners). These guidelines use 3 referral timelines: 
• Immediate: an acute admission or referral occurring within a few hours. 
• Urgent: the patient is seen within the national target for urgent referrals (currently 2 
weeks). 
• Non-urgent: all other referrals. 
Oral cancer is included in this document under “head and neck cancer including 
thyroid” but specific guidance for OSCC is given (Figure 1-07): 
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Figure 1-07: Descriptions of OSCC from the NICE Referral Guidelines for Suspected Cancer 
(2005).10 
 
 
These guidelines are quoted as “Recommendation Grade C” or “directly based on 
category III evidence or extrapolated recommendation from category I or II 
evidence” 10 (Table 1-02). This suggests that the evidence for these 
recommendations is either from well-designed non-experimental descriptive 
studies or case-control studies or case series. Alternatively, they may be 
extrapolated from randomised controlled trials (RCTs) or systematic reviews of 
RCTs 22, indicating the dearth of high quality evidence available relating to the 
referral of OSCC. 
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Table 1-02: Levels of evidence applied to NICE Referral Guidelines for Suspected Cancer. 
(Adapted from Eccles and Mason (2001) 22) 
 
The NICE Referral Guidelines on Suspected Cancer (2005) 10 additionally provide 
guidance on the role of primary care practitioners in investigation of OSCC which 
is “investigations for head and neck cancer in primary care are not recommended 
as they can delay referral.” Therefore the role of the dentist in diagnosis of OSCC 
is limited to examining patients and referring any suspect lesions i.e. essentially 
screening patients for OSCC. 
 
These guidelines also provide relevant guidance for the management of patients 
from different cultures. “Primary healthcare professionals should provide culturally 
appropriate care, recognising the potential for different cultural meanings 
associated with the possibility of cancer, the relative importance of family decision-
making and possible unfamiliarity with the concept of support outside the family.” 
10
 This would suggest that patients ideally need culturally appropriate advocates to 
interpret cancer related information whenever the referring practitioner is not of the 
same cultural background as the patient. 
 
Evidence 
category 
Source 
Ia Evidence from systematic review or meta-analysis of 
randomised controlled trials  
Ib Evidence from at least one randomised controlled trial  
IIa Evidence from at least one well-designed controlled study 
without randomisation  
IIb Evidence from at least one well-designed quasi-experimental 
study, such as a cohort study  
III Evidence from well-designed non-experimental descriptive 
studies, case-control studies, or case series  
IV Evidence from expert committee reports, opinions and/or 
clinical experience of respected authorities  
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1-1.13  The Epidemiology of Oral Cancer in the UK 
Cancer registration databases are held by 8 regional Cancer Registries in England 
along with registries in Wales, Scotland and Northern Ireland. Directly collated 
data is presented by the National Cancer Intelligence Network (NCIN) 
[http://www.ncin.org.uk]. Additionally for England the governments Office for 
National Statistics (ONS) [http://www.ons.gov.uk] provides data from the regional 
cancer registries in its yearly report. Cancer Research UK presents this data for 
the UK on their website [http://www.cancerresearchuk.org/cancer-
info/cancerstats/types/oral]. The latest data shows that in 2009, 6,236 people were 
diagnosed with OSCC making up 2% of all cancers diagnosed in the UK. 
Therefore OSCC is the UK’s 15th most common cancer and in 2010 directly 
resulted in 1,985 deaths with the lifetime risk of developing OSCC in the UK 
estimated to be 1 in 93 for men and 1 in 186 for women. 
 
1-1.14  Oral Cancer and Geography in the UK 
The incidence rates for OSCC in the UK in 2009 show that there are more than 10 
new oral cancer cases for every 100,000 people in the UK (Table 1-03). 
 
Table 1-03: Oral Cancer (C00-C06,C09-C10,C12-C14): 2009. Number of New Cases, and 
Incidence Rates per 100,000 Population Countries of the UK (Adapted from 
www.cancerresearchuk.org/cancer-info/cancerstats/types/oral/incidence) 
  
  
  
England Wales Scotland Northern Ireland UK 
Cases 3,246 236 501 114 4,097 Male 
Incidence Rate 12.7 16.1 19.9 13 13.5 
Cases 1,689 121 270 59 2,139 Female 
Incidence Rate 6.4 7.9 10.1 6.5 6.8 
Cases 4,935 357 771 173 6,236 Persons 
Incidence Rate 9.5 11.9 14.8 9.7 10.1 
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The geographical variation in incidence across the UK reflects the prevalence of 
the two most well established risk factors which are excessive alcohol 
consumption and smoking. This North-South divide in oral cancer incidence 
(particularly for males) has existed across the UK since at least the 1990s 12.  
 
1-1.15  Oral Cancer and Age 
Oral cancer incidence in the UK is strongly related to age. For men, age-specific 
incidence rates increase sharply from the mid-forties and peak at ages 60-69, 
before falling in the over 70s. Age-specific incidence rates increase much more 
gradually for women, from around age 45, but peaking in the over-80s. (Figure 1-
08) 
 
Figure 1-08: Oral Cancer (C00-C06,C09-C10,C12-C14): 2007-2009. Average Number of New 
Cases Per Year and Age-Specific Incidence Rates per 100,000 Population, UK. 
(www.cancerresearchuk.org/cancer-info/cancerstats/types/oral/incidence) 
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1-1.16  Oral Cancer Trends over Time 
The incidence rates for all cancers increased by 20% in males during the period 
from 1975-2009 and by 40% in females with almost this entire rise occurring 
before the late 1990s. Over the last 10 years (1998-2009), the incidence rates 
increased by just 3% and 5%, respectively. (Figure 1-09). 
 
Figure 1-09: All Cancers Excluding Non-Melanoma Skin Cancer (C00-97 excl. C44): 1975-2009. 
European Age-Standardised Incidence Rates per 100,000 Population, by Sex, Great Britain. 
(www.cancerresearchuk.org/cancer-info/cancerstats/types/oral/incidence)   
            
            
           
 
As with all cancers in total, OSCC incidence rates have increased since the mid-
1970s. However, a large proportion of the increase has occurred since the late 
1980s (Figure 1-10). Immigrants from the Indian sub-continent, may have partly 
contributed to the rising trend 51. This also suggests that OSCC will become a 
more significant cancer issue in the UK in the future. 
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Figure 1-10: Oral Cancer (C00-C06,C09-C10,C12-C14): 1975-2009. European Age-Standardised 
Incidence Rates per 100,000 Population, by Sex, Great Britain. 
(www.cancerresearchuk.org/cancer-info/cancerstats/types/oral/incidence)   
            
      
   
1-1.17  Oral Cancer Incidence Worldwide 
Cancer registration systems are available in affluent countries such as the UK but 
80% of the world’s populations live in regions that are not covered by such 
systems 52. Therefore, the International Agency for Research on Cancer (IARC) 
attempted to use all available data to estimate worldwide cancer incidence in the 
2008 GLOBOCAN project [http://globocan.iarc.fr]. An estimated 400,000 new 
cases of cancer of the lip and oral cavity (ICD-10 C00-C08) and pharynx excluding 
the nasopharynx (C09-C10, C12-14) were diagnosed across the world in 2008, 
which is about 3% of all cancers Worldwide 52.  
 
For lip and oral cavity cancer (ICD-10 C00-C08) the incidence rates are highest in 
South-Central Asia (Figure 1-11). Much of the geographical variation in incidence 
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can be attributed to differences in tobacco smoking and alcohol consumption, 
whilst areca nut extract usage is an important risk factor for some South Asian and 
Chinese populations. In high-risk countries such as Sri Lanka, India, Pakistan and 
Bangladesh, cancer of the lip and oral cavity is either the most common or second 
most common cancer in men, accounting for up to 15% of all new cases of cancer 
in males 52. 
 
Figure 1-11: Lip and Oral Cavity Cancer (C00-C08): 2008 Estimates. World Age-Standardised 
Incidence Rates per 100,000 Population, World Regions. (www.cancerresearchuk.org/cancer-
info/cancerstats/types/oral/incidence)     
 
1-1.18  Mouth Cancer and Ethnicity 
Incidence of all cancers as a whole is substantially lower in Asian populations in 
the UK compared to the White population as shown in Figure 1-12, even when 
worst case scenario assumptions have been made for the large number of cases 
of unknown ethnicity in the data set 11.   
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Figure 1-12: Rate Ratios for All Malignant Neoplasms Excluding Non-Melanoma Skin Cancer (C00-
C97 excl. C44) (with 95% confidence intervals) by major ethnic group (White ethnic group = 1), 
Males and Females, UK. (Adapted from: Cancer Incidence and Survival by Major Ethnic Group, 
England. 2002-2006. National Cancer Intelligence Network 2009 11) 
 
 
The same NCIN report 11 reveals a very different distribution for mouth cancer 
amongst Asian populations in the UK (Figure 1-13). Results have only been 
presented for White, Asian and Black ethnic groups due to the small number of 
patients for the other ethnic groups and again there is a large proportion of 
unknown ethnicity (approximately 20%) for which a number of statistical scenarios 
have been calculated. However, the contrast with the data for all cancers is clear, 
as Asian women in the UK have significantly higher incidences of mouth cancer 
than the White population. The picture is less clear for Asian males because the 
apparent differences shown in Figure 1-13 were not statistically significant. Moles 
et. al. 2008 53 confirmed this with data from the Thames Cancer Registry showing 
that after controlling for socioeconomic deprivation, South Asian males showed a 
marginally higher relative risk of oral cancer (OR 1.36; 95% CI: 1.11-1.67) than 
non-South Asian males. Whilst, South Asian females had a much higher risk of 
these cancers (OR 3.67; 95% CI: 2.97-4.53) than non-South Asian females. This 
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suggests that UK Asians are significantly different from the UK population as a 
whole in their risk for oral cancer.  
MALES      
FEMALES  
 
Figure 1-13: Rate Ratios for Mouth Cancer (C00-C08) (with 95% confidence intervals) by major 
ethnic group (White ethnic group = 1), Males and Females, UK. (Adapted from: Cancer Incidence 
and Survival by Major Ethnic Group, England. 2002-2006. National Cancer Intelligence Network 
2009 11) 
 
 
 
 
1-1.19  Head and Neck Cancer and Social Deprivation 
NCIN report that head and neck cancer shows a strong association with social 
deprivation (Figure 1-14) such that the incidence rates in the most deprived 
quintile of the population were 2.1 times that in the most affluent quintile 12. It is 
also known that risk factors for cancer, especially smoking, are strongly influenced 
by socio-economic determinants 12. Additionally, within London exist some of the 
most deprived boroughs in the UK, such as Tower Hamlets and Newham, which 
also have the highest proportion of Asian immigrant populations 54.   
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Figure 1-14: Cancer incidence by deprivation quintile, England, 2000 – 2004. (Adapted from: 
Cancer Incidence by Deprivation, England. 1995-2004. National Cancer Intelligence  
Network 2008 12) 
 
 
1-1.20  The TNM Classification of Oral Cancer 
The TNM classification is the globally accepted method of describing the 
anatomical extent of any cancer. The OSCC specific TNM classification is shown 
below 55:  
 
 T — Primary tumour  
TNM  
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour 2 cm or less in greatest dimension 
T2 Tumour more than 2 cm but not more than 4 cm in greatest dimension 
T3 Tumour more than 4 cm in greatest dimension 
T4a (lip) Tumour invades through cortical bone, inferior alveolar nerve, floor of mouth, 
or skin (chin or nose) 
T4a (oral cavity) 
Tumour invades through cortical bone, into deep/extrinsic muscle of tongue 
(genioglossus, hyoglossus, palatoglossus, and styloglossus), maxillary sinus, 
or skin of face 
T4b (lip and oral 
cavity) 
Tumour invades masticator space, pterygoid plates, or skull base; or encases 
internal carotid artery 
 Note: Superficial erosion alone of bone/tooth socket by gingival primary is not sufficient to classify a tumour as T4. 
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 N - Regional Lymph Nodes (Cervical) 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension 
N2 Metastasis as specified in N2a, 2b, 2c below 
N2a Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 
cm in greatest dimension 
N2b Metastasis in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension 
N2c Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension 
N3 Metastasis in a lymph node more than 6 cm in greatest dimension 
 Note: Midline nodes are considered ipsilateral nodes.  
 
 
 M – Distant metastasis 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
 
 
 
 
1-1.21  Clinical Staging and Prognosis 
The TNM classification also allows clinicians to stage OSCCs which can then be 
correlated with survival outcomes.    
 
 Stage Grouping 
Stage 0 (precancer) Tis N0 M0 
Stage I (early) T1 N0 M0 
Stage II (locally advanced) T2 N0 M0 
T1, T2 N1 M0 Stage III (spread to lymph) 
T3 N0, N1 M0 
T1, T2, T3 N2 M0 Stage IVA (metastatic) 
T4a N0, N1, N2 M0 
Any T N3 M0 Stage IVB (metastatic) 
T4b Any N M0 
Stage IVC (metastastic) Any T Any N M1 
 
 
Two year survival statistics (Table 1-04) reveal that small early OSCCs (stage I) 
without lymphatic spread have a substantially better prognosis than more 
advanced disease at diagnosis. Metastatic spread either to the regional lymph 
nodes or distant (stage III or IV) worsens the prognosis still further. Therefore early 
detection of OSCC is fundamental for improving outcomes as greater than 60% of 
OSCC are currently stage III or IV on presentation 56.   
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Table 1-04: Staging at diagnosis and two-year survival for cancers of the oral cavity, South West of 
England 1996-2000. (Adapted from: www.cancerresearchuk.org/cancer-
info/cancerstats/types/oral/incidence) 
 
  
  
  
Oral cavity 
(% of cases) 
2-year 
Survival (%) 
All cases  62.0 (57.3-66.7) 
I Early disease 21 87.5 (80.6-94.4) 
II Locally advanced 17 68.6 (57.6-79.6) 
III Tumour in lymph nodes 15 52.5 (40.0-65.0) 
IV Metastatic 36 46.0 (38.0-54.0) 
Unknown 11 68.2 (54.5-81.9) 
 
 
1-1.22  Management of Oral Cancer 
OSCCs are staged at diagnosis to give an indication of prognosis as well as 
treatment strategies. Standard treatment usually involves surgical resection of the 
tumour with a wide margin. Neck dissection may be required to remove associated 
lymph nodes as well as flap reconstruction of the defect 57. Radiotherapy is 
conventionally used in combination with surgery when clear excision margins are 
not possible due to the extent of the tumour resulting in unacceptable 
disfigurement or debilitation, if excised completely 58. Some OSCCs may also be 
untreatable, such as stage IV lesions with distant metastases, where management 
would be limited to palliation. Therefore, earlier diagnosis of smaller less-advanced 
OSCCs is beneficial in terms of morbidity as well as mortality as late detection 
necessitates more invasive treatment producing significant facial deformity and 
difficulty in eating, speaking, taste and the increased risk of frequent or rapidly 
progressing infections. 
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1-1.23  Screening and Case-Finding 
Screening for disease implies an ongoing, structured healthcare intervention 
designed to detect disease at an asymptomatic stage when its natural course can 
be readily interrupted if not cured. ‘Screening’ is defined as the application of a test 
to people who are apparently free from disease in order to determine those who 
might have the disease from those who probably do not. In contrast, ‘case-finding’ 
is defined as a diagnostic test that is applied to a patient who has abnormal signs 
or symptoms in order to establish a diagnosis and aid treatment planning. In the 
literature, screening (detection) and case-finding (diagnosis) are used 
interchangeably.  
 
1-1.24  The UK National Screening Committee 
Because of the potential for over-diagnosis (false positives) and associated cost 
implications the UK National Screening Committee lists 22 criteria relating to both 
the condition and the screening test that should be met before a screening 
programme is introduced 59.  
 
The Condition 
1. The condition should be an important health problem 
2. The epidemiology and natural history of the condition, including development from 
latent to declared disease, should be adequately understood and there should be a 
detectable risk factor, disease marker, latent period or early symptomatic stage. 
3. All the cost-effective primary prevention interventions should have been implemented 
as far as practicable. 
4. If the carriers of a mutation are identified as a result of screening the natural history of 
people with this status should be understood, including the psychological implications. 
 
The Test 
5. There should be a simple, safe, precise and validated screening test. 
6. The distribution of test values in the target population should be known and a suitable 
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cut-off level defined and agreed. 
7. The test should be acceptable to the population. 
8. There should be an agreed policy on the further diagnostic investigation of individuals 
with a positive test result and on the choices available to those individuals. 
9. If the test is for mutations the criteria used to select the subset of mutations to be 
covered by screening, if all possible mutations are not being tested, should be clearly set 
out. 
 
The Treatment 
10. There should be an effective treatment or intervention for patients identified through 
early detection, with evidence of early treatment leading to better outcomes than late 
treatment. 
11. There should be agreed evidence based policies covering which individuals 
should be offered treatment and the appropriate treatment to be offered. 
12. Clinical management of the condition and patient outcomes should be optimised in 
all health care providers prior to participation in a screening programme. 
 
The Screening Programme 
13. There should be evidence from high quality Randomised Controlled Trials that the 
screening programme is effective in reducing mortality or morbidity. Where screening is 
aimed solely at providing information to allow the person being screened to make an 
“informed choice” (e.g. Down’s syndrome, cystic fibrosis carrier screening), there must 
be evidence from high quality trials that the test accurately measures risk. The 
information that is provided about the test and its outcome must be of value and readily 
understood by the individual being screened. 
14. There should be evidence that the complete screening programme (test, diagnostic 
procedures, treatment/ intervention) is clinically, socially and ethically acceptable to 
health professionals and the public. 
15. The benefit from the screening programme should outweigh the physical and 
psychological harm (caused by the test, diagnostic procedures and treatment). 
16. The opportunity cost of the screening programme (including testing, diagnosis and 
treatment, administration, training and quality assurance) should be economically 
balanced in relation to expenditure on medical care as a whole (i.e. value for money). 
Assessment against this criteria should have regard to evidence from cost benefit and/or 
cost effectiveness analyses and have regard to the effective use of available resource. 
17. All other options for managing the condition should have been considered (e.g. 
improving treatment, providing other services), to ensure that no more cost effective 
intervention could be introduced or current interventions increased within the resources 
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available. 
18. There should be a plan for managing and monitoring the screening programme and 
an agreed set of quality assurance standards. 
19. Adequate staffing and facilities for testing, diagnosis, treatment and programme 
management should be available prior to the commencement of the screening 
programme. 
20. Evidence-based information, explaining the consequences of testing, investigation 
and treatment, should be made available to potential participants to assist them in 
making an informed choice. 
21. Public pressure for widening the eligibility criteria for reducing the screening 
interval, and for increasing the sensitivity of the testing process, should be anticipated. 
Decisions about these parameters should be scientifically justifiable to the public. 
22. If screening is for a mutation the programme should be acceptable to people 
identified as carriers and to other family members. 
 
In 2010 Speight and Warnakulasuriya 60 attempted to address these criteria for 
oral cancer screening. The major issues were: 
Criteria 2 - The natural history of OSCC is only party understood as PMDs exist but 
their progression to OSCC is unclear. 
Criteria 6 - For visual examination of the oral tissues the test values in the target 
population are unknown so an appropriate test cut-off value is unclear for when to 
refer detected lesions or even when a lesion is present. Dentists use a variety of 
clinical examination findings to make their diagnosis but the decision to refer occurs 
only for lesions presenting as advanced OSCC 61. 
Criteria 15 - There is no data on potential psychological harm from false positives in 
oral cancer screening.  
They concluded that “given these substantial obstacles, it seems that screening 
cannot at the present time be advocated.” Although they accepted that “there is a 
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deep feeling within the profession that there should be some sort of screening 
programme for oral cancer.” 60 
 
1-1.25  Sensitivity and Specificity 
Sensitivity and specificity are statistical measures of the performance of a binary 
classification test e.g. the outcomes are either screen positive or negative.  
 
Figure 1-15: The standard 2x2 table for calculation of sensitivity and specificity of a screening 
programme. (Adapted from Lingen et. al. 2008 13) 
 
Sensitivity measures the proportion of subjects with the disease who test positive 
e.g. the percentage of people with OSCC who are screened positive. 
 
The specificity determines the proportion without the disease who test negative 
e.g. the percentage of healthy people who are screened negative. 
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For any test, there is usually a trade-off between sensitivity and specificity e.g. in 
an OSCC screening programme the dentists may screen positive non-specific 
PMDs (low specificity) in order to reduce the risk of missing an OSCC (high 
sensitivity). Furthermore, sensitivity and specificity must be considered together to 
evaluate a screening programme as theoretically any dentist who screened 
positive every participant in the trial would have 100% sensitivity (as all OSCCs 
would have been screened positive) but specificity would be abysmal as all 
healthy participants were not screened negative. 
 
The positive predictive value (PPV) determines the proportion of subjects with 
positive screening results that do have the disease. 
 
The negative predictive value (NPV) gives the proportion of negative screening 
results that do not have the disease. 
 
 
There are no defined values for the ideal screening test so it is desirable to have 
both high specificity (few false positives) and high sensitivity (few false negatives). 
The acceptable trade-off between sensitivity and specificity depends on the 
consequences of failing to detect the disease versus the costs, anxieties and other 
associated burdens from false positive results.  
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Studies have shown that oral cancer can be detected by direct visual examination 
of the oral mucosa with overall sensitivity 85%, specificity 97%,  PPV 70% and 
NPV 98% 62. In contrast, visual screening for skin lesions such as melanoma, has 
shown much higher sensitivity (93%) 63 suggesting that the heterogeneity of early 
OSCC and particularly PMD clinical presentations hampers detection. For this 
reason OSCC screening by direct visual examination will always result in a low 
PPV, indicative that many of the screen positive results are false positives. 
Therefore, it will be necessary to follow up any screen positive result with a more 
reliable test, such as scalpel biopsy and histological assessment, to obtain a more 
accurate assessment as to whether OSCC is actually present. Nevertheless, a low 
PPV screening test, such as direct visual assessment for OSCC, can be useful 
because it is inexpensive and convenient. The strength of direct visual 
assessment for OSCC as a screening test is in its high NPV, indicating that if an 
individual is screened negative, there is a high level of confidence that the 
individual is healthy. 
 
When interpreting sensitivity and specificity calculations the prevalence of the 
disease is important, because if the disease is rare, such as OSCC, then even a 
very high sensitivity and specificity of the screening test will result in a high 
proportion of false positive outcomes. We can conclude that visual screening for 
OSCC, even in a high-risk population, will inevitably result in many false positives, 
the potential significance of which has not been investigated 60. 
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1-1.26  Cost-Effectiveness of Screening for Oral Cancer  
A recent report by the NHS Health Technology Assessment Programme (HTA) 
attempted to assess the cost effectiveness of screening for OSCC in UK primary 
care services 64. Eight screening methodologies were modelled in primary care 
settings as a one-off screening of a hypothetical population, over 40 years of age, 
followed for 60 years. The main outcome measures were mean lifetime costs and 
quality-adjusted life-years (QALYs) of each alternative screening scenario and 
incremental cost-effectiveness ratios (ICERs) to determine the additional costs or 
benefits of one strategy over another. The authors state that the targeted ‘high-
risk’ screening strategies they modelled, utilise an approach in which high-risk 
patients are identified based on known risk factors of demographic and lifestyle 
characteristics (e.g. age, gender, smoking and alcohol) 64, 65. These are risk factors 
for the UK population as a whole and may exclude the South Asian origin sub-
population because their main risk factor for OSCC (areca nut extract usage) is 
not included in the modelling system. 
 
1-1.27  Modelling Data from an ‘Expert Panel’ 
In the HTA report 64 a complex set of statistical models were meticulously 
presented for each scenario but inevitably much of the data utilised information 
gained from an ‘expert panel’ on those areas for which there is no suitable data in 
the literature. An appropriate example of this would be the calculation of cost of 
oral cancer detection in primary care. Sixteen GDPs, who had recently been 
involved in a pilot oral cancer screening programme in their own dental practices, 
were sent questionnaires asking questions related to the time taken for a basic 
NHS examination and the extra time needed to carry out and record a thorough 
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examination of the oral soft tissues. Expert opinion was also sought from a number 
of experienced GDPs and hospital specialists. The actual costs were determined 
from published fee scales for GDPs. The costs allowed only for the additional time 
the dentist would need to examine the soft tissues and record the information. No 
costs were allowed for additional consumables, since it was assumed that the 
mucosal examination would be carried out as a part of a routine dental 
examination. Unfortunately, there is no indication why only 4 of 16 GDPs returned 
completed questionnaires but the mean extra time required to carry out a mucosal 
examination was 2.63 minutes. Expert opinion suggested that this was a 
reasonable time and was equivalent to the extra time allowed within the General 
Dental Services for an ‘extended examination’. The cost difference between a 
routine examination and an extended examination was £3.40 therefore this was 
used as an approximation of the cost of an OSCC mucosal examination. Clearly, 
there is no way of quantifying the accuracy of this approximation to take into 
account other aspects of an extended examination such as periodontal probing, or 
the accuracy of the dentist’s mucosal examination. As this cost is fundamental to 
undertake any modelling exercise of cost effectiveness, generic inaccuracies and 
approximations must be assumed to be accounted for by statistical error 
calculations such as the probability distributions assigned to each input parameter 
in the model. The author’s discussion states “Despite the low response rate, the 
responses from the GDPs were only used to check the robustness of the 
assumption related to one specific model input. As such, the overall response rate 
was not a significant limitation of the study” confirming that, out of necessity, much 
of the information was from an ‘expert panel’ because there was no suitable data 
in the literature. 
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An attempt was made to quantify the ‘expert panel’ levels of uncertainty involved, 
using the ‘Trial Roulette approach’ 66. The clinical experts were provided with a 
questionnaire to complete in order to quantify their beliefs in a series of 
parameters. Diagrams provided on the questionnaire represent betting streets, 
similar to those used on a gaming table. Each column represents a range of 
potential values for a particular parameter. The clinical experts were instructed that 
they had 20 gaming tokens to place in some or all of the columns to represent 
their current belief and uncertainty in the parameters being discussed. Following a 
brief discussion of the question, the clinician’s were asked to start by placing two 
of the counters at the upper and lower limits of their belief about the parameter 
value. They were then requested to place the remaining 18 counters so as to 
express their remaining uncertainty about the particular parameter value. The 
mean responses are then used to quantify the level of uncertainty involved in the 
expert’s opinion on the question and provide numerical values for the probability 
distributions assigned to that parameter in the model.  This approach was used for 
unknown parameters such as the malignant transformation rate of potentially 
malignant disorders and the progression of cancer with time assessed as 
increasing clinical stage 64. A multitude of other assumptions and estimates were 
required to create the complex models developed for this study, each of which is 
transparently presented in the report but their implications were too often 
incalculable.  
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1-1.28  The Cost of Oral Cancer to the NHS 
Despite the apparent limitations, the HTA Cost-Effectiveness of Screening 
for Oral Cancer in Primary Care report 64 provides some data on the approximate 
total costs over a 3-year period for the management of the stages of OSCC with 
cost of: precancer £1869; stage I £4914; stage II £8535; stage III £11,883 and 
stage IV £13,513. This study models total cost to the NHS but does not take into 
account any patient-related expenses or impact on productivity. The indication 
being that early detection of OSCC is advantageous in purely monetary terms due 
to the cheaper treatment required for smaller lesions.  
 
1-1.29  Outcomes of Screening Strategies Modelled in the UK 
With the restrictions of the modelling system the HTA Cost-Effectiveness of 
Screening for Oral Cancer in Primary Care report 64 revealed their “Strategy A” (no 
screening) was always the cheapest option. The modelled screening strategies 
were: 
 
(A) No screening - intended to reflect current practice, where lesions may be identified in 
routine care either via self-referral or through case finding during routine check-ups. 
 
(B) Invitational screen (general medical practice) – all patients registered with a GP 
are invited for a visual screen. Patients who comply with the invitation receive a visual 
examination by the GP and any suspicious lesions are referred to secondary care. 
 
(C) Invitational screen (general dental practice) – all patients registered with a GDP 
are invited for a visual screen. Patients who comply with the invitation receive a visual 
examination by the GDP and any suspicious lesions are referred to secondary care. 
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(D) Opportunistic screen (general medical practice) – all patients who attend their GP 
during the first year receive a visual examination by the GP and any suspicious lesions 
are referred to secondary care. 
 
(E) Opportunistic screen (general dental practice) – all patients who attend their GDP 
during the first year receive a visual examination by the GDP and any suspicious lesions 
are referred to secondary care. 
 
(F) Opportunistic ‘high-risk’ screen (general medical practice) – all patients who 
attend their GP and are identified as being at high risk during the first year receive a visual 
examination by the GP and any suspicious lesions are referred to secondary care. 
 
(G) Opportunistic ‘high-risk’ screen (general dental practice) – all patients who attend 
their GDP and are identified as being at high-risk during the first year receive a visual 
examination by the GDP and any suspicious lesions are referred to secondary care. 
 
(H) Invitational screen (secondary care specialist) – the entire population is invited for 
a visual screen. People who comply with the invitation receive a visual examination by a 
secondary care specialist and any suspicious lesions receive a biopsy. 
 
With the principal objective to maximise health gains from available NHS 
resources the proposal that a cost per QALY value of around £20,000–30,000 is 
considered value for money by the NHS 67, was adopted. With this restriction, 
screening strategies B, C, E and H were excluded under all of the modelled 
outcomes.  
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The authors conclude opportunistic ‘high-risk’ screening in general dental practice 
(Strategy G), was the most cost-effective screening model. Screening by GPs 
(Strategy D and F) was only marginally more expensive despite their lack of 
specific training and consequently lower assumed sensitivities and specificities in 
oral visual examination. This was attributed to a higher population coverage in 
medical practices than dental surgeries 64.  
 
Importantly, opportunistic ‘high-risk’ screening in general dental practice (Strategy 
G) was only cost effective against no screening (Strategy A) with the unproven 
assumption that intervention following screening reduced malignant transformation 
rates by 10-20%, which reportedly cost £15,790 to £18,919 per QALY gained, 
compared to no screening. If no effect on malignant transformation rates was 
assumed then the cost was over £20,000 (£22,850) per additional QALY 
compared with no screening 64.  
 
The model does not allow for any incalculable potential negative effects of 
screening such as negative impacts on QoL from cancer detection anxiety and 
treatment related pain and anxiety. Similarly the model does not allow for possible 
positive psychosocial effects of negative screening for oral cancer. 
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1-1.30  Oral Cancer Screening Trials in the Literature 
The ideal approach to the evaluation of any clinical intervention is the randomised 
controlled trial (RCT) 68. However, where there are large gaps in knowledge or 
where a disease is of low prevalence, making a clinical trial overly costly or of 
uncertain value, other approaches such as observational or modelling studies, 
may be of more immediate worth 69. A PubMed search using the Medical Subject 
Headings indexing system (MeSH) with Boolean operator combination terms 
("Mouth Neoplasms"[Mesh]) AND ("Mass Screening"[Mesh] OR "Early Detection 
of Cancer"[Mesh]) produces 488 citations from 1963 to 2012. 87 of these are 
review articles, including an updated Cochrane review 70 and the latest update 
from a panel convened by the American Dental Association’s Council on Scientific 
Affairs 71 as well as a review by the authors 62 of the HTA Cost-Effectiveness of 
Screening for Oral Cancer in Primary Care 64.  
 
In 2010 The Cochrane collaboration updated their 2003 review on Screening 
Programmes for the Early Detection and Prevention of Oral Cancer 70. This update 
assesses an additional 330 articles (1719 in total) but due to the stringent criteria 
for inclusion (http://www.cochrane-handbook.org) still focuses on the single 
Trivandrum Oral Cancer Screening Study, in Kerala, India 5 as the only RCT to 
meet these criteria, notwithstanding their own conclusion that this study has a 
“high risk of bias”. Therefore, this Cochrane review concludes “that overall there is 
not enough evidence to decide whether screening by visual inspection reduces the 
death rate for oral cancer.” Unfortunately, the ‘not enough evidence to decide’ 
outcome is often the conclusion from Cochrane reviews due to the scarcity of high 
quality RCTs in clinical dentistry.  
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The American Dental Association utilised a different approach to provide clinical 
guidance, by convening a panel of experts to review the literature and make 
recommendations.  Their latest 2012 Evidence-Based Clinical Recommendations 
Regarding Screening for Oral Squamous Cell Carcinomas 71 assessed 332 
systematic reviews and 1499 other clinical studies, settling on 5 systematic 
reviews and 4 clinical studies to use as a basis for developing recommendations, 
which included the Trivandrum Oral Cancer Screening Study 5. Their conclusion 
was similar to the Cochrane group with “insufficient evidence to determine if 
screening alters disease-specific mortality in asymptomatic people seeking dental 
care.”71 
 
The authors of the NHS HTA Cost-Effectiveness of Screening for Oral Cancer in 
Primary Care published their own review on the effectiveness of screening for oral 
cancer 62 in which 1114 relevant citations were identified and 28 included in the 
systematic review. Again this included the Trivandrum Oral Cancer Screening 
Study 5 and again it was concluded that “there are insufficient available data to 
make an unequivocal determination as to the effectiveness of oral cancer 
screening programmes”. 
 
1-1.31  Limitations of Oral Cancer Screening Reviews 
Due to the lack of clinical trial data the highest quality of evidence related to Oral 
Cancer screening studies appears to come from systematic reviews or meta-
analysis of systematic reviews. All of the review articles comment on the 
heterogeneity of the reported studies including aspects as fundamental as 
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objectives, study design, geographic location, clinical setting, numbers and 
characteristics of participants, screening personnel, methods of recruitment and 
nature of data collected and presented. Even the term ‘oral cancer’ as stated 
previously can include cancers at sites as different as the lip, salivary glands, 
tongue and nasopharynx with each having its own unique epidemiology, aetiology, 
pathology and natural history. It has been suggested that combining data for 
salivary gland malignancies and OSCC is as rational as grouping breast and lung 
cancers together simply because of their anatomic proximity 72.  
 
1-1.32  The Trivandrum Oral Cancer Screening Study1-6  
Widely referenced in the literature and undoubtedly one of the largest and longest 
running oral cancer screening trials was undertaken in Kerala, in the South-West 
of India. Trivandrum (Thiruvananthapuram) is the capital of Kerala state and home 
of the University of Kerala.  
 
The trial employed a cluster randomised controlled study design with an intention 
to treat (ITT) analysis of 13 population clusters, of which 7 were randomly 
allocated to 3 rounds of screening (intervention arms), while standard care was 
provided in the other 6 clusters (control arms).  
 
Trained health workers undertook visual inspection at 3-year intervals in the 7 
intervention arms commencing in October 1995 with the first round of screening 
completed in May 1998, the second completed in June 2002 and the third 
completed in October 2004. Health workers were trained and provided with 
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manuals on oral visual examination with colour photographs and descriptions of 
benign and malignant oral lesions.  
 
Oral visual inspections were performed in daylight with flashlights and intraoral 
mucosa was visually examined and palpated along with the neck for enlarged 
lymph nodes. The clinical findings were recorded as normal, non-referable lesions 
and referable lesions. Interestingly the ability of these trained healthcare workers 
at detecting oral cancer appears to be equivalent to qualified dentists when 
compared to studies undertaken in the Western world 64. 
 
Inclusion criteria were healthy participants aged 35 years and older, excluding all 
those who were bedridden, suffering from tuberculosis or other debilitating 
diseases and who had been diagnosed with oral cancer prior to entry into the 
study. In each cluster the number of eligible participants varied from 8000 to 
18,500.  
 
Screen-positive individuals were referred for clinical examination by dentists or 
physicians for confirmation. Oral biopsies were performed on those with clinically 
confirmed homogeneous leukoplakia, non-homogeneous leukoplakia, OSF and 
oral cancer. Surgical excision was carried out for leukoplakia wherever possible. 
All PMDs were regularly reviewed to assess for disease progression. Only 26% of 
referred lesions actually underwent a biopsy to give a definitive diagnosis. 
Unfortunately, the reporting does not state whether the screen positive individuals 
were diagnosed by general medical and dental practitioners who had received 
formal training or were standardised in the identification of positive lesions. 
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The control group clusters were also visited by health workers who recorded the 
same sociodemographic information and measured height, weight, blood pressure 
and respiratory peak flow measurements. The control group health workers were 
not trained to undertake an oral examination. 
 
1-1.33  Outcomes of the Trivandrum Screening Trial1-6 
Of the 96517 eligible participants in the intervention group, 8688 individuals never 
received the invitation and 174 refused screening. In total, 87655 (91%) were 
screened at least once, 53312 (55%) twice, and 29102 (30%) three times. As the 
study employed an ITT analysis bias was minimised despite the significant drop-
out rate.  
 
5145 of those screened (5.9%) had referable lesion and 3218 (63%) of these 
screen positive subjects complied with referral but no indication was given of why 
so many failed to comply. The control group consisted of 95,356 people of which 
80,086 (84%) were assessed. 
 
205 oral cancers and 77 oral cancer deaths were recorded in the intervention 
group compared with 158 cases and 87 deaths in the control group giving a 
standardised mortality rate ratio of 0.79 (95% CI 0.51-1.22).  The author’s 
extrapolate this finding to suggest that oral cancer screening has the potential to 
prevent 37,000 oral cancer related deaths worldwide. 5 
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The proportion of oral cancers detected at an early stage (i.e. stage I or II) was 
higher in the intervention arm than the control arm (42% versus 24%). The 
incremental cost per life-year saved was US$ 835 for all individuals eligible for 
screening and US$ 156 for high-risk individuals (tobacco or alcohol users). In this 
study, oral cancer screening by visual inspection was performed for under US$ 6 
per person. Taken together the authors suggested that targeted ‘high risk’ 
screening of the Trivandrum population was the most cost-effective approach. 6 
 
Data from 282 oral cancer cases and 1410 matched controls were analyzed using 
multivariate logistic regression models. Tobacco chewing was the strongest risk 
factor associated with oral cancer. The adjusted odds ratios for chewers were 3.1 
(95% CI = 2.1-4.6) for men and 11.0 (95% CI = 5.8-20.7) for women. Effects of 
chewing paan with or without tobacco on oral cancer risk were elevated for both 
sexes. Bidi smoking increased the risk of oral cancer in men (OR 1.9; 95% CI = 
1.1-3.2). Dose-response relations were observed for the frequency and duration of 
chewing and alcohol drinking, as well as in duration of bidi smoking. 1  
 
Sixty-three percent of 5145 screen-positive individuals complied with referral. 
Controlling for all other factors, individuals older than 44, and those with more 
advanced lesions were more likely to comply with referral (p<0.001). Individuals 
living in better housing were less likely to comply with referral (OR 0.79; 95% CI = 
0.65-0.95).2 The significance of the poor referral compliance rate is immense as 
this indicates many individuals with suspected or frank malignancy remain 
untreated with potentially no healthcare provision. Furthermore, accurate 
assessment of the efficacy of the screening programme is impossible as sensitivity 
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and specificity calculations can only be estimated. Additionally, screening trials in 
the UK and Western world usually report referral compliance rates approaching 
100% 62  indicating significant differences in the characteristics of the population or 
healthcare system which may invalidate extrapolation of findings from these 
studies to UK populations.   
 
1-1.34  Cuba’s National Oral Cancer Screening Programme 
Cuba is the only country in the world to report a national oral cancer screening 
programme 73. Oral cancer accounts for 4% of all cancers annually so a national 
screening programme was commenced in 1984. This covers 12-26% of the 
population annually and identified 16% of the 4412 new oral cancers diagnosed in 
Cuba from 1984 to 1990. Additionally tumour staging on diagnosis was improved 
such that the proportion of early tumours on diagnosis in 1983 was 24% which 
increased to 49% in 1990. However staging data was available for only 
approximately half the tumours indentified and there was no change in oral cancer 
mortality attributable to the screening programme. 73 
 
1-1.35  Diagnostic Aids for Oral Cancer Detection 
With the majority of OSCC being detected at an advanced stage, an inevitable 
suggestion is that at least some early lesions are missed or ignored by patients 
and oral health care practitioners. A variety of diagnostic aids to improve the 
clinician’s ability to detect potentially malignant lesions or early tumours have been 
developed. Some are true screening aids, designed to be used on apparently 
healthy individuals to help detect early malignancy whilst others aid in case-finding 
by helping clinicians to diagnose which detected lesions are malignant.  
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1-1.36  Biopsy and Histopathological Examination 
Tissue sampling by scalpel or punch biopsy and subsequent histological 
examination is the gold standard for diagnosing oral lesions despite the degree of 
invasiveness resulting in both psychological implications for the patient as well as 
technical difficulties for the clinician e.g. for large lesions determining the most 
representative areas to avoid diagnostic errors 74. Biopsy specimens can also be 
affected by a number of artefacts resulting from crushing, stretching or incorrect 
fixation which make histological characterisation substantially more difficult 75. The 
subjective inaccuracy of oral epithelial dysplasia assessment in histopathology 
samples is also well documented 76 and as such, Scully et. al. (2008) recommend 
that if the pathology report denies malignancy, and yet clinically this is suspected, 
then discussion with the pathologist and a re-biopsy are invariably indicated 77. 
Also, there is significant concern with the potential for the initial biopsy to seed 
OSCC because of the increased frequency of neck metastasis from stage I and 
stage II cancers noted after biopsy and the presence of tumour cells in the 
peripheral blood detected shortly after incisional biopsy 78. Holmstrup et. al. (2006) 
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 even suggest that OSCCs maybe induced by the scalpel incision when PMDs 
are biopsied. Clearly less invasive and more accurate diagnostic aids are required 
for the detection of OSCC and PMDs.  
 
1-1.37  Oral Cytology using Brush Biopsy 
Exfoliate cytology using brushes (Figure 1-16) has been evaluated since the 
1980s as a minimally invasive alternative to scalpel biopsy of oral mucosal lesions. 
OralCDx (CDx Laboratories, Suffren, NY, USA) is a combination system of 
transepithelial oral brush biopsy with computer assisted analysis of the sample. 
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Outcomes are either ‘normal’ or abnormal (‘atypical’ or ‘positive’) with all abnormal 
results requiring further investigation such as conventional scalpel biopsy and 
histological assessment to provide a definitive diagnosis.  
 
 
Figure 1-16: Oral brush biopsy technique for the tongue and buccal mucosa. (From 
http://www.cdxdiagnostics.com/OralCDx.html) 
 
OralCDx was designed for the examination of visually detected clinical lesions that 
would otherwise not be subjected to biopsy because the level of suspicion for 
OSCC was low. The data on accuracy of OralCDx is limited but some very 
encouraging observations have been reported, such as Sciubba et. al. (1999) 80 
showing that 4.5% of 647 of these ‘clinically benign’ lesions when assessed by 
OralCDx were subsequently diagnosed as dysplastic or OSCC. Sensitivity and 
specificity calculations for malignancy detection with OralCDx in these ‘clinically 
benign’ lesions is impossible because, in the published literature, the remainder of 
these lesions are never definitively assessed by histology, to exclude further 
concealed dysplasia or malignancy. With current levels of knowledge this is an 
insurmountable hurdle for ethical reasons as these lesions are believed to be 
‘clinically benign’ in nature. Much of the data on the value of OralCDx is therefore 
derived from its application on clinically suspected OSCC which need conventional 
biopsy and histology whether OralCDx is applied or not 13. 
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Another significant issue arises from the inability of OralCDx to determine a 
diagnosis for detected cellular abnormalities without scalpel biopsy and histology. 
This would result in mucosal conditions which present with cytologic and 
morphologic epithelial changes being detected out-of-context as abnormal. For 
this reason OralCDx cannot reliably be used on common but benign, or at least 
currently non-malignant, mucosal conditions such as reticular LP 13. OralCDx 
application to OSF has not been reported but with the observed histological 
epithelial changes in OSF a similarly uninformative abnormal result maybe 
expected.  
 
Despite the immense potential in other clinical scenarios the conclusion must be 
that OralCDx would neither be a substitute for direct visual assessment of the oral 
mucosa in a screening trial nor eliminate the need for definitive diagnosis by 
scalpel biopsy and histological examination. 
 
1-1.38  Experimental Screening Aids 
A number of more-or-less experimental techniques for oral cancer detection have 
been described. These elicit vociferous debate in the literature as to their value as 
adjuncts to OSCC detection or the subsequent issue of lesion diagnosis, which 
may be a function of the evident commercial interest as much as specific clinical 
implication 13, 81-83. 
• Vital staining with toluidine blue (e.g. Oratest®) 
• Light based techniques (e.g. ViziLite®, VELscope®) 
 75 
Vital staining and light-based techniques have been evaluated specifically as true 
screening aids for clinically normal oral mucosa as distinct oral cytology which is 
an adjunct for aiding diagnosis of visible lesions that appear clinically benign. 
Overall the light based systems along with toluidine blue, when evaluated as 
screening or case-finding aids for OSCC, result in the general conclusion that 
there is insufficient data to support or refute their potential value 13, 60, 71, 77. 
Fortunately, a number of potential diagnostic aids are in development, such as 
DNA ploidy analysis 84, epigenetic biomarkers 85, optical coherence tomography 86 
and spectral cytopathology 87. These are unlikely to become viable diagnostic aids 
in OSCC screening in the immediate future as the clinical diagnosis ideally needs 
to be achieved rapidly without resorting to experimental laboratory procedures as 
the resultant infrastructural and expertise costs would likely render any screening 
programme non-viable. 
 
In 2012 there are currently no oral cancer screening trials listed on the UK NSC 
screening portal (http://www.screening.nhs.uk) with the latest review having been 
completed in June 2010 60 and not due for review until 2013/14. 
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1-2.01  AIMS AND OBJECTIVES 
OSCC remains an enigma because of the unexplainable disparity between its 
significant healthcare burden and the potential theoretical ease in decreasing 
morbidity and mortality with early detection. Most OSCCs develop as visible 
lesions in the mouth and these detectable early lesions can be easily treated with 
minimal morbidity. Frustratingly, the majority of OSCCs are still diagnosed at a 
much later stage when treatment is costly and both morbidity and mortality 
significant. OSCC therefore remains a promising target for a screening programme 
despite the evidence for screening efficacy currently being limited.  
The data presented suggests that targeted screening of high-risk sub-populations 
within in the UK is likely to be the most effective methodology. One such group is 
the South Asian population who are at significantly higher risk for OSCC than the 
UK population as a whole. They also present with unique PMDs, especially OSF, 
due to their specific habitual OSCC risk-factor, areca nut extract usage. Therefore, 
a screening programme aimed at this population would need to account for these 
cultural variations and utilise the literature on screening trials in South Asia against 
which the UK screening protocol can be evaluated. Targeted screening activity for 
OSCC in high risk South Asian populations, conducted in the UK, has not 
previously been reported in the literature. 
The Aims of this study are to: 
• Develop a novel targeted screening protocol for OSCC utilising the specific 
risk factors and disease processes prevalent in a UK based high-risk South 
Asian population. 
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• Evaluate outcomes of targeted screening activity for UK based South Asian 
populations assessed against screening outcomes in their native population 
compared to trials in the UK population as a whole.  
• Evaluate the potential for targeting screening to risk-factor specific PMDs, 
such as OSF, in the UK based South Asian populations who are at high-risk 
for OSCC. 
• Development of point-of-care immunohistological techniques to eradicate 
non-compliance with referral for positive screened individuals allowing 
targeted high-risk OSCC screening activity to be accurately evaluated and 
ethically implemented.   
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Chapter 2 
 
 
Development of an Oral Cancer Screening Protocol Targeting 
High-Risk Individuals in Tower Hamlets 
 
 
 
2-1.01  INTRODUCTION 
Oral cancer screening has been suggested as a viable proposition in high risk 
populations in the UK from extensive modelling exercises 64. However, these 
models utilise the aetiological risk factors and available epidemiological data for 
oral cancer prevalence in the UK population as a whole. South Asian populations 
in the UK, such as that in Tower Hamlets, are known to be significantly different in 
terms of socio-economic and cultural influences from the UK population as a 
whole. For example, the intake of excessive alcohol, a primary contributory risk 
factor for OSCC in the UK, is uncommon in the South Asian populations of the UK 
88
. South Asian populations in their native sub-continent are known to be at 
significantly higher risk of OSCC because of areca nut extract usage often in 
conjunction with tobacco 52 and areca compound usage is almost non-existent 
outside of these populations in the UK. Therefore, the applicability of modelling 
exercises for the UK population as a whole, to the South Asian sub-population is 
debatable. A review of the literature reveals no reported OSCC screening trials, 
specifically targeting this sub-population, in the UK. There are however studies 
from South Asia including one RCT considered by the Cochrane Oral Health 
Group, as sufficiently robust to warrant review 70. 
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2-1.02  Relevance of South Asian Studies to UK Populations  
Despite UK based South Asian populations having the same lifestyle related risk 
factors as their counterparts on the Asian subcontinent, OSCCs multifactorial 
aetiology suggests that differences in environment and healthcare systems may 
complicate comparisons. Inequalities in health, related to ethnicity, have been 
extensively studied because of their potential contribution to the understanding of 
the role of genetic and acquired risk factors (such as lifestyle and environment) in 
the development of disease, as well as evaluating the impact of the healthcare 
system. Additionally, the relative availability of national and international cancer 
databases has resulted in many of these studies focussing on health inequalities 
related to cancer 89. 
 
Migrant populations from South Asia resident in the UK are known to have a 
significantly higher risk of developing OSCC than non-South Asians in the UK 53 
and OSCC prevalence is much higher in South Asian countries than the UK 52. 
However, the UK based South Asians still display much lower rates of OSCC than 
their Asian subcontinent peers 53. This intermediate cancer risk between ‘current 
Western country’ and ‘native Asian country’ has also been shown in the USA 90, 
and Australia 91. The finding that South Asians in the UK have a significantly lower 
risk of all cancers as a whole but specifically experience higher levels of oral 
cancer, than the general UK population 11 indicates oral cancer specific risk factors 
are implicated. Moles et. al. (2008) 53 concluded that the lower socio-economic 
status of many South Asian immigrant populations, in the UK, can only partly 
account for the differences and suggested that the higher risk of oral cancer 
reflects the higher consumption of tobacco products and areca nut extracts. They 
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however acknowledge the limitations of their reliance on the Thames Cancer 
Registry including potential misclassification in assigning ethnicity on the basis of 
name and the inability to distinguish sub-ethnic groups within the South Asian 
population, despite evidence that risk behaviours vary greatly by religion and 
region of origin 53.  
 
It would appear that in South Asian populations at high risk for OSCC the same 
aetiological factors are implicated whether living in the UK or South Asia. A 
targeted screening programme based on the specific lifestyle risk factors, tobacco 
and areca nut usage, should logically be comparable between UK and South 
Asian populations, although the prevalence of OSCC is significantly lower in the 
UK. 
 
2-1.03  The South Asian Population in Tower Hamlets  
Tower Hamlets is an Inner London borough (Figure 2-01) and despite its central 
location in the capital city of England it is ranked as the third most deprived 
borough in England 54.  
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Figure 2-01: The London boroughs showing the Inner London position of Tower Hamlets. (Adapted 
from www.guardian.co.uk) 
 
 
Approximately 56% of the Tower Hamlets population are reported as ethnic 
groupings other than white British and one-third of the borough’s population is 
Bangladeshi (Figure 2-02). Totalling nearly 66000 this is the largest Bangladeshi 
community outside of Bangladesh 54. In comparison, out of the total population of 
England and Wales just 0.3% (159,500) is Bangladeshi 92. 
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Figure 2-02: 30% of the Tower Hamlets population is Bangladeshi. Adapted from 
www.towerhamlets.gov.uk and based on Office for National Statistics (2006) population estimates. 
 
 
Figure 2-03 shows the concentrated nature of the Bangladeshi population 
predominantly in Tower Hamlets although there is a smaller population in the 
adjacent borough of Newham to the east, which is ranked as the 6th most deprived 
borough of the UK 54. 
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Figure 2-03: Shows the concentrated nature of the Bangladeshi population within London with high 
proportion of Bangladeshi individuals, predominantly in the borough of Tower Hamlets. Adapted 
from www.guardian.co.uk based on 1991 Census data. 
 
 
 
This is markedly different to the distribution of other South Asian populations such 
as the Indian and the Pakistani groups in London (Figure 2-04) which are more 
dispersed and comparatively sparse in Tower Hamlets although there are 
significant populations in Newham. 
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Figure 2-04: The Indian and Pakistani populations in London. (Adapted from www.guardian.co.uk 
and based on 1991 Census data.) 
 
 
Within the borough of Tower Hamlets the Bangladeshi community is further 
concentrated to specific wards. These wards are shown in Figure 2-05, whilst 
Figure 2-06 shows the distribution of the Bangladeshi population to be most highly 
concentrated within the Whitechapel, Spitalfields and Banglatown, Bethnal Green 
South wards to the east of the borough and the Mile End East, Stepney Green and 
Limehouse wards in the centre of Tower Hamlets as well as the Bromley by Bow 
ward to the east.  
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Figure 2-05: The Inner London borough of Tower Hamlets comprises a number of geographically 
distinct wards. (Adapted from www.towerhamlets.gov.uk) 
 
 
 
Figure 2-06: Distribution of people of Bangladeshi origin in Tower Hamlets based on 1991 census 
data. (Adapted from www.nationalarchives.gov.uk)  
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Tower Hamlets is an ideal setting for conducting a screening project because it 
offers the opportunity to specifically target a large and relatively homogenous 
Bangladeshi South Asian community residing in a relatively small geographical 
area.    
 
2-1.04  Risk Factors for Oral Cancer 
In 2004 the annual Health Survey for England (HSE) focused on the health of 
minority ethnic groups 93. The sample was designed to yield additional interviews 
with members of minority ethnic groups, the largest of which is South Asian and 
comprises Indian, Pakistani and Bangladeshi 54. The Bangladeshi community, in 
particular, exhibits a high prevalence of a number of oral cancer risk factors, 
including smoking, chewing tobacco and chewing areca nut but not alcohol 
consumption when compared with the general adult population 88, 93. 40% of 
Bangladeshi men report being current smokers, compared to 24% of the general 
male population whilst Bangladeshi women are substantially less likely to report 
being current smokers compared to women from the general population (2% 
compared to 23%). Estimates of chewing tobacco or areca nut use range from 
16% of Bangladeshi women using paan with tobacco and 13% paan without 
tobacco 93 up to 48.5% of a sample of Bangladeshi women resident in Tower 
Hamlets using paan with tobacco 88.  
 
As expected the Bangladeshi community of Tower Hamlets shows significantly 
different OSCC risk factors from the UK population as a whole but comparable to 
other South Asian populations. Therefore, the outcomes of a screening 
programme in this population maybe better compared against reports of screening 
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undertaken on the Asian subcontinent than other UK trials particularly as 
screening programmes conducted in Bangladesh itself are not available in the 
literature.  
 
With a South Asian population of approximately 75,000 in Tower Hamlets 54 and a 
reported prevalence of OSCC approaching 20 per 100,000 in the South Asian 
population group 52 it would be likely that 15 OSCCs were present in the study 
population. A case-finding protocol targeting those individuals at highest risk would 
be expected to effectively detect these lesions with the need to only examine a 
small proportion of the total population. However there are many known factors 
which may interfere with the effectiveness of the screening programme.  
 
2-1.05  Uptake of Screening Services 
The models for screening evaluated by Speight et. al. (2006) 64 suggested that oral 
cancer screening by primary care general dental practitioners maybe the most 
cost-effective protocol. As with risk factors for OSCC the Tower Hamlets 
Bangladeshi population appears to be significantly different to the UK population 
as a whole. In a study of 158 Bangladeshi medical service users in Tower 
Hamlets, Pearson et. al. (2001) 94 showed that just 20% were regular dental 
attendees with another 13% having utilised an Emergency Dental Service in the 
past year and 25% having never visited a dentist 94. A variety of barriers to access 
have been postulated including language difficulties, a symptom orientated view of 
service and domestic isolation of women 95.  
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In the UK’s two national screening programmes, breast and cervical cancer, 
screening services are consistently poorly utilised by the UK South Asian 
population 96. Amongst all ethnic minority groups Bangladeshi’s were the least 
likely to have had any type of cancer screening with only 28% of eligible 
Bangladeshi women reported to have had a cervical smear 23. The main reasons 
reported for low uptake were a lack of knowledge about screening services, 
language barriers, inaccurate screening registers, including poor awareness of 
minority ethnic naming systems, all compounded for Asian women by extended 
visits to the Indian subcontinent and a lack of referral/recommendations by 
healthcare professionals 97. Studies attempting to improving the uptake rates are 
limited but personal visits have been shown to be more effective than posted 
leaflets 98 for cervical but not breast cancer screening 99, 100. Complex, multi-
strategies do consistently appear to improve uptake of cancer screening by ethnic 
minorities but are never cost-effective to undertake 101, 102. Additional interventions 
include practice receptionist training, follow up letters in various languages, offers 
of transport and health advocates on site.  
 
In conclusion, it appears that an OSCC screening strategy utilising existing 
primary care dental services is likely to be ineffective within the Tower Hamlets 
Bangladeshi high-risk population and a multi-strategy approach will be required to 
ensure adequate uptake.  
 
2-1.06  Protocols for Oral Cancer Screening in South Asia 
The Trivandrum Oral Cancer Screening Study 5 utilised a community based 
approach whereby screening was carried out in the subject’s home. Participants 
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were screened with minimal intrusion into their normal daily routine, as the highest 
risk population is unlikely to utilise existing care services, and this study achieved 
a 91% uptake rate. In the UK a number of procedural and legal issues could be 
envisaged with a similar protocol and other difficulties, such as language and 
cultural barriers, which may not be issues in the Asian subcontinent trial.  
 
2-1.07  The Practice of Dentistry 
There is a regulatory issue of utilising individuals without dental qualifications to 
undertake oral screening. A direct visual examination of the oral mucosa with the 
express intent of detecting OSCC would be construed as the ‘practice of dentistry’. 
The General Dental Council of the UK (www.gdc-uk.org) states “The Dentists Act 
1984 makes it a criminal offence for a person who is not a registered dentist or a 
registered dental care professional to practice dentistry, or hold themselves out - 
whether directly or by implication - as practicing or as being prepared to practice 
dentistry.” Therefore, registered dental practitioners who can take professional 
responsibility for their screening services, would be required in the UK. This has 
the secondary advantage of allowing screened subjects to be given personalised 
advice on their oral health but recruitment of dentists would necessarily incur 
higher cost than utilising other healthcare practitioners.     
 
2-1.08  Electoral Registers 
Use of electoral registers for sampling minority ethnic groups is known to be very 
expensive in terms of time and labour and in addition the completeness of the 
electoral register for minority ethnic groups has also been questioned 103. Pearson 
et. al. (2001) 94 when attempting to sample the Bangladeshi population reported 
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issues with Local Research Ethics Committee’s expressing concern about 
approaching subjects at home having gained information from other health 
resources such as medical practitioners. The implication being that only subjects 
responding to letters of invitation could be approached in their home. This would 
likely result in a very small and biased sample as studies with this methodology in 
Bangladeshi communities often have response rates as low as 17% 104. 
 
2-1.09  Language and Cultural Barriers 
Poor linguistic competence is a major barrier to access for the Tower Hamlets 
Bangladeshi population as only 27% of this population report they can understand 
English “well” or “fairly well” 105. Studies in the Bangladeshi population of Tower 
Hamlets have shown that Sylheti speaking interviewers are vital to improve uptake 
of services 94. Other measures that have been reported as useful to improve 
access include: materials developed and tested for specific cultural, ethnic, and 
linguistic groups; translation services including those of legally binding documents 
(e.g. consent forms), hospital signage, health education and public awareness 
materials and campaigns and ethnic media in languages other than English (e.g. 
television, radio, internet and newspapers) 97.  
 
Various aspects of culture can influence successful healthcare delivery to ethnic 
minority populations and this is likely to be a more persistent problem than 
language in highly transient populations such as the Bangladeshi community of 
Tower Hamlets. Cultural issues include: how illness, disease, and their causes are 
perceived; their behaviour in seeking health care and their attitudes toward 
healthcare providers as well as the views and values of those delivering health 
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care 97. Therefore, a screening programme targeting the Bangladeshi population 
needs to be culturally as well as linguistically competent. 
 
2-1.10  Summary 
Conventional models of targeted high-risk screening for oral cancer in the UK are 
unlikely to be suitable for the Bangladeshi population of Tower Hamlets due to the 
specific socio-economic and cultural risk factors prevalent within this population. 
We propose that a protocol specifically addressing these influences is required for 
an effective OSCC screening programme in this South Asian population. In 
addition, the assessment of outcomes of screening activity in the Tower Hamlets 
Bangladeshi population is better assessed against screening programmes 
undertaken in other South Asian populations than comparison to other UK studies.   
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2-2.01  DEVELOPMENT OF THE SCREENING PROTOCOL 
 
2-2.02  The Mobile Dental Unit 
In order to facilitate screening in the community the Tower Hamlets Primary Care 
Trust’s mobile dental unit was utilised. The mobile dental unit is a specially 
adapted van which has a fully functioning dental unit with chair and light powered 
by a diesel generator (Figure 2-07). 
 
  
Figure 2-07: The Tower Hamlets Primary Care Trust Mobile Dental Unit. External and internal 
images showing the fully functional, private and secure dental unit.  
 
 
This vehicle has been used within the Community Dental Service to provide 
routine dental services within the borough and appears to be a well accepted. It is 
a recommended means of improving access to dental services within the NHS as 
shown by Tower Hamlets Primary Care Trust’s own evaluation reports 106 although 
robust evidence for these claims is not available. In its implementation for OSCC 
screening the mobile dental unit would be the field base from which bilingual link 
workers would approach high-risk individuals and invite them for screening by the 
dentist. The dentist would remain on the mobile dental unit to utilise the reclining 
dental chair, dental light and mouth mirrors for accurate visual examination, aided 
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by the availability of dry gauze, ‘3 in 1’ air and water and the aspirator to wipe, 
wash or dry the mucosa as required. The privacy afforded by the mobile dental 
unit is required when assessing the patient’s complaints or relevant medical 
history and lifestyle risk factors. Cross infection control during examination could 
be maintained on the mobile dental unit at levels comparable with conventional 
dental clinics.   
 
2-2.03  The Community Advisory Group (CAG).  
To develop a delivery structure that is targeted but culturally appropriate as well as 
feasible, a Community Advisory Group was convened which comprised local 
stakeholders from Tower Hamlets Primary Care Trust (THPCT), Smoking 
Cessation and Dental Access teams; Barts and The London Cancer Services 
including Oral Medicine and Oral and Maxillofacial Surgery teams as well as 
practice nurses and patient and community representatives. This CAG had 
previously been involved in the ‘Bangaldeshi Stop Tobacco’ project developed in 
the Tower Hamlets area. The CAGs primary objective in the development of the 
screening protocol was to offer guidance on the promotion of oral cancer 
screening activity amongst the Bangladeshi community and the development of 
accompanying oral cancer awareness literature. Additionally, the CAG was 
involved in determining the screening locations of the mobile dental unit to 
maximise the number of high risk individuals assessed in the population. More 
formal qualitative research was conducted with the target population, by means of 
focus group discussions and key informant interviews, to further aid development 
of the oral cancer screening activity and accompanying literature. This was 
 95 
conducted by members of the Bangladeshi Stop Tobacco project in combination 
with their tobacco cessation small group and individual help sessions.   
 
2-2.04  Advertising and Promotion  
Information campaigns for oral cancer awareness have been evaluated in the 
literature with some evidence for leaflets leading to increased knowledge although 
predominantly in those of a higher educational level and younger age 107. News 
programs and TV campaigns show little improvement in awareness of oral cancer, 
at least in American populations 108. In Tower Hamlets, Sylheti is the regional 
variant of Bengali spoken by 98% of Bangladeshi people 105 but Sylheti does not 
have a written form of its own and Bengali is the language of literacy amongst this 
population and only 16% can read or write it 105. With the knowledge that multi-
strategy approaches consistently improve uptake of cancer screening by ethnic 
minorities 101, 102 promotion of the screening campaign and oral cancer awareness 
would involve specifically designed leaflets (Figure  2-08) as well as newspaper 
promotions and local radio advertising campaigns along with crucially timed 
announcements at the local mosques and community centres. 
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Figure 2-08: Cancer Research UK leaflet and poster in English and Bengali (from 
www.cancerresearchuk.org)
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2-2.05  Identification of Screening Sites  
The CAG was tasked with identifying sites where a significant number of high risk 
individuals would be approachable and the mobile dental unit could be sited. 
 
Figure 2-09: The sites in Tower Hamlets chosen for screening activity. 
(1) Watney Market, (2) East London Mosque, (3) Bethnal Green Road, (4) Brady Arts Centre, (5) 
Bromley By Bow Centre, (6) Asda, Isle of Dogs, (7) Mile End Leisure Centre and (8) Mile End Park. 
(Map adapted from www.bing.com). 
 
Figure 2-09 shows the locations chosen for their proximity to local facilities and 
travel routes. It was determined that most screening sessions should be in the 
wards with the highest proportion of Bangladeshi residents (Fig 2-06) therefore 
screening sites at Watney Market, The East London Mosque, Bethnal Green 
Road, Brady Arts Centre are in the western wards of Whitechapel, Spitalfields and 
Banglatown and Bethnal Green South. Mile End Leisure centre was chosen to 
target the populations of the central wards of Mile End East, Stepney Green and 
Limehouse whilst the Bromley by Bow location targeted the Bangladeshi 
population in the eastern ward of Bromley by Bow. It was suggested by the CAG 
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that although the available Census population data (Figure 2-06) didn’t support 
screening in the southern wards of Millwall and Blackwall and Cubitt Town on the 
Isle of Dogs these areas may now have significant Bangladeshi populations. Asda, 
Isle of Dogs was chosen as the location to target these individuals. Finally, a 
screening session at Mile End Park was required to target the northern wards of 
Tower Hamlets. Funding for 10 screening sessions was provided by Cancer 
Research UK based on the likely throughput of screened patients and relative 
density of high-risk Bangladeshi populations.  
 
2-2.06  Screening Criteria 
Oral cancer screening would involve a brief history to elicit any relevant presenting 
complaints or medical history followed by visual examination of the soft tissue of 
the oral cavity and oropharynx, and palpation of the neck for lymph node 
involvement. Screening would be conducted by registered dental practitioners 
recruited from the Community Dental Service in Tower Hamlets who had 
experience of dental treatment of the Tower Hamlets population. A refresher 
training session was provided to ensure compliance with the National Institute of 
Clinical Excellence guidelines on referral of suspected cancer 10 which determines 
a positive screen for OSCC to be: 
• An unexplained ulcer or lump in the mouth lasting more than three weeks 
• Unexplained red or white patches inside the mouth that are painful or swollen 
or bleeding. 
• Persistent undiagnosed symptoms in the mouth lasting longer than six weeks. 
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• An unexplained lump in the neck which has recently appeared or a lump which 
has not been diagnosed before that has changed over a period of three to six 
weeks. 
 
Minimal data collection on the individuals screened was attempted unless referral 
was indicated. This was a consensus decision of the CAG as it was felt that 
people were more likely to attend an anonymous drop-in service and the flow of 
patients would be quicker thereby removing some potential barriers to access in 
the Bangladeshi population. Preliminary data suggested that each patient could be 
screened in an average of 3 minutes but referrals would take significantly longer 
as the dentist would endeavour to reassure the patient and answer any questions 
to minimise anxiety during the wait for definitive ff. Data collection was approved 
by The East London and the City Research Ethics Committee and the Joint 
Research and Development Office of Bart’s and The London (REC 08/H0701/98). 
Data analysis utilised Excel 2003 (Microsoft, USA) with the StatPro add-on (Kelley 
School of Business, Indiana University). To allow for minimal data collection and 
anonymity all participants gave verbal and implied consent to take part in 
screening but written consent was obtained from those who needed and agreed to 
be referred.  
 
2-2.07  Development of Referral Pathways  
Screen positive individuals were referred directly from the mobile dental unit to the 
Department of Oral Medicine, Bart’s and the London Dental Institute for further 
investigation (Figure 2-10). The referral followed an urgent two-week referral 
pathway for suspected cancer and additional capacity was created on clinics 
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specifically for these referrals. Furthermore, individuals could also be referred 
directly to local stop tobacco services for cessation support. 
 
 
Figure 2-10: The referral form for suspected oral cancer directly from screening sessions to the 
Oral Medicine Unit at The Royal London Hospital.  
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2-2.08  Determination of Inclusion Criteria 
Individuals were actively recruited by the bilingual link workers at each screening 
site based on the proposed risk factors for oral cancer in South Asian populations:  
• Age 35 years or over 
• South Asian ethnic origin 
• Practising one or more of the risk behaviours of smoking or chewing tobacco, 
chewing areca nut compounds (paan) or alcohol usage.  
Individuals falling outside these inclusion criteria were not actively recruited by the 
link workers but were not excluded from screening if they wished to attend. 
 
 
2-2.09  The Delivery Process 
The targeted oral cancer screening of the Bangladeshi population of Tower 
Hamlets involved 10 screening sessions during 2006. The project and protocols 
were then to be evaluated against the literature on trials completed in South Asia 
and the UK.  
 
Screening was undertaken using a mobile dental unit which provided a clean, safe 
and confidential environment for examination of the illuminated oral mucosa in the 
supine position with the availability of all the instruments and amenities that would 
be present in a permanent dental clinic. Use of the mobile dental unit addressed 
all of the CAGs issues arising from pre-trial attempts at mucosal examination with 
portable equipment which included: inconsistent lighting intensity; patient 
confidentiality and modesty concerns; difficulty gaining adequate oral mucosal 
access in the upright position with associated concerns about examiners posture if 
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screening for an entire working day and lastly issues with maintaining appropriate 
levels of cross-infection control. 
 
Ensuring the cultural acceptability of the oral cancer screening activity was the role 
of bi-lingual (English/Sylheti) advocates with experience of health promotion 
activity in this community. In addition to providing language support they were 
involved in actively recruiting participants to the oral cancer screening sessions 
and onto tobacco cessation services. Advocates further facilitated the referral 
process and attended outpatient appointments at the secondary referral centre, if 
required. This ensured as many patients as possible complied with referral. 
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2-3.01  RESULTS  
In 2006 the oral cancer screening programme, targeting high risk individuals in the 
Bangladeshi community of Tower Hamlets, was commenced. A total of 10 
screening sessions were undertaken and each session was approximately seven 
hours in duration and undertaken between 0930 and 1630 with flexible break times 
dependent on the flow of patients.  
 
2-3.02  Numbers Screened 
In 10 screening sessions a total of 485 individuals were screened, an average of 
48 people per session, although this varied from 19 on the quietest session at 
Bromley by Bow to 82 on the busiest on Bethnal Green Road (Table 2-01). The 
Bromley by Bow sessions was also the only day on which the weather was wet 
and may have contributed to the scarcity of individuals recruited for screening.  
 
Table 2-01: Numbers screened and referred from each screening session. 
Screening Session Location Screened Referred Dentist 
2006 Wednesday 14th June  Brady Arts Centre 57 3 AL 
 Saturday 24th June  Asda, Isle of Dogs 68 0 AL 
 Friday 30th June East London Mosque 61 9 AR 
 Saturday 1st July Bethnal Green Road 82 2 AL 
 Saturday 15th July Mile End Leisure Centre 45 0 AL 
 Saturday 29th July Mile End Park 42 1 AL 
2007 Saturday 30th June East London Mosque 51 1 AL 
 Saturday 16th July Watney Market 27 4 AR 
 Wednesday 20th July Bromley By Bow Centre 19 0 AL 
 Saturday 23rd July Brady Arts Centre 33 0 DR 
  TOTAL 10 SESSIONS 485 20  
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2-3.03  Referrals to Secondary Care Services 
Of the 485 people screened 20 (4.1%) were referred with suspected cancer for 
further investigation (Table 2-01).  
 
2-3.04  Referrals by Screening Site 
Table 2-01 shows 3 screening sites yielded no referrals although 132 individuals 
were screened. One session at Brady Arts Centre also yielded no referrals despite 
33 screenings although the earlier session at this site by a different dentist 
screened 57 and referred 3 (Table 2-01). The Asda, Isle of Dogs site resulted in 68 
individuals screened but none referred. In contrast at the Watney Market site just 
27 were screened but 4 (15%) were referred. East London Mosque was visited on 
two occasions resulting in 112 screenings and 10 referrals (9%). Therefore, 50% 
of all referred patients were screened at the East London Mosque site but only 
22% of all screened individuals were seen at this location and 20% of referrals 
were from Watney market despite just 6% of all screenings being at this site 
(Figure 2-11). 
 
 
Figure 2-11: Proportion of individuals screened at each site (Total screenings 485) and percentage 
of referrals by screening site (Total 20 referrals). 
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2-3.05  Referrals by Dentist 
Dentist AR referred 13 (15%) of 88 screened at two sessions and Dentist AL, 
despite screening at seven sessions referred just seven (2%) of 364 individuals 
screened.  Dentist DR screened 33 in one session and none were referred (Figure 
2-12).  
 
  
  
Figure 2-12: Percentage of screened patients referred by Dentist. (Total 20 referrals). 
 
 
2-3.06  Outcomes of Referrals to Secondary Care Services 
Despite the involvement of the advocates in chasing referrals and offering to 
attend appointments with the positively screened individuals, six patients (30%) of 
the 20 referred failed to attend the secondary referral centre for definitive 
diagnosis (Table 2-02). Attempts were made to make contact with these 
individuals by both telephone and post and then by home visit. For ten of the 14 
referred patients were a definitive diagnosis was determined either following 
biopsy and histological examination (8 patients) or from clinical examination by the 
supervising Oral Medicine consultant where biopsy was not indicated (2 patients). 
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Table 2-02: Definitive diagnosis and outcome after referral to secondary care services of positively 
screened individuals. (DNA= did not attend secondary referral centre; *= definitive diagnosis 
confirmed by histology). Four diagnosed with potentially malignant disorders are highlighted. 
 
Patient Primary Diagnosis Outcome 
ALbra-1 oral submucous fibrosis* review 
ALbra-2 hyperkeratosis* review 
ALbra-3 mild/moderate dysplasia* review 
ARelm-1 DNA - 
ARelm-2 hyperkeratosis discharge 
ARelm-3 hyperkeratosis discharge 
ARelm-4 DNA - 
ARelm-5 hyperkeratosis discharge 
ARelm-6 hyperkeratosis* review 
ARelm-7 physiological pigmentation discharge 
ARelm-8 hyperkeratosis* review 
ARelm-9 DNA - 
ALbgr-1 mild/moderate dysplasia* review 
ALbgr-2 DNA - 
ALmep-1 DNA - 
ALelm-1 severe dysplasia* review 
ARwat-1 hyperkeratosis discharge 
ARwat-2 hyperkeratosis* discharge 
ARwat-3 DNA - 
ARwat-4 hyperkeratosis discharge 
 
 
2-3.07  Definitive Diagnosis 
Figure 2-13 shows the definitive diagnosis for the 14 screen positive referrals who 
attended the referral centre. There were no OSCC detected during this screening 
project however, three referred patients were diagnosed with dysplastic lesions 
one of which was severe dysplasia and the others mild/moderate dysplasia. In 
view of the associated risk factors these lesions were surgically excised and the 
patients remain under review as well as being referred to ancillary services to aid 
tobacco/paan cessation. 
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Figure 2-13: Definitive diagnosis for 14 positively screened patients attending the secondary care 
centre. 
 
 
One referred patient was diagnosed with the potentially malignant mucosal 
disorder OSF and remains under review for evidence of malignant change as well 
as being helped to reduce tobacco and paan usage. In total four out of 14 (28.6%) 
of the positive screened patients were diagnosed with PMDs (Figure 2-14).   
 
 
 
Figure 2.-14: Potentially malignant disorders (PMDs) and benign lesions within the positively 
screened population who attended for biopsy. (Total 14)  
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Of the 14 positively screened patients who attended the secondary referral centre, 
eight (57%) underwent scalpel biopsy and histological examination. The other 6 
were diagnosed clinically by the Oral Medicine specialist as benign lesions with no 
indication for histological evaluation (Figure 2-15).  
 
 
Figure 2-15: Method of achieving the definitive diagnosis for screen positive individuals at the 
tertiary referral centre. (Total 14) 
 
These latter six were also able to be discharged from further follow-up along with 
one of the biopsy patients diagnosed with hyperkeratosis. Ten patients were 
diagnosed with benign lesions, nine of which were hyperkeratosis and the other 
presenting with physiological pigmentation. However, of these 10 patients with 
confirmed benign lesions only seven with minimal risk factors and access to 
appropriate follow-up within primary dental care services, were able to be 
discharged from further review in the Department of Oral Medicine. Therefore, 
seven out of 14 (50%) of positively screened individuals who attended for 
diagnosis remain under review at one year after the last screening session (Figure 
2-16). 
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Figure 2-16: Outcome of referral for the positively screened population who attended the 
secondary referral centre at 1 year after the last screening session. (Total 14).   
 
 
Two of the four patients diagnosed with PMDs were screened at Brady Arts centre 
with the others at East London Mosque and Bethnal Green Road respectively. 
 
Figure 2-17: The proportion of all referred patients with lesions diagnosed as PMDs by referring 
dentist. 
 
Dentist AL referred seven individuals in total of which five attended the secondary 
referral centre and were sent for biopsy. Four of these five (80%) were diagnosed 
with potentially malignant disorders. Dentist AR referred 13 in total of which nine 
attended and three underwent a biopsy but all were diagnosed with benign lesions 
(Table 2-02 and Figure 2-17). 
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2-4.01  DISCUSSION 
Of the 435 people screened in ten sessions, 20 (4.1%) were referred for further 
investigation of suspicious lesions. This referral rate is broadly consistent with that 
reported in previous oral cancer screening initiatives 62, 109 and in particular is of 
the same order of magnitude as the 5.9% referral rate reported in the Trivandrum 
Oral Cancer Screening Study 5. This would suggest the screening protocol overall 
is comparable to other programmes in the published literature.  
 
2-4.02  Gold Standard Outcomes 
Despite 435 individual screenings of a high risk population for oral cancer there 
were no cases of OSCC detected. Therefore, it is impossible to assess the results 
on the basis of the ideal gold standard for one-off oral cancer screening 
programmes, which is histologically confirmed OSCC. The fact that 6 (30%) of the 
20 individuals referred to the secondary referral centre did not attend for further 
investigation of their suspicious oral mucosal lesions makes assessment of a gold 
standard outcome even less accurate. However, there are also insurmountable 
ethical issues in obtaining the true sensitivity of a screening process by histological 
gold standard because all screened individuals theoretically need a biopsy for 
histological diagnosis confirming either OSCC or not. Simply determining a 
histological diagnosis for all referred lesions only, would be ethically more 
acceptable but risks introducing verification bias. For this reason most studies 
determine screening success by some form of ‘soft’ gold standard such as the 
number of positively screened individuals or the proportion subsequently 
diagnosed (either clinically or histologically) with PMDs or OSCC 109. 
 111 
2-4.03  Evaluation of Clinical Outcomes 
Utilisation of the soft gold standard outcome of a PMD diagnosis with the 14 
patients who attended for definitive diagnosis yields a PPV of 28.6% (4 true 
positives out of 14). As these individuals present with significant risk factors for 
OSCC this may be regarded as a more suitable gold standard for screening 
outcomes than simply being referred to the secondary care centre, thereby 
eliminating those referred with benign lesions. This position has further 
advantages in that some severe dysplastic lesions in these high-risk populations 
are likely to be managed in the same manner as a small primary OSCC without 
nodal spread or metastases i.e. a T1N0M0 malignancy. These lesions are either 
excised during the biopsy process or surgically or laser ablated if more 
widespread. The patient would then remain under regular review with efforts made 
to educate and minimise associated risk factors. Further biopsies are required 
whenever the mucosal appearance changes to catch any malignant transformation 
early.  
 
2-4.04  Referral Compliance  
Only 14 (70%) of the 20 individuals referred to the secondary referral centre 
attended for further investigation of their suspicious oral mucosal lesions. This was 
despite the best efforts of the advocates to phone and visit the positively screened 
individuals as well as offering to attend at their hospital appointment. Reasons for 
non-attendance were investigated in patients who initially refused to comply with 
referral but subsequently did attend. Causes for initial non-attendance included 
language barriers, non-receipt of appointment letters and difficulty attending the 
hospital. This indicates that the model of screening, in a community setting with 
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ethnically-matched advocates was able to overcome some specific barriers to 
access that still exist in the hospital. However, there is significant room for further 
improvement in compliance with referrals. Overall, the compliance rate is 
comparable to the 63% referral compliance reported in the Trivandrum Oral 
Cancer Screening Study 5 . In contrast, screening programmes in the UK usually 
report very high levels of compliance, approaching 100% 62. This suggests that the 
Tower Hamlets Bangladeshi population is behaving more akin their South Asian 
peers when responding to oral cancer screening and supports the notion that 
studies in these populations are more comparable than studies in UK populations. 
 
2-4.05  Potential for Inter-Examiner Variability 
Although inter-examiner correlation was not directly assessed in the protocol the 
differences in referral rate indicates a potential for significant variability. Dentist AL 
referred 1.9% of screened individuals and 80% of these were subsequently 
diagnosed with potentially malignant lesions whilst dentist AR referred 14.8% of 
screened individuals, of which, all who complied with referral were diagnosed with 
benign lesions. This could be due to the different populations screened on different 
days and at different sites but qualitative post-screening evaluation indicated this 
was also due to difficulty in diagnosing mucosal lesions in people who chew areca 
and tobacco products, where the mucosa is heavily stained. Additionally, there is 
ambiguity within the NICE guidelines on referral of suspected malignancy and in 
particular the one-off nature of screening does not allow for lesions to be observed 
before referral, as is possible in other primary dental care settings. This variability 
is consistent with the literature on screening sensitivity, which reflects the 
examiners ability to make a correct positive diagnosis, and values in the range 
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0.60-0.95 have been reported with a weighted pool average of 0.80 109. 
Additionally, this variability is most pronounced for the type of PMDs detected in 
this study with larger oral cancers more easily diagnosed 110. The suggestion is 
that inter-examiner variability in this population could be reduced by utilising 
dentists with more specific experience of managing patients with paan-related 
mucositis. Ideally, the levels of inter-examiner variability need to be assessed 
quantitatively by a protocol whereby all dentists assess the same patient 
independently in a blinded manner.  
 
2-4.06  Screening Site and Screening Effectiveness 
There was considerable difference in the proportion of referrals coming from each 
screening site. The screening session on the Isle of Dogs proved very popular with 
68 individuals being screened however there were no referrals and it was noted 
that there were relatively fewer high-risk individuals assessed in comparison to 
other sites such as the East London Mosque and Watney Market. These latter 
sites are in the areas of highest Bangladeshi population whilst the Isle of Dogs 
was included at the request of the CAG in the interest of equality (Figure 2-06). 
Whilst on site at the Isle of Dogs the mobile dental unit was parked in a 
supermarket car park and the screening team were routinely approached by 
families and younger people requesting a screening with proportionally fewer high-
risk individuals to be actively targeted. In comparison, the East London Mosque 
site is just outside one the UK’s largest Mosque’s where over 5000 worshippers 
can be simultaneously accommodated for congregation and prayers. The Brady 
Arts Centre site was similarly situated in an area if high Bangladeshi population 
density and in close proximity to another Bangladeshi centre of worship. Other 
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sites at which proportionally more individuals were referred included Bethnal 
Green Road and Watney Market both busy high street shopping districts and 
again in the wards of Tower Hamlets with highest Bangladeshi population density. 
From this it can be suggested that the most productive sites for screening were 
both in the areas of highest Bangladeshi population and in close proximity to 
regularly utilised amenities such as worship sites and shopping facilities. At other 
sites significant numbers of individuals maybe screened but relatively few will be 
high-risk. At these sites the unquantifiable secondary benefits of increasing 
awareness of oral cancer, that maybe associated with a community based 
screening programme, are likely to be the main benefit. 
 
2-4.07  Minimal Data Collection 
Minimal data collection on the individuals screened was attempted unless referral 
was indicated. This was a consensus decision of the CAG as it was felt that 
people were more likely to attend an anonymous ‘drop-in’ service and the flow of 
patients would be quicker thereby removing some potential barriers to access for 
the Bangladeshi population. Preliminary data suggested that each patient could be 
screened in an average of 3 minutes but referrals would take significantly longer 
whilst the dentist informed and reassured the patient and answered any questions 
in order to minimise anxiety. On the busiest session, with an average 6 hours of 
active screening, 82 patients were screened indicating each screening lasted 
approximately 4 minutes taking into account that on this occasion 2 patients were 
referred. Experience from the screening sessions indicated that at busy sites 
patients were kept waiting for considerably longer than four minutes but the 
bilingual advocates attempted to either convince high-risk individuals to wait or 
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return at other times on the same day. If asked to attend other sessions they were 
also asked to bring along any high-risk friends or relatives who may also wish to 
be screened. It was not possible to quantify how many patients re-attended or 
even if patients were screened on more than one occasion due to the paucity of 
data collected. 
 
As no individuals refused to answer questions about their risk habits to the dentist 
when assessing risk profile it would appear feasible to collect this data without 
interfering with the consultation time or discouraging patients. The dentist could 
also complete a simple mouth map of oral mucosal lesions observed, whether 
requiring referral or not. This would provide evidence of the proportion of 
individuals with mucosal abnormality screened at each session and allow for inter-
examiner variability quantification. 
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2.5.01  CONCLUSION 
The screening outcomes we achieved suggest that a community based screening 
approach is viable within the Tower Hamlets population. Analysing the soft gold 
standards of (a) numbers of positive screened individuals and (b) numbers of 
PMDs diagnosed suggests that this protocol is comparable to other programmes 
in the published literature. Because of the predominantly South Asian population 
screened, the outcomes are better modelled against screening programmes from 
the Asian subcontinent due to their specific cultural and lifestyle risk factors for 
OSCC. The screening protocol could be improved by more extensive data 
collection without creating barriers to access and by focussing on sites of highest 
footfall in the areas of highest proportion Bangladeshi population.  
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Chapter 3 
 
 
Evaluation of a Targeted High-Risk Screening Programme for 
Oral Cancer in Tower Hamlets and Newham 
 
 
 
3-1.01  INTRODUCTION 
Evaluation of the outcomes of the ten session pilot screening programme in Tower 
Hamlets during 2006 was encouraging. In addition to the 4 PMDs detected in high-
risk individuals there was some indication that screening in the community 
accessed individuals that would not conventionally utilise healthcare services. This 
was most directly from asking those that initially failed to attend their referral 
appointment at the secondary care centre but were eventually convinced to do so. 
The fact that six positively screened individuals never attended the hospital may 
also indicate some barriers to access for this service that the mobile dental 
screening was able to overcome. In addition, the oral cancer awareness 
programme in conjunction with the screening sessions was very well accepted as 
reported by community representatives in the CAG. In particular, they commented 
on the targeting of lifestyle factors specific to the Tower Hamlets Bangladeshi 
population e.g. paan supari, in a manner comprehensible to this population as 
paan usage is an integral ritual, tradition and culture of Bangladeshi society. This 
is consistent with the available data on minority ethnic group’s utilisation of cancer 
services where direct methods of user involvement are preferred 111. 
 
Evaluation of the screening protocol revealed several areas where development 
could significantly improve the programme such as data collection, the referral 
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process and screening site allocation. Therefore, an optimised ‘Phase II’ screening 
protocol was developed with the CAG stakeholders and additional funding 
allocated for implementation.   
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3-2.01  DEVELOPMENT OF AN ENHANCED SCREENING PROTOCOL 
 
3-2.02  Identification of Phase II Screening Sites in Tower Hamlets 
Twenty four further screening sessions were planned in Tower Hamlets. The 
original ten screening sessions were fairly evenly divided between the wards in 
Tower Hamlets, with exact locations of the mobile dental unit based on advice 
from the CAG using census data and local knowledge. 
 
Figure 3-01: Phase II screening sites in Tower Hamlets. (1) Watney Market, (2) East London 
Mosque, (3) Bethnal Green Road, (4) Brady Arts Centre, (5) Spitalfields Practice, (6) Stroudley 
Walk, (7) Shahajalal Mosque, (8) Wapping Bangladeshi Association, (9) Bethnal Green Library, 
(10) Stebon Primary School, (11) Collingwood Estate One, (12) Aden House Womens Association, 
(13) Whitechapel Sports Centre, (14) Lifra Hall, (15) Redcoat Community Centre, (16) Globe Town 
Market. (Map adapted from www.bing.com.) 
 
 
Evaluation of the outcomes of screening suggested that the most productive sites 
were in the areas of highest Bangladeshi population and in close proximity to 
regularly utilised amenities such as worship and shopping facilities. Phase II 
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screening sites were chosen, in conjunction with the CAG, with this information in 
mind and less emphasis on distributing screening sites evenly around the 
borough. Figure 3-01 shows the new locations clustered around the most 
productive previous sites of Watney Market, East London Mosque, Bethnal Green 
Road and Brady Arts Centre with their proximity to local facilities and travel routes 
within the areas of highest Bangladeshi population. The Asda Isle of Dogs site was 
abandoned (Figure 2-09) and not replaced with a new venue in the proximity. A 
new location at Shahajalal Mosque in the St Katharine’s and Wapping ward was 
chosen because of the activity of the local Bangladeshi association as a meeting 
point for elders. Unfortunately, it was not possible to use the Mile End Park site 
due to temporary parking restrictions for the Mobile Dental Unit during the planned 
screening activity time so a nearby alternative was chosen at Globe Town Market 
to target the North Eastern wards of Tower Hamlets. 
 
3-2.03  Screening in Newham 
In addition to Phase II screening sessions in the borough of Tower Hamlets, five 
sessions were to be carried out in the neighbouring borough of Newham (Figure 3-
02) because of the known similarities in cultural and socioeconomic risk factors for 
oral cancer amongst the Newham population. Figure 2-03 shows the high 
proportion of Bangladeshi’s in the population of specific areas of Newham, as 
occurs in Tower Hamlets. However, there are significant differences in the ethnic 
mix in comparison to Tower Hamlets because Newham also has high proportions 
of Indian and Pakistani individuals (Figure 2-04). 
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Figure 3-02: The London boroughs showing the adjacent position of Newham to Tower Hamlets. 
(Adapted from www.guardian.co.uk)  
 
 
Newham is also the 6th most socio-economically deprived borough in England 54. 
Therefore, whilst Tower Hamlets provides a relatively homogenous Bangladeshi 
population in which to target OSCC screening activity, Newham potentially allows 
evaluation of the strategy in a more diverse South Asian population. The local 
advertising campaign and oral cancer awareness programme was conducted in 
Punjabi and Hindi as well as Sylheti to target the Indian and Pakistani populations 
in addition to the Bangladeshi. Punjabi is the most commonly understood 
language of the Pakistani population and Hindi for the Indian population of the UK 
54
. The link workers recruited specifically for the Newham project were fortunately, 
and as is common amongst many speakers of these languages, able to converse 
in both Punjabi and Hindi. 
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3-2.04  Identification of Screening Sites in Newham 
Five sessions were planned in the borough of Newham and a separate CAG was 
convened, again comprising local stakeholders from the PCT, Smoking Cessation 
and Dental Access teams, Barts and The London Cancer Services, Oral Medicine 
and Oral and Maxillofacial Surgery teams, community organisations and patient 
representatives. It was determined the most appropriate locations in the borough 
centred on the Green Street shopping precinct due to the high volume of passing 
individuals, proximity to travel services and the ability to station a mobile dental 
unit. The locations at the north, central and south ends of Green Street market are 
shown in Figure 3-03.  
 
    
 
 
Figure 3-03: The sites in Newham chosen for screening activity. (1) Shaftesbury Road, (2) Green 
Street (South), (3) Green Street Market. (Map adapted from www.bing.com). 
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3-2.05  Roles of the Bilingual Advocate 
The most concerning issue from the 2006 screening activity in Tower Hamlets was 
the non-compliance of six (out of 20) individuals screened positive with referral to 
the secondary care centre for definitive diagnosis. The bilingual advocate’s 
primary role was to provide language support during screening sessions and to 
follow up the referral process. In Phase II, the advocates had a more integral role 
in the delivery process, before, during and after the screening sessions. They were 
more involved in actively recruiting participants to the oral cancer screening 
sessions and onto tobacco cessation services. Advocates attended screening 
sites in advance to advise local people of the upcoming screening activity 
particularly in local community associations. Advocates further facilitated the 
referral process and kept in contact with individual patients including attending 
outpatient appointments at the secondary referral centre. The intention was to 
eliminate drop-out of positively screened individuals before definitive diagnosis at 
the secondary referral centre. The time-lag for a referral appointment was less 
than 2 weeks because of specific capacity created on the Oral Medicine clinics for 
positively screened individuals from each session.  
 
3-2.06  Dentist Calibration 
Despite the small sample size, there was apparent variability in the numbers of 
screened patients being referred by each dentist confirmed by their expressions of 
difficulty in determining which lesions to refer. The literature suggests that 
sensitivity and specificity of visual screening for OSCC is unaffected by who is 
undertaking the screening 109 and although it would be disingenuous to calculate 
sensitivity and specificity values from our results, even with the soft gold 
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standards, this was not our qualitative experience. This maybe due to the 
specificities of the Tower Hamlets population with the difficulties of assessing paan 
users who routinely have significant paan associated mucositis and red-brown 
staining of the mucosa with whiter hyperkeratotic areas (Figure 3-04).  
 
 
 
Figure 3-04: The reddish-brown staining and whiter keratotic areas of buccal mucosa and teeth 
associated with paan usage, characteristic of the Tower Hamlets population. (From: Norton (1998) 
14)  
 
 
Within our small sample, dentists with more experience of managing these oral 
mucosal lesions (OMLs) were less likely to refer screened individuals and upon 
referral the patient was more likely to need a biopsy. Studies around the world 
have repeatedly shown that dentist’s knowledge of oral cancer is inconsistent 
suggesting their discriminative ability in assessment of OMLs maybe variable even 
if detection of OSCC is more consistent 112-115. This would suggest that inter-
examiner variability could be reduced by utilising fewer dentists and clinicians with 
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more specific experience of managing patients with paan-related staining. 
Therefore for Phase II, two dentists with specific interest and experience of 
managing patients with oral mucosal disease were recruited. A more robust 
standardisation and calibration process was developed utilising the WHO ‘blue 
book’ Pathology and Genetics of Tumours of the Head and Neck 21. It was agreed 
that the fast track referral was only suitable for lesions requiring urgent biopsy i.e. 
frank OSCC or erythroplakia or non-healing ulcers at a high risk site. Other 
common oral mucosal findings such paan-associated-mucositis or hyperkeratosis 
would not be referred unless there was another specific lesion of concern. These 
patient’s would however be advised to reduce their risk factors and seek regular 
check-ups at their own dentist and especially if symptoms developed. If required 
they were to be referred via a routine referral route onto the Oral Medicine clinics.   
 
3-2.07  Quantification of Inter-Examiner Variability 
To quantify levels of inter-examiner variability during screening, DMFT was used 
as a suitably quick and objective oral assessment which can be completed 
independently in a blinded manner on the same patient during the same screening 
session. DMFT describes the prevalence of dental caries in an individual and is 
obtained by calculating the number of Decayed (D), Missing (M) and Filled (F) 
Teeth (T) in an individual. This is an objective measure of dental disease with well 
defined diagnostic criteria that have been used by over 130 health administrations 
throughout the world and has a proven capacity to yield reliable, useful, and 
internationally comparable data on oral health status 116. Based on experience of 
dentistry in this population and WHO best practice recommendations the DMFT 
diagnostic criteria utilised in this study were: 
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-  Maximum DMFT is 32 as all four wisdom teeth are included in the charting to prevent 
inconsistency due to the common scenario of lost first and second molars leaving just 
the third molars which may then be mis-charted as second molars. 
-  If a tooth has both a caries lesion and a filling it is calculated as D only. 
-  Incipient (non-cavitated) carious lesions were not charted as D. 
 
All patients seen in 3 one hour blocks at three separate screening sessions were 
independently assessed by both screening dentists for DMFT. As this does not 
give any reliable information on the clinician’s ability to assess for OSCC the 
presence of OMLs was also recorded in a blinded manner for these patients. 
 
3-2.08  Patient Information Collection 
From the 2006 screening programme it was determined that patient data collection 
was unlikely to prevent or discourage individuals from attending for screening. 
More extensive data collection would primarily aid in assessing the accuracy of 
screening activity in targeting high-risk individuals. The biggest risk appeared to be 
in extending the time taken for each individual screening as the busiest sessions 
already resulted in patients waiting or being asked to return at another session.  
 
Demographic details were to be collected from all patients screened if they were 
willing to give this information. Screening would not be denied if a participant did 
not wish to give their details. Patient details necessary to provide evidence of high 
risk status were: age, nationality, gender and risk habits (tobacco or areca nut 
consumption or alcohol usage). This is unlikely to add to screening session time 
because this information would routinely be obtained verbally as part of the OSCC 
risk profile determination by the dentist during the screening. In the interests of 
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brevity, information on other factors potentially linked to OSCC, such as education 
level and socioeconomic status, which would require validated questionnaires to 
elucidate accurately, were not attempted by the screening dentists. Additionally, 
no specific attempt was to be made to determine the constituents of paan i.e. 
whether tobacco was included, unless referring a screen positive individual. 
Similarly with smoking, quantification would not be required (numbers of pack 
years, ounces of tobacco etc) for every patient.  
 
Experience from screening in Tower Hamlets indicated that a significant proportion 
of people examined had pre-existing OMLs, although not necessarily PMDs. The 
clinical diagnosis, or description if diagnosis was unknown, of all OMLs was to be 
recorded whether referred or not. This was facilitated by developing a list of clinical 
diagnosis agreed between the screening dentists and reviewed as necessary 
throughout the programme. OSCC predominantly develops at specific sites in the 
mouth suggesting that OMLs at different sites carry different risks of malignant 
conversion, therefore the site of lesions was recorded on a mouth map to 
determine the proportion of OMLs at high risk sites. Chapter 4 provides more 
specific details of OML recording in the screened population.    
 
Data collection was approved by The East London and the City Research Ethics 
Committee and the Joint Research and Development Office of Bart’s and The 
London (REC 08/H0701/98). Data analysis utilised Excel 2003 (Microsoft, USA) 
with the StatPro add-on (Kelley School of Business, Indiana University) and 
STATA 10 (StataCorp LP, Texas, USA). To allow for anonymity all participants 
initially gave verbal and implied consent to take part in screening but written 
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consent was obtained for recording of patient related data for all screened 
patients, if they agreed for data to be recorded. Refusing to participate in the data 
collection exercise did not prevent patients from being screened or referred. No 
attempt was made to elicit why participants may not wish to allow recording of their 
data. 
 
3-2.09  Inclusion Criteria 
The criteria used successfully in 2006 were implemented again, where individuals 
were actively recruited by link workers based on the proposed risk factors for oral 
cancer in South Asian populations:  
• Age 35 years or over 
• South Asian ethnic origin 
• Practising one or more of the risk behaviours of smoking or chewing tobacco, 
chewing areca nut compounds (paan) or alcohol usage.  
Individuals falling outside these inclusion criteria were not actively recruited by the 
link workers but were not excluded from screening if they wished to attend. 
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3-3.01  RESULTS 
In 2008 the Phase II oral cancer screening programme, targeting high-risk 
individuals in the Bangladeshi community of Tower Hamlets, was commenced. A 
total of 24 screening sessions were undertaken and each session was 
approximately seven hours in duration and undertaken between 0930 and 1630 
with flexible break times dependent on the flow of patients. A similar protocol was 
undertaken in the neighbouring borough of Newham with five screening sessions 
targeting high-risk individuals in Newham’s more diverse South Asian population. 
These sessions were approximately 8 hours in duration from 0930-1700 due to the 
extra availability of Newham’s mobile dental unit. 
 
3-3.02  Numbers Screened 
In total 835 people were screened during the 24 sessions held in Tower Hamlets, 
an average of 35 per session, with a range from 12 to 47 with the busiest site on 
Bethnal Green Road, as in the 2006 screening programme (Table 3-01). The five 
Newham sessions yielded an average of 55 people screened per session and 276 
screened in total with a range of 24 to 76 individuals (Table 3-02). Five sessions 
suffered significant inclement weather which may have directly affected screening 
numbers, these were: 
 Green Street (South) in Newham on Friday 21st March,  
 Spitalfields Practice on Wednesday 9th April, 
 Wapping Bangladeshi Association on Saturday 19th April  
 Redcoat Community Centre on Friday 23rd May 
 Globe Town Market on Monday 26th May  
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Table 3-01: Numbers screened and referred from each screening session in Tower Hamlets 
Screening Session Location Screened Referred Dentist 
2008 Wednesday 26th March East London Mosque 42 4 AL 
  Monday 31st March Watney Market 41 5 NS 
  Wednesday 2nd April Bethnal Green Road 43 6 AL 
  Saturday 5th April Stroudley Walk Centre 40 3 AL 
  Monday 7th April Spitalfields Practice 37 8 NS 
  Wednesday 9th April Spitalfields Practice 21 3 AL 
  Monday 14th April Shahajalal Mosque 35 3 NS 
  Wednesday 16th April  Wapping Bangladeshi Association 34 2 AL 
  Saturday 19th April  Wapping Bangladeshi Association 21 0 AL 
  Wednesday 23rd April Bethnal Green Library 36 2 AL 
  Friday 25th April Stebon Primary School 40 1 AL 
  Monday 28th April Brady Arts Centre 47 4 NS 
  Wednesday 30th April Collingwood Estate Club 15 2 AL 
  Saturday 3rd May Aden House Women’s Association 12 1 AL 
  Monday 5th May Bethnal Green Road 47 1 NS 
  Wednesday 7th May Whitechapel Sports Centre 46 1 AL 
  Monday 12th May Bethnal Green Road 43 0 NS 
  Wednesday 14th May Lifra Hall 42 2 AL 
  Saturday 17th May East London Mosque 46 1 AL 
  Monday 19th May  Watney Market 31 0 NS 
  Wednesday 21st May East London Mosque 41 2 AL 
  Friday 23rd May Redcoat Community Centre 22 1 AL 
  Monday 26th May Globe Town Market 20 1 NS 
  Wednesday 28th May  Whitechapel Sports Centre 33 2 AL 
   TOTAL 24 SESSIONS 835 55   
 
 
 
Table 3-02: Numbers screened and referred from the screening sessions in Newham. 
 
Screening Session Location Screened Referred Dentist 
2008 Friday 21st March Green Street (South) 24 1 AL 
  Saturday 22nd March Green Street Market 64 5 AL 
  Sunday 30th March Green Street Market 41 2 NS 
  Saturday 26th July Shaftesbury Road 71 1 AL 
  Sunday 27th July Shaftesbury Road 76 2 AL 
  TOTAL 5 SESSIONS 276 11  
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3-3.03  Patient Data 
Data recording was completed for all 1111 screened participants in Newham and 
Tower Hamlets. Despite the similarities in screening protocols (inclusion criteria, 
advertising, staff etc.) the populations screened in Tower Hamlets and Newham 
markedly differ in aspects of their demographics and more importantly their risk 
factors for OSCC (Table 3-03). This suggests these differences are predominantly 
inherent socioeconomic and cultural properties of the populations screened. 
 
Table 3-03: Demographics and risk factors for the screened population compared to the referred 
population in Tower Hamlets and Newham.(* student t test, ^ chi-squared) 
 
Tower Hamlets Newham 
 Screened Referred Screened Referred 
Number of people 835 55 
  
  276 11  
Age in years - mean (SD) 42.3 (15.9) 52.0 (14.1) p<0.05* 38.9 (12.4) 49.9 (15.1) p<0.05* 
Gender mix - M:F 55:45 36:64 p<0.05^ 67:33 64:36 p=0.53^ 
   
Bangladeshi 84% 96% P<0.05^ 27% 64% P<0.05^ Ethnicity -   
Other South Asian 7% 0% P<0.05^ 39% 27% P<0.05^ 
   
Smoking 44% 40% p=0.41^ 37% 55% P<0.05^ 
Paan (+/- tobacco) 58% 95% P<0.05^ 21% 64% P<0.05^ Risk Factors - 
Alcohol 12% 7% p=0.05^ 31% 45% P<0.05^ 
 
 
3-3.04  Age of the Screened Population 
The standard deviation of the mean age for both Tower Hamlets and Newham 
screened populations, includes the under 35 age group, suggesting a significant 
proportion screened were younger patients (Table 3-03). It could be accepted that 
older individuals are less likely to attend a chance screening on a mobile dental 
unit if access was difficult but some of the screening sites chosen in Tower 
Hamlets were specifically targeting older people who use day centres, where the 
staff were actively involved in recruiting those at high-risk. Despite the clear 
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overlap in age ranges between the screened population in Tower Hamlets and 
Newham shown by the descriptive standard deviation data the means of the two 
groups were significantly different (p=0.0052) suggesting that the targeting of older 
people in Tower Hamlets was effective. The referred sub-populations were also 
significantly older than the general screened population in both Tower Hamlets 
and Newham (Table 3-03), which is consistent with age being a known risk factor 
for OSCC. The Trivandrum Oral Cancer Screening Study 5 reported mean ages of 
the screened population to be about 49 years, similar to the referred populations 
here. 
 
3-3.05  Gender of the Screened Population 
In Tower Hamlets the male to female ratio was 55:45 and considerably more even 
than Newham (67:33) (Table 3-03). Some sites in Tower Hamlets were specifically 
targeting females e.g. Aden House Women’s Association and one of the sessions 
at Spitalfields practice where 100% of those screened were female. Newham 
screening was on a busy high-street with no specific attempt to target women so 
the 67% male predominance suggests that in this population, men’s uptake of 
screening services is significantly greater than women’s, which is consistent with 
the literature 97. However, this effect appears to be effectively compensated for by 
specifically targeting women in the Tower Hamlets screening protocol. The 
referred population consisted of significantly more women in the Tower Hamlets 
group than the screened population whilst the Newham referred and screened 
population gender mix was equivalent. 
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3-3.06  Ethnicity of the Screened Population 
Census data shows the ethnic make-up of Tower Hamlets and Newham boroughs 
is substantially different, with a more homogenous South Asian population of 
predominantly Bangladeshi origin in Tower Hamlets. Whereas, the South Asian 
population in Newham has a much higher proportion of Indian’s and Pakistani’s in 
addition to Bangaldeshi (Figure 2-04). This was evident in the screened 
populations with Tower hamlets comprising 84% Bangladeshi and just 7% of the 
other South Asian groups making a total of 91% of South Asian origin. In Newham, 
just 27% of those screened were Bangladeshi whilst 39% were other South Asian 
groups, giving 66% in total of South Asian origin (Table 3-03). Location of the 
mobile unit is likely to be a major cause of this difference as many Tower Hamlets 
sites were closely associated with community facilities utilised specifically by 
South Asian populations e.g. the East London Mosque. In contrast, the Newham 
screening sites were all in the borough’s main shopping precinct and therefore the 
screened population would be more likely to represent the overall population. The 
referred population was again significantly different to the screened people in both 
Tower Hamlets and Newham with a higher proportion of Bangladeshi individuals 
referred than screened. 
 
3-3.07  Reported Risk Factors 
Each screened patient was specifically asked if they indulged in any of three risk 
factors for OSCC which were smoking, paan usage and alcohol consumption. The 
finding that 58% of the Tower Hamlets group use paan (Table 3-03) indicates the 
effectiveness of specifically targeting this clearly visible risk factor in this 
population where the prevalence of paan usage has been variably reported as 
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between 13 to 48.5% 88, 93. However, just 21% of the Newham cohort were paan 
users, presumably related again to the screening locations. Approximately, two 
fifths of both populations were smokers but alcohol use was reportedly much 
higher in the Newham group (31% compared to 12%) indicative of the ethnic mix 
where alcohol is not a significant risk factors amongst the Bangladeshi population 
specifically 88. Overall the demographic and risk factor descriptive data would 
suggest the screening activity was extremely successful at targeting the high-risk 
paan using population in Tower Hamlets. This is reinforced by 95% of referred 
individuals using paan, which is significantly higher than the general screened 
population in Tower Hamlets although the levels of alcohol and smoking in the two 
groups were equivalent. In contrast, the Newham referred population were 
significantly more likely to use both paan and alcohol as well as smoke than the 
whole Newham screened population. 
 
3-3.08  Referrals to Secondary Care Services 
Of the 835 people screened in Tower Hamlets 55 (6.6%) were referred with 
suspected cancer for further investigation (Table 3-01) whilst 11 (4.0%) of 276 
were screened positive in the Newham campaign (Table 3-02). 
 
3-3.09  Referrals by Screening Site 
In Tower Hamlets all of the screening sites yielded referrals so although there 
were 3 sessions at which no individuals were screened positive, other sessions at 
the same site produced at least one referral (Table 3-01).  
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Figure 3-05: (A) The proportion of referred patients from each screening site in Tower Hamlets and 
(B) the proportion of patient examinations by screening location. (Total screened = 835, Total 
referred = 55). 
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At Spitalfields Practice, 58 people were screened in 2 sessions and 11 (19%) 
referred. This equates to just 7% of all screened patients being seen at this 
location, yet 19% of all referrals originated from here. It was noted that the 
adjacent general medical practice had actively recruited patients to be screened 
following publicity in the preceding weeks. As in the 2006 screening programme 
East London Mosque and Bethnal Green Road were sites contributing significant 
proportions of all referrals (13% each) and were also sites at which substantial 
proportions of all screened individuals were seen (16% and 11% respectively). 
The other sites revisited from 2006 were Brady Arts Centre and Watney Market 
which produced 7% and 9% of referrals from 6% and 9% of all screenings, 
respectively (Figure 3-05).  
 
All three sites in Newham also yielded screen positive individuals for referral 
(Table 3-02). The majority of referrals (64%) were from the two sessions on Green 
Street Market but only 38% of all screenings were at this site, whilst Shaftesbury 
Road accounted for 53% of screenings but only 27% of referrals (Figure 3-06). 
 
 
Figure 3-06: Proportion of individuals screened at each site in Newham (Total screenings 276) and 
percentage of referrals by screening site (Total 11 referrals). 
 
 138 
3-3.10  Referrals by Dentist 
In total Dentist AL screened 534 individuals at 16 sessions in Tower Hamlets and 
referred 33 (6%) whilst Dentist NS screened 301 at 8 sessions, referring 22 (7%). 
On the Newham screening programme Dentist AL screened 235 patients at 4 
sessions, referring 9 (4%) whilst Dentist NS screened 41 and referred 2 (5%) 
suggesting a good degree of consistency between both examiners (Figure 3-07). 
 
Figure 3-07: Percentage of screened patients referred on the Tower Hamlets and Newham 
screening programme by Dentist AL and NS. (Total 66 referrals). 
 
 
 
3-3.11  Inter-Examiner Variability  
17 patients were independently assessed by both examiners in series for OMLs 
and DMFT scores (Table 3-04). All patients included were at least partially dentate 
and intra-examiner agreement on DMFT was very high indicated by a correlation 
value of 0.97 (Figure 3-08) although the limitations of DMFT assessment in 
indicating ability to detect oral cancer by direct visual examination are accepted.  
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Table 3-04: Pearson correlation for 17 independently screened patients assessed for DMFT and 
the presence of OMLs. * indicates the patient screened positive for OSCC and referred by both 
clinicians. 
 
 DMFT score OML detected 
 
Patient 
Examiner NS Examiner AL Examiner NS Examiner AL 
NS310301 14 17 - - 
NS310302 4 5 paan mucositis paan staining 
NS310303 26 23 - - 
NS310304* 4 4 leukoplakia + paan staining erythroleukoplakia + paan staining 
Session 
1 
 
 
 
 
NS310305 0 0 - - 
NS070425 5 6 - - 
NS070426 4 3 - - 
NS070427 3 3 periapical abscess UL5 - 
NS070428 9 7 traumatic ulcer traumatic ulcer 
Session 
2 
 
 
 
 
NS070429 0 0 - - 
NS050504 4 3 periodontal abscess abscess + sinus tract 
NS050505 17 21 - - 
NS050506 3 3 - - 
NS050507 0 0 frictional keratosis frictional keratosis 
NS050508 3 2 median rhomboid glossitis median rhomboid glossitis 
NS050509 19 16 - - 
Session 
3 
 
 
 
 
 
 
NS050510 7 8 - - 
Average 7.2 7.1 7 lesions 6 lesions 
Correlation 0.97 0.88 
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Figure 3-08: Shows the correlation (r = 0.97) between examiners for DMFT scores. 
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There was however good correlation for detection of OMLs with a correlation of 
0.88 for lesions detected, however only seven lesions were evident in the 17 
patients. Dentist AL detected 6 lesions and the extra one picked up by dentist NS 
was identified as a periapical abscess of an upper left second premolar although it 
was not possible to determine if this was associated with a sinus tract or papillae 
at time of assessment. Upon further discussion the two examiners decided that if 
no sinus tract was evident, dentoalveolar pathology would not be included. On a 
later screening calibration session another dental (periodontal) abscess with 
draining sinus tract was noted by both clinicians indicating agreement on this 
issue.  Further evidence for these dentists level of agreement in detection and 
assessment of OMLs is the one referral by both examiners, independently 
reported as a clinical diagnosis of “erythroleukoplakia” and “leukoplakia in paan 
staining”. The histological diagnosis remains unavailable as this patient failed to 
attend the secondary referral centre despite exhaustive attempts to contact them.  
 
3-3.12  Outcomes of Referrals to Secondary Care Services 
Despite the direct involvement of the culturally appropriate advocates in chasing 
referrals and offering to attend appointments with the positively screened 
individuals, 14 patients (25%) of the 55 referred  from Tower Hamlets and one 
(9%) of the 11 referred from Newham screening sessions failed to attend the 
secondary referral centre for definitive diagnosis (Table 3-05 and Table 3-06). As 
previously, all feasible attempts were made to make contact with these individuals 
by both telephone and post and home visit. Additionally, two patients attended for 
their initial Oral Medicine consultant clinic appointment, where they were advised a 
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biopsy was required, but then failed to attend for the biopsy itself despite repeated 
attempts to contact them.  
 
 
Table 3-05: Definitive primary diagnosis and outcome after referral to secondary care services of 
positively screened individuals from Newham. (DNA= did not attend secondary referral centre; *= 
definitive diagnosis confirmed by histology; #= did not return for biopsy after initial diagnosis at 
consultant clinic). Four diagnosed with potentially malignant disorders are highlighted. 
 
Newham (Total Referrals 11) 
Patient Primary Diagnosis Outcome 
AL210307 hyperkeratosis* discharge 
AL220304 oral submucous fibrosis* review 
AL220308 DNA - 
AL220317 hyperkeratosis* review 
AL220331 hyperkeratosis* review 
AL220363 hyperkeratosis* discharge 
NS300302 oral submucous fibrosis* review 
NS300333 candidiasis review# 
AL260712 mild/moderate dysplasia* review 
AL270754 lichenoid* review 
AL270771 hyperkeratosis* discharge 
 142 
Table 3-06: Definitive primary diagnosis and outcome after referral to secondary care services of 
positively screened individuals from Tower hamlets. (DNA= did not attend secondary referral 
centre; *= definitive diagnosis confirmed by histology; #= did not return for biopsy after initial 
diagnosis at consultant clinic). 13 diagnosed with potentially malignant disorders are highlighted. 
 
Tower Hamlets (Total Referrals 55) 
Patient Primary Diagnosis Outcome 
AL260314 hyperkeratosis* review 
AL260337 DNA - 
AL260339 oral submucous fibrosis* review 
AL260342 hyperkeratosis* review 
NS310304 DNA - 
NS310334 DNA - 
NS310331 mild/moderate dysplasia* review 
NS310330 lichen planus* review 
NS310339 hyperkeratosis* review 
AL020409 DNA - 
AL020411 hyperkeratosis review# 
AL020430 DNA - 
AL020439 hyperkeratosis* discharge 
AL020441 oral submucous fibrosis* review 
AL020443 haemangioma discharge 
AL050408 DNA - 
AL050423 hyperkeratosis* review 
AL050431 hyperkeratosis* discharge 
NS070401 fibro-epithelial polyp* discharge 
NS070405 DNA - 
NS070415 hyperkeratosis* review 
NS070417 DNA - 
NS070422 hyperkeratosis* review 
NS070422 lichenoid* review 
NS070423 lichenoid* review 
NS070434 hyperkeratosis* review 
AL090411 mild/moderate dysplasia* review 
AL090419 hyperkeratosis* discharge 
AL090421 candidiasis* review 
NS140418 mild/moderate dysplasia* review 
NS140429 DNA - 
NS140434 DNA - 
AL160402 mild/moderate dysplasia* review 
AL160427 severe dysplasia* review 
AL230418 physiological pigmentation discharge 
AL230426 DNA - 
NS280407 hyperkeratosis* review 
NS280412 Hyperkeratosis* review 
NS280422 hyperkeratosis* review 
NS280436 haemangioma discharge 
AL250403 hyperkeratosis review 
AL300401 hyperkeratosis* review 
AL300413 hyperkeratosis* discharge 
AL030505 DNA - 
NS050503 hyperkeratosis* review 
AL070519 oral submucous fibrosis* review 
AL140528 hyperkeratosis* review 
AL140539 hyperkeratosis* review 
AL170545 DNA - 
AL210504 physiological pigmentation discharge 
AL210516 hyperkeratosis* discharge 
AL230522 oral submucous fibrosis* review 
NS260516 DNA - 
AL280512 mild/moderate dysplasia* review 
AL280531 hyperkeratosis* discharge 
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3-3.13  Definitive Diagnosis 
The screening protocols and examiners were the same for both Tower Hamlets 
and Newham programmes and resulted in a relatively small number of referrals, 
therefore the outcomes are presented together. Figure 3-09 shows the definitive 
diagnosis for the 51 attendees at the secondary referral centre from both Tower 
Hamlets and Newham screening sessions.  
 
Figure 3-09: Definitive diagnosis for 51 positively screened patients attending the secondary care 
centre. 
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3-3.14  Potentially Malignant Disorders 
As with the screening programme in 2006 there were no frank oral cancers 
detected. Seven patients were diagnosed with dysplastic lesions, one of which 
was severe dysplasia with the highest probability of OSCC, hence it was 
completely excised. One moderately dysplastic lesion was superinfected with 
candidal hyphae, which was treated with repeat courses of antifungals until a third 
biopsy, taken some months later, showed only mild focal dysplasia. All patients 
diagnosed with dysplastic lesions remain under regular review and were enrolled 
into a tobacco cessation programme to help manage their risk factors for oral 
cancer. Many patients presented with more than one OML and therefore the 
primary diagnosis from the Oral Medicine specialist is presented e.g. a patient 
referred for a paan-associated leukoplakia diagnosed histologically as dysplastic 
who also had lichen planus and at the time of assessment a discharging sinus 
tract from a dental abscess, would only be reported as dysplasia. 
 
Six referred patients were diagnosed with the potentially malignant mucosal 
disorder OSF and remain under review for evidence of malignant change as well 
as being helped to reduce tobacco and particularly paan usage. Four others were 
diagnosed with lichen planus or lichenoid type mucosal lesions, which in view of 
their associated risk factors of tobacco and areca nut consumption, must also be 
regarded as potentially malignant. With the seven dysplastic lesions a total of 17 
out of 51 (33%) of the positive screened patients were diagnosed with PMDs 
(Figure 3-10).  
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Figure 3-10: Potentially malignant disorders (PMDs) and benign lesions within the positively 
screened population who attended for biopsy (Total 51).   
 
 
3-3.15  Histological Diagnosis 
Of the 51 positively screened patients who attended the secondary referral centre, 
46 (90%) required scalpel biopsy and histological examination. The other 5 were 
diagnosed clinically by the Oral Medicine specialist as benign lesions with no 
indication for histological evaluation (Figure 3-11). Two scheduled for biopsy never 
attended the hospital to have the procedure completed. 
 
 
Figure 3-11: Method of achieving the definitive diagnosis for screen positive individuals at the 
tertiary referral centre. (Total 14) 
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3-3.16  Benign Lesion Management 
The majority of referred patients were diagnosed with benign lesions (Figure 3-10). 
Hyperkeratosis without evidence of dysplasia was diagnosed in 52.9% (Figure 3-
09). Despite lacking evidence of malignancy or dysplasia only a small proportion of 
the patients diagnosed with benign hyperkeratosis were in a position to be 
discharged i.e. no significant risk of developing PMDs or having access to 
appropriate primary care services to monitor their OMLs. For this reason, 73% of 
all referred patients remain under review in the Oral Medicine department 1 year 
after the last screening session (Figure 3-12). Two patients presented with benign 
lesions diagnosed as physiological pigmentation who were discharged to the care 
of their General Dental Practitioner with appropriate advice on the management of 
risk factors for oral cancer. Also discharged were two patients presenting with 
small haemangiomas which did not require surgical intervention. Another patient 
discharged from further follow-up, after histological evaluation, was shown to have 
an ulcerated fibro-epithelial polyp.  
 
 
 
Figure 3-12: Outcome of referral for the positively screened population who attended the secondary 
referral centre at 1 year after the last screening session. (Total 51).   
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3-4.01  DISCUSSION 
In total 835 people were screened in Tower Hamlets and 55 referred (6.6%), whilst 
276 were screened in Newham and 11 referred (4.0%). These referral rates are 
broadly comparable with the 2006 screening campaign (4.1%) and that reported in 
previous oral cancer screening initiatives 62, 109. In particular, this is of the same 
order of magnitude as the 5.9% referral rate reported in the Trivandrum Oral 
Cancer Screening Study 5. This would suggest the screening protocol overall is 
comparable to other programmes in the published literature and supports the 
notion that customising a delivery model to a South Asian population, wherever it 
maybe located, is both effective and feasible.  
 
3-4.02  Evaluation of Clinical Outcomes 
No OSCC was confirmed in the total screened population of 1111 high-risk 
individuals but 17 patients were diagnosed with PMDs ranging from OSF to 
lichenoid changes in addition to lesions with histologically confirmed dysplastic 
changes. 15 screen positive patients failed to attend for definitive diagnosis 
despite the best efforts of the cultural advocates and hospital teams.  
 
Benign oral mucosal hyperkeratosis was by far the most common lesion 
diagnosed in 52.9% of screen positive individuals who attended for definitive 
diagnosis. In this population most suspected OSCC would be in individuals with a 
paan chewing habit where the rough fibres of the betel quid may cause frictional 
damage to the epithelial surface of the mucosa, thereby presenting as 
hyperkeratotic white patches. Additionally, the presence of lime and other irritants 
in the paan preparation could cause chemical irritation to the mucosa which would 
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also result in a hyperkeratotic reaction of the tissue. The keratosis would be 
histologically classified as benign if there was no evidence of dysplastic change 
despite the patient’s associated risk factors. However, because of these risk 
factors 73% of the referred patient’s remain under review even if initially diagnosed 
with a benign lesion.  
 
3-4.03  Poor Compliance with Referrals 
Unfortunately, just 51 (78%) of the 65 individuals referred to the Department of 
Oral Medicine attended for further investigation of their suspicious oral mucosal 
lesions, leaving 15 screen positive individuals without definitive diagnosis (Table 3-
05 and Table 3-06). This was despite the best efforts of the advocates to phone 
and visit these patients as well as offering to attend at their hospital appointment. 
Although far from ideal this compliance rate is comparable to the published 
evidence and in particular compares favourably to the 63% referral compliance 
reported in the Trivandrum Oral Cancer Screening Study 5 . In contrast, screening 
programmes in the UK usually report very high levels of compliance, approaching 
100% 62. The referral compliance rate was 70% in the 2006 Tower Hamlets 
screening programme and any improvement in 2008 can be attributed to the 
extensive and proactive measures taken to ensure compliance and cultural 
acceptability. The referral compliance rate in UK studies generally being 
substantially higher than the Trivandrum study may be attributable to the use of 
qualified dental personnel which anecdotal experience suggests increases 
patients’ confidence in the screening diagnosis and therefore they may be more 
amenable to further investigation in comparison to the diagnosis of non-dental 
personnel. The screening dentist’s reported patients often taking the opportunity to 
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ask related dental questions during their screening as many of the patients at risk 
of OSCC also had other dental disease. The overall percentage of missed 
outpatient appointments at Bart’s and The London is 21.4% 117 which is broadly in 
line with the findings of this trial and suggests that there are institutional barriers to 
access in addition to cultural features of the population.  
 
Regrettably, there are still 15 individuals with suspicious oral mucosal lesions who 
have refused to attend for further investigation, in spite of all reasonable attempts 
by both the secondary referral centre and bilingual cultural advocates who have 
experience of dealing with health access issues in the local community. As in 
2006, reasons for non-attendance at referral appointments were investigated. It 
was determined that two of these non-compliers had permanently returned to 
Bangladesh. Whether this was in any way related to the screen positive OSCC 
result in unclear as there is known to be a high population turnover in this 
community. 
 
Overall these results indicate that the model of OSCC screening, in a community 
setting with ethnically-matched advocates was able to overcome some specific 
barriers to access for the South Asian population, that remain at the hospital 
secondary referral service. However, there is significant room for further 
improvement in compliance with referrals to match that observed in other UK 
populations. One solution is to have the definitive diagnostic process carried out in 
the community which would be possible on a mobile dental unit. Our results 
indicate that on average 3-4 people were screened positive per session and 90% 
required biopsy to confirm diagnosis. Therefore, a second clinician available to 
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undertake the biopsy would eliminate the risk of patients not attending the 
secondary referral centre. The assumptions being that patient’s would agree to an 
immediate biopsy and will attend the hospital for further treatment if required. 
 
3-4.04  Data Collection Effects on Screening 
In total 835 people were screened during the 24 sessions held in Tower Hamlets, 
an average of 35 per session, with the most screenings in a single session 
occurring on Bethnal Green Road, as in the 2006 programme (Table 3-01 and 
Table 2-01). The average number of patients seen per session in 2006 was 
substantially higher at 48 indicating that the data collection process may have 
reduced the dentist’s capacity to screen patients. However, the five Newham 
sessions yielded an average of 55 people screened per session which taking into 
account the extra half-hour of screening time at Newham would indicate a 
Newham screening rate almost equivalent to that in Tower Hamlets 2006 
programme. This variance maybe due to the other data being collected in Tower 
Hamlets by link workers and tobacco cessation workers from Bangladeshi people 
after screening. This may have interfered with their ability to recruit patients into 
screening thereby reducing the numbers screened at Tower Hamlets where there 
were proportionally more Bangladeshi individuals. Conversely the data collection 
by the dentists didn’t affect the screening rate because it was information routinely 
elicited when assessing cancer risk. Additionally, dentist AL speaks Punjabi so 
would have been able to communicate directly with many of the Newham locals 
without an interpreter whilst dentist NS doesn’t. This may account for dentist AL 
screening more patients per session than dentist NS at Newham although dentist 
NS only attended one session. Approximately equivalent numbers were screened 
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by both dentists at the sessions in Tower Hamlets and neither dentist speaks 
Sylheti.  
 
Data collection when integrated into the screening process does not interfere with 
the running of a screening programme but information collection in addition to that 
normally elicited in the clinical consultation appears to be detrimental to the 
primary objective of OSCC screening.     
 
3-4.05  Targeting High Risk Individuals 
In Tower Hamlets and Newham all of the screening sites yielded referrals for 
suspected OSCC. In 2006 three screening sites resulted in no screen positive 
individuals. This indicates that the site selection policy for Phase II was better at 
targeting high-risk individuals even if fewer were screened at each session in 
Tower Hamlets. In addition, there maybe some order-effect as the awareness of 
the screening programme resulted in the Spitalfields Medical Practice actively 
recruiting its patients, to be screened. Consequently, the 19% referral rate from 
this site was substantially higher than the average of 6.6% in Tower Hamlets 
(Figure 3-05). 
 
Demographic data also suggests the population screened were at high-risk (Table 
3-03). The screened population in Tower Hamlets were almost exclusively South 
Asian (91%) and then predominantly of Bangladeshi origin (84%). The population 
screened in Newham were more heterogeneous but also majority South Asian 
(66%), although a more diverse group of Indian’s, Pakistani’s and Bangladeshi’s. 
The linking of South Asian population’s lifestyle risk factors to OSCC risk is 
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confirmed by 58% of the homogenous Bangladeshi Tower Hamlets group using 
paan and 44% smoking. Although, just 21% of the Newham cohort were paan 
users, 37% smoked and 31% drank alcohol. There was no attempt at 
quantification of these risk factors for the majority of screened individuals unless 
screened positive but overall the demographic and risk factor descriptive data 
would suggest the screened population displayed high levels of lifestyle risk 
factors for OSCC.  
 
Further evidence comes from the dentists screen positive referral rate. In the 2006 
Tower Hamlets campaign the overall referral rate was 4.1% whereas in 2008 it 
was 6.6% so it would appear more high-risk patients are being screened because 
of the higher referral rate. Dentist AL was involved in both programmes and 
refereed 2% of screened patients in 2006 compared to 6% in 2008 but this may 
also be partially due to gaining more experience of OML diagnosis in the interim.   
 
Overall it would appear that OSCC screening by (1) use of a mobile dental unit at 
community facilities with high footfall of South Asian people and (2) active 
recruitment of individuals displaying high risk behaviours by bilingual link workers, 
specifically targets the high-risk South Asian population.  
 
3-4.06  Inter-Examiner Variability 
In contrast to the patients attending for screening, the level of inter-examiner 
variability should be a relatively controllable variable. We succeeded in achieving 
very high levels of correlation between the examiners by a rigorous 
standardisation and calibration process and utilising fewer examiners with more 
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specific interest and experience in oral mucosal disease. The independent 
measures of DMFT assessment and OML detection used for assessment of 
variability, yielded correlation co-efficients of 0.97 and 0.88 respectively. In 
addition, the two dentist’s referral rate of screen positive individuals was 
remarkably consistent at 6-7% in Tower hamlets and 4-5% in Newham. This 
indicates the calibration and standardisation process was robust.  
 
3-4.07  Gold Standard Outcomes 
Despite 1111 individual screenings in a high risk population for oral cancer there 
were no OSCCs detected. Therefore, and as in 2006, it is impossible to assess the 
results on the basis of the ideal gold standard for one-off oral cancer screening 
programmes, which is histologically confirmed OSCC. Without a gold standard 
outcome it is impossible to determine the commonly calculated measures of 
sensitivity or specificity to describe the effectiveness of a screening process. 
 
Due to ethical concerns with biopsy of normal tissues and OSCC being rare, 
various ‘soft’ gold standards have been suggested as more appropriate for UK 
screening programmes 109. The simplest is the number of positively screened 
individuals. In our study, screen positive referral rates varied greatly dependent on 
the screening dentist (in 2006 for dentist AR ~15% and dentist AL ~2%) but this 
variance can be reduced by robust standardisation and calibration (in 2008 for 
dentist NS ~7% and dentist AL ~6%). However, the majority of these screen 
positive individuals don’t actually have OSCC or even PMDs (Table 3-06 and 
Table 3-07).  
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The other commonly reported soft gold standard outcome measure is the 
proportion of screen positive patients subsequently diagnosed (either clinically or 
histologically) with PMDs or OSCC. This would be inaccurate with a substantial 
non-compliance rate, as in the studies on South Asian populations, and relies 
heavily on the subjective opinion of the specialist clinician charged with making the 
gold standard diagnosis, if histology is not indicated. This subjectivity maybe little 
better, in visual diagnosis of OMLs, than the screening clinicians and even if 
biopsy is indicated there are issues with where and how to accurately biopsy a 
large lesion. All outcome measures reliant on a definitive diagnosis will have 
similar issues. 
 
With the known uncertainties in OSCC pathogenesis and diagnosis an alternative 
gold standard is the requirement for a biopsy in addition to visual assessment to 
confirm the diagnosis. As visual detection alone is utilised during screening the 
rationale is that malignancy could not be satisfactorily excluded without the biopsy. 
In 2008, 90% of referred patients, who attended the secondary referral centre, 
required a biopsy (Figure 3-11), considerably more than the 57% in 2006 (Figure 
2-15) indicating this may be an appropriate measure of a more effective screening 
campaign. 
 
To negate the need for a definitive diagnosis an appropriate soft gold standard 
could be, whether or not a screen positive individual is discharged immediately 
following definitive diagnosis or requires long term follow-up. This is the clinical 
decision the specialist would need to make based on a number of interplaying 
factors including the suspected diagnosis and the patient’s risk factors. It would be 
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heavily dependant on the healthcare system but is readily applicable in the UK 
where healthcare is free at the point of delivery, in secondary referral centres. In 
2006, 50% of referred patients were discharged after definitive diagnosis because 
lesions were benign and there was minimal risk of future malignancy developing 
(Figure 2-16), whilst in 2008 just 27% were able to be discharged from further 
follow-up, at 1 year (Figure 3-12). This suggests that patients at higher risk of 
malignancy were referred in 2008 and in the UK healthcare system there is an 
obligation to follow-up these patients as well as reducing their acquired risk factors 
for OSCC. 
 
The sensitivity and specificity of visual screening for oral cancer has repeatedly 
been reported as sufficient to justify screening programmers despite the lack of 
robust evidence in the literature 64, 118. In the UK, in view of the complex 
presentation of PMDs particularly in South Asian populations, a successful 
outcome of screening should be considered as a screen positive individual who 
requires long term follow-up, specifically for development of OSCC, due to the 
presence of PMDs or significant risk factors. The well reported deficiencies of a 
‘soft’ gold standard are acknowledged as this definition accommodates the clinical 
judgement of the specialist in oral oncology at the secondary referral centre but is 
the most appropriate strategy for UK based screening activity.  
 
 
Table 3-07: 4x4 table of screening outcomes using the gold standard measure of whether 
individuals require long term follow-up for OSCC. Assuming the worst case scenario that all 
patients who fail to attend the secondary referral centre would require review.   
 
 review discharge 
screen +tve 52 14 
screen -tve 0 1045 
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On this basis OSCC screening specificity was 98.7% (1045 out of 1059) and 
positive predictive value 79% (52 out of 66)  with ‘sensitivity’ and ‘NPV’ at 100% as 
would be expected from any definition of a gold standard that only assesses the 
positive screened individuals. For patient safety we assume the worst case 
scenario that all patients who did not comply with referral would have been 
reviewed and not discharged. These figures are comparable to the literature on 
OSCC screening where overall specificity is 97% and PPV 70% despite the 
disparity in gold standard outcomes utilised and heterogeneity of study 
methodologies 62. The 79% PPV indicates that approximately 1 in 5 screen 
positive individuals were false positives attributable to specific difficulties in 
assessing the screened population, such as differentiating discrete lesions from 
generalised paan-related staining. Importantly, high specificity indicates very few 
false negatives amongst the discharged (healthy) population suggesting few 
patients who actually require follow-up would be misdiagnosed. 
 
Qualitatively, it may be considered surprising that the screening dentists referred 
14 patients with no significant pathology. However, this would be consistent with 
the varied presentation of OSCC in high-risk individuals and the inability of the 
examining clinician to review patients prior to referral because of the ‘one-off’ 
nature of this screening protocol. It would be normal practice for a clinician, in 
another dental scenario, to review a PMD before referral e.g. they may reduce a 
denture base or ask the patient to not wear the prosthesis for a week to eliminate 
the possibility of constant light trauma as the aetiology for a persistent ulcer. This 
opportunity was not available in the one-off opportunistic screening methodology 
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as the patient can either be referred or discharged therefore a persistent ulcer, as 
per the NICE guidelines, would need to be referred.   
 
3-4.08  Financial Considerations 
The cost per screened individual was calculated at approximately £24 including all 
associated direct costs such as staff and hire of fully equipped mobile dental units 
but not including consultant time and hospital facilities for follow-up appointments. 
This cost is approximately half the figure for the NHS breast screening programme 
which stands at £45.50 per screen, suggesting targeted OSCC screening may be 
financially viable or at least is not overtly cost-prohibitive. Additionally, there is 
potentially financial scope to provide additional diagnostic services that may 
eradicate the uncertainty of direct visual screening for OSCC.   
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3-5.01  CONCLUSION 
The use of mobile dental units located in community settings and supported by 
cultural advocates offers an effective means of targeting high-risk South Asian 
populations for OSCC screening. The study methodology offers insights for the 
further development of oral cancer screening interventions for disadvantaged 
communities in the UK.  
 
The main concern is that despite implementing all feasible proactive measures 
such as remaining in contact by phone and visiting patients as well as offering to 
attend at their hospital appointment a significant proportion of screen positive 
individuals still fail to attend the secondary referral centre. This results in patients 
who have been told they need further investigation at an oral cancer screening 
event, not receiving the healthcare they need. The psychological and social impact 
of this is unknown but potentially very serious. Secondarily, the resultant 
incomplete data collection leads to inaccuracies in the evaluation of the screening 
programme. 
 
To undertake further screening for OSCC in high-risk South Asian populations, 
mechanisms must be implemented to prevent drop-out of screen positive 
individuals.  
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Chapter 4 
 
 
The Prevalence of Oral Mucosal Lesions in the Screened 
Population Targeted as High-Risk for Oral Cancer 
 
 
 
4-1.01  INTRODUCTION 
It was observed in the 2006 pilot screening programme that many screened 
individuals presented with OMLs particularly in relation to OSCC risk habits such 
as paan usage and smoking, which made visual examination more difficult for the 
dentist. However, as minimal data was collected in the pilot project, to preserve 
anonymity, it was not possible to evaluate this observation. In the 2008 Phase II 
screening, more data collection was undertaken in order to determine if those 
screened were actually at high-risk for OSCC. Demographic data discussed in 
Chapter 3 suggests that the screened population was at high-risk due to the 
reported levels of OSCC risk behaviours such as paan usage and smoking. 
However, an assessment of the prevalence of oral mucosal lesions in the 
screened population would be necessary to confirm this as most OSCCs develop 
in PMDs presenting as visible lesions of the mucosa 29. Additionally, early OSCC, 
being a cancer of the superficial epithelial lining of the intraoral mucosa should be 
detectable as a mucosal abnormality even if not presenting as a typical PMD.  
 
4-1.02  Direct Visual Examination and Oral Cancer 
The literature records that oral cancer can be detected by direct visual 
examination of the oral mucosa with overall sensitivity 85%, specificity 97%, PPV 
70% and NPV 98% 62. The low PPV indicates direct visual examination is likely to 
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result in false positives which are attributed to the heterogeneity of early OSCC 
and particularly PMD clinical presentations. The number of false positives will 
further be potentiated by the rarity of OSCC in the population. The presence of 
large numbers of OMLs or specific PMDs adversely affects the screening 
clinician’s ability to accurately detect OSCC on direct visual examination, 
potentially indicating this modality is inappropriate for such populations without 
diagnostic aids. 
 
4-1.03  Leukoplakia 
Much of the literature on PMDs focuses on leukoplakia as one of the commonest 
recognised potentially malignant OMLs in the Western World. The term 
leukoplakia is defined as “white plaques of questionable risk having excluded 
(other) known diseases or disorders that carry no increased risk for cancer” 15. 
Leukoplakia is a clinical term with no specific histological presentation and 
additional clinical descriptions that are used to assist in the characterisation of 
leukoplakia are: 
• Aetiological description e.g. clearly associated with tobacco or areca nut 
use or idiopathic. 
• Site descriptions e.g. giving anatomical sub-site in the mouth or oropharynx  
• Size or extent of the lesion(s). 
 
Clinical diagnosis of leukoplakia is outlined in the schematic presented in Figure 4-
01 from Warnakulasuriya et. al. (2007) reporting on a WHO Collaborating 
Centre for Oral Cancer and Precancer workshop 15. 
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Figure 4-01: Schematic representation of the steps in diagnosis of oral leukoplakia. (from 
Warnakulasuriya et. al 2007 15)  
 
 
 
The WHO Working Group also provided an extensive list of other possible 
diagnosis which need to be excluded for white patches to be classified as 
leukoplakia (Table 4-01). 
 
Table 4-01: Disorders that need exclusion to diagnose leukoplakia. (from Warnakulasuriya et. al 
2007 15) 
 
 
 
 163 
4-1.04  The Prevalence of PMDs  
Petti (2003) 119 analysed the literature on prevalence of PMDs, focussing on 
leukoplakia and the much rarer erythroplakia, and calculated a global prevalence 
of between 1.49% (95% CI, 1.42-1.56] and 2.6% (95% CI: 1.72–2.74) dependent 
on methodology. There is no equivalent figure in the literature for other PMDs and 
only assessing leukoplakia and erythroplakia is likely to significantly underestimate 
the prevalence of PMDs in the Tower Hamlets and Newham populations as other 
risk factor specific conditions, such as OSF, are significant issues in these South 
Asian populations.  
 
4-1.05  PMDs in the UK Bangladeshi Population 
Pearson et. al. (2001) 23 conducted a screening activity amongst Bangladeshi 
general medical practice patients in Tower Hamlets. Over a period of 3 months, 
137 patients aged over 40 were approached in the medical practice waiting room 
and agreed to take part in a structured interview before undergoing an oral visual 
examination. They detected OMLs in 40% of participants with no gender 
predilection (Table 4-02). Of all detected lesions, 64% (n = 34) were leukoplakia 
and these presented in 25% of the screened population, with the next most 
common lesion being acute abscess (n = 6) followed by the related dental 
pathology of a sinus (n = 4). OSF was detected in 1 female patient. Ulcers were 
reported in 3 females but not specifically as suspicious for OSCC, although a 
separate category for ulceration due to dentures was recorded. Benign mucosal 
conditions, such as aphthous stomatitis are much more likely to present as oral 
ulceration than malignancy, especially as aphthous stomatitis is commoner in 
women. Therefore, from their list of identified OMLs those that can be classified as 
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PMDs make up 67-73% (n = 37-40) of all OMLs, depending on whether the 3 
ulcers were included as suspicious. 
 
Table 4-02: Oral mucosal lesions detected in a screened Bangladeshi population in Tower 
Hamlets. (from Pearson et. al. (2001) 23) 
 
 
 
Even amongst medical practice users Pearson et. al. (2001) 23 reported paan 
usage rates at 88% amongst females and 69% in males whilst 60% of females 
and 71% of males used tobacco, either smoked or chewed. Alcohol consumption 
was not reported but with the over 40 age criteria and the reported risk factors this 
would suggest the majority of the screened population were high-risk for OSCC.  
 
This study has significant methodological differences to our targeted screening 
protocol that may make comparison of results difficult. Primarily, they did not 
actively recruit high-risk individuals but simply inviting those in a general medical 
practice waiting room to take part. Their screened population maybe health 
conscious because they are recruiting from medical practice attenders or 
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conversely the sampled population maybe chronically ill and therefore not 
representative of our targeted high-risk screened population.   
 
Despite the variety of studies on the prevalence of risk factors for OSCC in the 
Tower Hamlets, Newham or East London populations, any other studies of OML 
prevalence were scarce in the literature. An abstract by Haque et. al. 1997 120 
reported an OSF prevalence of 0.7% amongst 150 individuals in the Bangladeshi 
population of East London but methodology was unclear in the limited write-up. 
Even broadening the search criteria to Asian populations in the UK revealed just 
one further study reported by Mattin (1989) 121 in a University of London MSc 
Thesis. In a predominantly Indian origin population based in Southampton they 
recorded OMLs in 19% of patients, with frictional keratosis related to denture wear, 
the commonest finding. Two subjects were reported with paan staining of the oral 
mucosa and OSF prevalence in the sample was 0.7%.    
 
4-1.06  PMD Prevalence in South Asia 
Studies from various regions of India predominate in the literature search for 
prevalence of OMLs in South Asian populations outside the UK. There were no 
reports from Bangladesh. The Trivandrum Oral Cancer Screening Study 2-6 does 
not report the prevalence of OMLs but risk factors for OSCC are recorded. 
Chewing habits are reported in approximately 25% of males and females whilst 
smoking is prevalent in 60% of males and just 1% of females. Drinking habits were 
reported in 40% of males and 0.1% of females. This information was collected in 
the patient’s home and may reflect cultural acceptability of the different habits 
amongst men and women.     
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Saraswathi et. al. (2006) 24 reported on 2017 individuals seen in a Chennai 
hospital dental department in a 3 month period. OMLs were detected in 4.1% with 
leukoplakia in 0.59% and OSF in 0.55% (Table 4-03). The commonest lesion was 
the benign hyperpigmentation smoker’s melanosis in 1.14% and stomatitis nicotina 
in 0.89% although the prevalence of smoking was 15.02%. A chewing habit was 
prevalent in 8.78% and alcohol use by 6.99%. 
 
Table 4-03: Oral mucosal lesions detected in a screened population in Chennai, India. (from 
Saraswathi et. al. (2006) 24) 
 
 
 
 
Byakodi et. al. (2011) 25 reported on 24422 individuals seen at a hospital dental 
outpatient department in Sangli, India, in an 18 month period. OMLs were detected 
in 2.55% with aphthous ulcers the commonest lesion in 0.80% followed by OSF in 
0.68%, leukoplakia in 0.36% and OSCC in 0.34% (Table 4-04). The reported risk 
habits were 9% of the population smoked, 23 % chewed tobacco and 18% were 
described as ‘alcoholics’.  
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Table 4-04: Oral mucosal lesions detected in a screened population in Sangli, India. (from Byakodi 
et. al. (2011) 25) 
 
 
 
 
Mehrotra et. al. (2008) 122 reported on 3030 people screened on 10 days at a 
hospital dental department in Vidisha, India. OMLs were detected in 8.4% but 16% 
refused scalpel biopsy and the clinical diagnosis were not presented. Risk factors 
were, 21% smoked and 42% were tobacco chewers with alcohol usage not 
reported.  
 
Other studies have targeted specific South Asian population groups, usually 
believed to be a higher risk of OMLs, and not just the attendees at a hospital 
dental department as in the three studies above. In Rajasthan state, Dagli et. al. 
2008 123 reported leukoplakia in 33.3% of 513 mine workers and OSF in 1.8% with 
59% using tobacco and 60% using alcohol. This study did not report on any other 
specific OMLs except papilloma, which was present in 1.8%. Although the 
presentation is unclear there is some data suggesting that 324 of the 513 people 
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screened presented with some OMLs indicating that the total prevalence of OMLs 
was 63%.    
 
Despite the heterogeneity evident in these studies when taken together the 
prevalence of OMLs in Indian populations presenting to hospital outpatient 
departments is likely to be in the range 2 - 8% with common PMDs including OSF 
(0.5 - 0.7%) and leukoplakia (0.3 - 0.6%). The reporting of other non-PMD but 
common OMLs appears inconsistent as smoking related changes are common in 
the Chennai study but not reported at all in Sangli despite 9% of the screened 
population smoking. Conversely aphthous ulceration is the commonest lesion in 
Sangli but is not recorded at all in Chennai. Chewing habits are relatively common 
in both populations but chewer’s mucositis is reported in 0.25% of the Chennai 
population and not at all in Sangli. These studies have large enough populations to 
believe that common OMLs should occur in both without methodological 
weaknesses, unless the studied populations are significantly different. Additionally, 
when assessing specific high-risk Indian populations, such as mine-workers, there 
is some evidence that the prevalence of OMLs maybe much higher.  
 
4-1.07  Summary 
Assessment of the prevalence of abnormalities of the oral mucosa present in the 
screened population is necessary to determine if the screened population is truly 
at high-risk of OSCC. The literature gives no reliable indication of the prevalence 
of OMLs in the Tower Hamlets and Newham screened populations as no studies 
have attempted to specifically target individuals with OMLs. This suggests the 
available literature may significantly underestimate the prevalence in our screened 
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population. Importantly for future screening programmes, the presence of large 
numbers or a substantial range of OMLs is likely to be the cause of misdiagnosis 
and resultant reduced accuracy of OSCC screening by direct visual examination in 
this population.
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4-2.01  STUDY PROTOCOL 
A population-based survey was designed to record the prevalence of OMLs in 
those screened for OSCC without adversely interfering with the primary objective. 
The pilot study revealed that at busy screening locations, potential patients were 
being kept waiting and tended to leave the mobile dental unit without being 
screened, if they were not seen within a few minutes. Each screening was to last 
no more than 3-4 minutes on average and therefore data collection had to be 
optimised to avoid extending the screening time.  
 
Data collection was approved by The East London and the City Research Ethics 
Committee and the Joint Research and Development Office of Bart’s and The 
London (REC 08/H0701/98). Data analysis utilised Excel 2003 (Microsoft, USA) 
with the StatPro add-on (Kelley School of Business, Indiana University) and 
STATA 10 (StataCorp LP, Texas, USA). To allow for anonymity all participants 
initially gave verbal and implied consent to take part in screening but written 
consent was obtained for recording of patient related data for all screened 
patients, if they agreed for data to be collected. Refusing to participate in the data 
collection exercise did not prevent patients from being screened or referred. No 
attempt was made to elicit why participants may not wish to allow recording of their 
data. 
 
4-2.02  Clinical Diagnosis 
The clinical diagnosis or a description of mucosal pathology, if diagnosis was 
unclear, of all OMLs was to be recorded whether referred or not. Standardisation 
was aided by developing a defined list of OML clinical diagnosis based on the 
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recently up-dated nomenclature by Warnakulasuriya et. al. (2007) 15 and the list 
utilised by Pearson et. al. (2001) 23 in their study of the Tower Hamlets 
Bangladeshi population (Table 4-02). Other lesions and conditions were as 
described in Cawson's Essentials of Oral Pathology and Oral Medicine 7th Edition 
(2002) 8. The list was not exhaustive and was to be updated by agreement 
between both examiners, as necessary throughout the screening programme. The 
final list of OML clinical diagnosis is shown in Table 4-05.  
 
 
Table 4-05: Agreed clinical diagnosis of oral mucosal pathology to standardise description of 
lesions detected in the screened population.   
 
WHITE PATCHES ULCERS 
CANDIDOSIS +/-  ACUTE PSEUDOMEMBRANOUS etc . APHTHOUS ULCER +/- MINOR / HERPETIFORM / MAJOR 
ERYHTROLEUKOPLAKIA ULCER +/- OSCC / TRAUMATIC / CHEMICAL etc 
FRICTIONAL KERATOSIS 
 
LEUKOEDEMA LUMPS 
LEUKOPLAKIA DENTAL ABSCESS 
LICHENOID REACTION EPULIS 
LICHEN PLANUS (LP) +/-. RETICULAR / PLAQUE etc FIBROEPITHELIAL POLYP (FEP) / PYOGENIC GRANULOMA 
SINUS TRACT MUCOCELE 
WHITE SPONGE NAEVUS OSTEOMA (BUT NOT LINGUAL/PALATAL TORI) 
  
RED PATCHES SPECIFIC PALATAL LESIONS 
ERYHTROPLAKIA DENTURE STOMATITIS 
HAEMANGIOMA SMOKERS PALATE 
  
OTHER COMMON CONDITIONS SPECIFIC TONGUE LESIONS 
ANGULAR CHEILITIS GEOGRAPHIC TONGUE 
DESQUAMATIVE GINGIVITIS ATROPHIC GLOSSITIS 
GINGIVAL HYPERPLASIA MEDIAN RHOMBOID GLOSSITIS 
ORAL SUBMUCOUS FIBROSIS (OSF) 
 
PAAN STAINING 
 
 
 
 
 
Where multiple mucosal abnormalities are related to one pathological process the 
examiners agreed to record all detectable lesions e.g. in OSF there would usually 
be paan staining and may also be dental disease presenting as a mucosal sinus 
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tract. This would allow an accurate measure of the prevalence of all mucosal 
abnormalities as well as specific lesions in the screened population and give an 
idea of difficulty in assessing this population for OSCC. Paan staining specifically 
was recorded as it was reported to complicate OSCC detection and clinical 
diagnosis by the dentists in the 2006 Tower Hamlets pilot project. It can also be 
difficult to differentiate paan staining from inflammatory paan-related mucositis 
without histological evaluation.   
 
4-2.03  Intraoral Site 
As OSCC predominantly develops at specific sites in the mouth it is believed that 
OMLs at different sites carry different risks of malignant conversion 29. Therefore, 
the site of lesions was recorded on a mouth map to permit assessment of the 
proportion of OMLs at high risk sites (Figure 4-02).  
 
Figure 4-02: Mouth map used to delineate position and extent of oral mucosal lesions detected in 
the screened population. 
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Where discrete lesions were detected they would be noted at each site e.g. a 1cm 
x 1cm leukoplakia on the right buccal mucosa and another 0.5cm x 1cm on left 
floor of mouth in the same patient would be recorded as two leukoplakias whilst 
conditions would be recorded per patient e.g. reticular lichen planus classically 
presenting as bilateral buccal mucosal lesions would be recorded as 1 condition, 
unless there was, for example, an associated desquamative gingivitis, in which 
case they would be recorded as two conditions at two different sites (i.e. buccal LP 
and gingival desquamative gingivitis).   
 
Extra-oral examination findings were not recorded unless directly relevant e.g. 
lymph node involvement suggesting metastatic spread of an OSCC, in order to 
avoid the screening consultation taking too long. 
 
4-2.04  Risk Factors for Oral Cancer 
All patient screened for OSCC were asked about their risk habits, including 
smoking or areca nut extract usage or alcohol consumption as this is part of the 
risk assessment process for OSCC. Recording this marginally increased screening 
session time because the information would usually only be obtained verbally 
unless referral was indicated. No specific attempt was to be made to determine the 
constituents of paan i.e. whether tobacco was included, unless referring a screen 
positive individual where the risk factors would be discussed in greater detail in the 
normal circumstance. Similarly with smoking and alcohol consumption, 
quantification would not be attempted (pack years, ounces of tobacco, use of 
filters, units of alcohol etc) for every patient.  
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4-3.01  RESULTS  
The patient demographic data and risk factor prevalence of the 1111 screened 
participants in Tower Hamlets and Newham is presented and discussed in 
Chapter 3. 
 
4-3.02  Numbers of Detected Oral Mucosal Lesions 
In total 1438 OMLs were detected in 604 (54%) individuals in the screened 
population of 1111 individuals (Table 4-06). 
 
Table 4-06: All mucosal lesions detected in the screened population. 
 
LEUKOPLAKIA 60 
ERYHTROLEUKOPLAKIA 11 
LICHEN PLANUS (RETICULAR) 41 
LICHEN PLANUS (EROSIVE) 1 
LICHENOID REACTION 6 
CANDIDOSIS (ACUTE PSEUDOMEMBRANOUS) 10 
FRICTIONAL KERATOSIS 520 
LEUKODEMA 74 
WHITE SPONGE NAEVUS 1 
FORDYCE SPOTS 29 
WHITE PATCHES 
SINUS TRACT 24 
ERYHTROPLAKIA 5 RED PATCHES 
HAEMANGIOMA 2 
ULCER (OSCC) 3 
ULCER (TRAUMATIC) 15 
MINOR APHTHOUS ULCERS 25 
ULCERS 
HERPETIFORM APHTHOUS ULCERS 1 
MUCOCELE 2 
FIBROEPITHELIAL POLYP (FEP) / PYOGENIC GRANULOMA 11 
EPULIS 1 
DENTAL ABSCESS 4 
LUMPS 
OSTEOMA (NOT LINGUAL/PALATAL TORI) 2 
DENTURE STOMATITIS 10 SPECIFIC PALATAL 
LESIONS SMOKERS PALATE 39 
GEOGRAPHIC TONGUE 3 
MEDIAN RHOMBOID GLOSSITIS 2 SPECIFIC TONGUE LESIONS 
ATROPHIC GLOSSITIS 1 
PAAN STAINING 522 
DESQUAMATIVE GINGIVITIS 1 
ANGULAR CHEILITIS 2 
ORAL SUBMUCOUS FIBROSIS (OSF) 7 
OTHER SPECIFIC 
CONDITIONS 
GINGIVAL HYPERPLASIA 3 
TOTAL NUMBER OF LESIONS DETECTED 1438 
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A total of 32 different OMLs were diagnosed in the population ranging from 
unquestionably benign leukoedema to the possibly already malignant 
erythroplakia.  
 
4-3.03  Common Lesions in the Screened Population 
Frictional keratosis and paan staining were by far the commonest lesions 
detected, comprising 522 (36%) and 520 (36%) of all OMLs respectively.  
Leukoedema was the next most common OML detected in 74 people 
consequently comprising 5.1% of all OMLs (Table 4-06). Leukoedema is an 
entirely benign normal variation of buccal mucosa but is an important finding as it 
has been reported to appear as a false positive result when examined with light 
based tissue reflectance aids to oral visual assessment 81. 
 
Only 23 cases (1.6% of all OMLs) of the apparently common condition minor 
aphthous ulceration were detected. This could be because of the sporadic nature 
of these ulcers but the condition also predominantly affects younger people so this 
low prevalence might be expected when targeting older individuals. Minor 
aphthous ulcers are also known to be uncommon in smokers 8 so the high rates of 
smoking reported may provide another explanation for the infrequency of 
detection. 
 
4-3.04  Prevalence of Leukoplakia 
Sixty leukoplakias were reported, representing 4.1% of all OMLs detected in the 
screened population (Table 4-06). This is considerably lower than that reported by 
the 2001 Pearson et. al. (2001) 23 study in Tower Hamlets and more consistent 
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with the later trials reported in 2006 and 2011 in India 24, 25. This may in part be 
due to the updating of the definition of leukoplakia since 2001 15 so some clinically 
detectable white patches previously called leukoplakia may have been further 
classified by cause, for example, as frictional keratosis. Some evidence of this 
comes from the fact that 32 different lesions were reported in our study whilst 
Pearson et. al. (2001) 23 reported just thirteen different OMLs (Figure 4-02).  
 
4-3.05  Prevalence of Oral Submucous Fibrosis 
Seven cases of OSF were detected amongst the 522 people with apparent paan 
staining (Table 4-06) and 586 people in total reported paan usage (Table 3-03). As 
quantity and frequency of paan use were not collected the apparent lack of paan 
staining in 44 individuals who reported paan usage could represent the most 
infrequent users or those with meticulous oral hygiene. The detection of 7 OSF 
cases represent 0.5% of all OMLs and 0.6% of all screened individuals which is 
consistent with the literature on the Bangladeshi population in East London 
indicating prevalence of 0.7% 120 and 1.8% 23 considering the small sample sizes 
in these previous studies and the detection of just 1 OSF case in each study.   
 
4-3.06  Detection of Rare Lesions 
Some very rare lesions were also detected such as 1 patient with white sponge 
naevus and another with herpetiform aphthous ulceration (Table 4-06). This could 
indicate the oral cancer awareness programme, surrounding the screening 
initiative, was making people look in their mouth for OSCC. There was some 
qualitative reporting by the clinicians to this effect, as people attended screening 
sessions specifically for an intraoral lesion they had noticed such as one of the 
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geographic tongue lesions detected. Fordyce spots are uncommon benign lesions 
usually presenting in older people, so detection of 29 patients with these lesions 
would also suggest a proportion of older people were screened.  
 
4-3.07  Referred Patients 
The clinical diagnosis at time of screening of the 66 patients referred with 
suspected cancer is presented, along with the definitive diagnosis (where 
available) in Table 4-07 for Newham and 4-08 for Tower Hamlets. 
 
 
Table 4-07: Definitive diagnosis and screened diagnosis for the 11 patients referred from Newham 
screening sessions. Shaded screening diagnosis are considered accurate with the definitive 
diagnosis. (DNA= did not attend secondary referral centre; *= definitive diagnosis confirmed by 
histology; #= did not return for biopsy after initial diagnosis at consultant clinic, R= right side, L= left 
side). 
 
Patient Primary Diagnosis Outcome Screened Diagnosis 
AL210307 hyperkeratosis* discharge leukoplakia R FOM + paan staining 
AL220304 oral submucous fibrosis* review OSF + leukoplakia R FOM + paan staining 
AL220308 DNA - leukoplakia R ventral tongue 
AL220317 hyperkeratosis* review leukoplakia R buccal + paan staining 
AL220331 hyperkeratosis* review leukoplakia R FOM 
AL220363 hyperkeratosis* discharge erythroleukoplakia L ventral tongue 
NS300302 oral submucous fibrosis* review OSF + leukoplakia R buccal + paan staining 
NS300333 candidiasis review# leukoplakia L ventral tongue 
AL260712 mild/moderate dysplasia* review leukoplakia R FOM + paan staining 
AL270754 lichenoid* review leukoplakia R buccal sulcus + LP 
AL270771 hyperkeratosis* discharge leukoplakia R buccal + paan staining 
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Table 4-08: Definitive diagnosis and screened diagnosis for the 55 patients referred from Tower 
Hamlets screening sessions. Shaded screening diagnosis are considered accurate with the 
definitive diagnosis. (DNA= did not attend secondary referral centre; *= definitive diagnosis 
confirmed by histology; #= did not return for biopsy after initial diagnosis at consultant clinic, R= 
right side, L= left side). 
Patient Primary Diagnosis Outcome Screened Diagnosis 
AL260314 hyperkeratosis* review leukoplakia R+L buccal sulcus + paan staining 
AL260337 DNA - erosive LP L buccal 
AL260339 oral submucous fibrosis* review OSF and non-healing ulcer R ventral tongue 
AL260342 hyperkeratosis* review leukoplakia R buccal sulcus + paan staining 
NS310304 DNA - leukoplakia R ventral tongue + paan staining 
NS310334 DNA - leukoplakia R buccal sulcus + R FOM 
NS310331 mild/moderate dysplasia* review erythroleukoplakia R FOM + paan staining 
NS310330 lichen planus* review erythroleukoplakia R ventral tongue + LP 
NS310339 hyperkeratosis* review leukoplakia R+L buccal + paan staining 
AL020409 DNA - leukoplakia R buccal sulcus + paan staining 
AL020411 hyperkeratosis review# leukoplakia L buccal sulcus + L ventral tongue 
AL020430 DNA - ulcer (OSCC) R FOM 
AL020439 hyperkeratosis* discharge erythroleukoplakia L FOM + paan staining 
AL020441 oral submucous fibrosis* review OSF + erthyroleukoplakia R FOM/ventral tongue + paan staining 
AL020443 haemangioma discharge leukoplakia L buccal sulcus + erythroplakia L palate + paan staining 
AL050408 DNA - leukoplakia R FOM + paan staining 
AL050423 hyperkeratosis* review leukoplakia R buccal sulcus 
AL050431 hyperkeratosis* discharge leukoplakia R+L buccal sulcus + paan staining 
NS070401 fibro-epithelial polyp* discharge erythroleukoplakia R buccal + paan staining 
NS070405 DNA - leukoplakia R ventral tongue + paan staining 
NS070415 hyperkeratosis* review leukoplakia R buccal sulcus + paan staining 
NS070417 DNA - leukoplakia R+L buccal sulcus + gingivae + paan staining 
NS070422 hyperkeratosis* review leukoplakia R FOM + paan staining 
NS070422 lichenoid* review lichenoid + leukoplakia R FOM 
NS070423 lichenoid* review leukoplakia R ventral tongue + LP 
NS070434 hyperkeratosis* review leukoplakia R buccal + paan staining 
AL090411 mild/moderate dysplasia* review ulcer (OSCC) R ventral tongue + paan staining 
AL090419 hyperkeratosis* discharge leukoplakia L FOM + paan staining 
AL090421 candidiasis* review erythroleukoplakia R buccal + paan staining 
NS140418 mild/moderate dysplasia* review erythroplakia L FOM 
NS140429 DNA - leukoplakia R ventral tongue + paan staining 
NS140434 DNA - leukoplakia R FOM 
AL160402 mild/moderate dysplasia* review erythroplakia L ventral tongue + paan staining 
AL160427 moderate/severe dysplasia* review erythroplakia R FOM + paan staining 
AL230418 physiological pigmentation discharge leukoplakia R buccal sulcus 
AL230426 DNA - erythroplakia R ventral tongue + paan staining 
NS280407 hyperkeratosis* review leukoplakia R ventral tongue + paan staining 
NS280412 hyperkeratosis* review leukoplakia L FOM + paan staining 
NS280422 hyperkeratosis* review erythroleukoplakia L FOM + paan staining 
NS280436 haemangioma discharge leukoplakia R buccal + L FOM + paan staining 
AL250403 hyperkeratosis review leukoplakia R+L FOM + paan staining 
AL300401 hyperkeratosis* review leukoplakia L ventral tongue + paan staining 
AL300413 hyperkeratosis* discharge leukoplakia R+L buccal 
AL030505 DNA - leukoplakia R FOM + paan staining 
NS050503 hyperkeratosis* review leukoplakia L FOM + paan staining 
AL070519 oral submucous fibrosis* review OSF + leukoplakia L FOM + paan staining 
AL140528 hyperkeratosis* review leukoplakia L FOM + paan staining 
AL140539 hyperkeratosis* review leukoplakia R+L buccal + paan staining 
AL170545 DNA - leukoplakia R ventral tongue + paan staining 
AL210504 physiological pigmentation discharge erythroleukoplakia R ventral tongue + paan staining 
AL210516 hyperkeratosis* discharge leukoplakia R ventral tongue/FOM 
AL230522 oral submucous fibrosis* review OSF + leukoplakia R buccal 
NS260516 DNA - leukoplakia R FOM 
AL280512 mild/moderate dysplasia* review erythroleukoplakia R ventral tongue + paan staining 
AL280531 hyperkeratosis* discharge ulcer (OSCC) L ventral tongue + paan staining 
 179 
As no OSCC was detected in those who attended for definitive diagnosis the 
diagnosis are effectively all false positives. However, as discussed in Chapter 3 
the gold standard outcome of ‘patients who cannot be discharged from further 
follow-up’ is a more appropriate target for screening activity in the UK. The 
discharged patients have a range of screening clinical diagnosis including 
leukoplakia, erythroleukoplakia and even erythroplakia confirming the difficulty a 
screening dentist has in making a clinical diagnosis with PMDs. 
 
51 of 66 patients attended for definitive diagnosis of their screen positive status 
and Tables 4-07 and 4-08 show 17 of 51 (33%) of screening diagnosis could be 
considered accurate. The screening diagnosis were most accurate for the more 
clinically distinct PMDs such as OSF where all 6 cases were accurately reported 
and LP or lichenoid reactions where all 4 patients were also accurately reported. 
 
4-3.08  Complex and Benign Lesions 
Of 1438 oral mucosal lesions detected in the screened population, 54% were 
clinically diagnosed as benign and no patients with these lesions were referred. 
This implies the clinicians can readily exclude malignancy even if risk factors are 
prevalent. Of the 46% of lesions that were not definitively benign only a proportion 
were referred (Figure 4-03) as either PMDs in high risk individuals or suspected 
malignancy. The large number of clinically ‘not-benign but also not definitively 
malignancy’ OMLs detected indicates the difficulty in assessing this high-risk 
population for OSCC by direct visual examination. These should be termed 
‘complex lesions’ to distinguish them from the ‘benign lesions’ and also from the 
referred PMDs or malignancy. 
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Figure 4-03: The clinically benign lesions detected and the complex lesions, of which some were 
referred because malignancy could not be excluded by direct visual examination in high risk 
individuals. 
   
 
4-3.09  Proportions of OMLs Detected and Referred 
Amongst the clinically complex lesions, Figure 4-04 shows that 100% of 
erythroleukoplakias, erythroplakias and ulcers suspected to be OSCC were 
referred to the tertiary referral centre. One erosive LP lesion detected was also 
referred as this would be consistent with the presentation of OSCC. 93% of 
detected leukoplakias were referred due to the presence of significant risk factors 
such as tobacco and paan usage with the remainder detected in low risk 
individuals and therefore classified as routine referrals and inappropriate for a 
suspected cancer pathway. 67% of lichenoid reactions and 12% of reticular LP 
were also referred but always when present in conjunction with other lesions more 
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indicative of OSCC, such as erythroleukoplakia. Six out of 7 patients with OSF 
were referred because of the presence of associated lesions of concern and the 
other was also already under the care of the hospital. Paan staining itself was not 
an indication for referral, as it is endemic in areca nut extract users, but 11% of 
individuals also had other referable lesions. 
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Figure 4-04: The percentage of detected oral mucosal lesions referred to the secondary referral 
centre.  
 
 
4-3.10  Site of Lesions 
Mucosal lesions were detected throughout the oral cavity (Table 4-09) with the 
largest proportion (48%) on the buccal mucosa including the buccal sulcus. The 
buccal area was also the largest single site for the complex (36%) and referred 
(35%) OMLs. The buccal mucosa is also often the site of frictional keratosis 
related to the occlusion and therefore was also the single commonest site for 
benign mucosal lesions. There were no clinically benign lesions reported on the 
FOM or ventral tongue, which are conventionally high-risk sites for OSCC (Figure 
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4-05) and there were no referred lesions and very few complex lesions on the 
dorsum of the tongue consistent with this being a very rare site for OSCC.  
 
Table 4-09: Intraoral site of detected oral mucosal lesions in the screened population presented as 
the percentage of lesions at each site. 
 
Percentage of lesions at each intraoral site 
  
  
Buccal 
mucosa 
Labial 
mucosa 
Gingivae 
Residual 
alveolar 
ridge 
Palate Floor of 
mouth 
Ventral 
tongue 
Dorsal 
tongue 
Lateral/
tip of 
tongue 
Commisure 
Referred 
lesions 35% 6% 7% 0% 1% 30% 21% 0% 0% 0% 
Complex 
lesions 36% 12% 25% 3% 1% 8% 8% 1% 5% 1% 
Benign 
lesions 71% 8% 5% 2% 6% 0% 0% 1% 6% 0% 
All 
lesions 48% 11% 19% 3% 3% 6% 5% 1% 5% 1% 
 
 
 
bu
c
ca
l m
u
co
s
a
la
bia
l m
u
c
os
a
gin
giv
ae
re
si
du
a
l a
lv
eo
la
r 
rid
ge
pa
la
te
flo
or
 
of
 
m
o
u
th
v
en
tra
l t
on
gu
e
do
rs
al
 
to
n
gu
e
la
te
ra
l/ti
p 
of
 
to
n
gu
e
co
m
m
is
u
re
0%
10%
20%
30%
40%
50%
60%
70%
80%
Referred Lesion
Complex Lesion
Benign Lesion
All Lesions
 
Figure 4-05: Intraoral site of detected oral mucosal lesions in the screened population presented as 
the percentage of clinically benign lesions, clinically complex lesions and its subgroup of refereed 
lesions, at each site, as well as all detected lesions shown by site. 
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4-3.11  Lesion Detection and Gender 
The total screened population of 1111 people was 58% male and 42% female 
however the 1438 lesions detected were predominantly in females (64%) (Table 4-
10). Analysing the breakdown of lesions in the referred group when classified as 
complex or benign, confirmed this female predominance in the detected OMLs. 
Pearson et. al. (2001) 23 reported a similar male:female mix in the screened 
population (56:44) but their 55 detected OMLs were reported in the same 
proportions (56:44) as the population screened. 
 
Table 4-10: Gender mix in the screened population with Chi squared analysis confirming the 
significant difference in the proportion of males and females in the population with mucosal lesions 
but no significant difference between the groups of lesion.(* = evaluated against the all lesions 
group, ^ = evaluated against the referred lesions subgroup,  “ = evaluated against the complex 
lesions subgroup and & = evaluated against all screened individuals) 
  
Total number of people screened 1111  
Males 645 58% 
Females 466 42% 
 
Total number of people with lesions 604  
Males 217 36% 
Females 387 64% 
0.000008& 
   
All Lesions Detected 1438  
Males 544 38% 
Females 894 62% 
 
Referred Lesions 131  
Males 54 41% 
Females 77 59% 
0.537* 
 
Complex Lesions 656  
Males 216 33% 
Females 440 67% 
0.288* 0.089^ 
 
Benign Lesions 782  
Males 328 42% 
Females 454 58% 
0.418* 0.056^ 0.839” 
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Paan chewing, in particular is known to be a cultural ritualistic trait amongst 
Bangladeshi women 88 although there was no difference in rates of paan usage 
reported between men and women in this population. In contrast smoking in the 
Bangladeshi population has been reported to be predominantly a male trait 23, 88 
but again there was no difference, in our screened population. Pearson et. al 
(2001) 23 reported 53% of males smoking and just 5% of women although paan 
usage was more evenly distributed with 88% of women and 69% of men. This 
discrepancy maybe related to the brevity of data collection and not attempting to 
elucidate further details of paan and smoking habits in our study, in order not to 
interfere with the primary objective of OSCC screening. Additionally, the dentists 
were utilising interpreters to gather much of the information throughout the 
screening process with the Bangladeshi patients who often did not speak English. 
There may be translation issues in specifically explaining the difference between 
smoking tobacco and chewing tobacco or the distinction between areca nut 
containing compounds with and without tobacco. The other possibility is related to 
the screening methodology in Tower Hamlets, which at some locations focussed 
on encouraging women to attend by placing the mobile dental unit at specific sites 
such as Aden House Women’s Association and actively recruiting participants 
utilising the staff at these community locations. This may account for the 
predominance of OMLs in women in the screened population as ladies with oral 
lesions may have congregated awaiting screening. There is some evidence of this 
effect in the data as when OMLs were present in women screened in Newham the 
average number of lesions per individual was 1.5 compared to 2.5 for men in 
Newham, 2.4 for women in Tower Hamlets and 2.7 for men in Tower Hamlets 
(Table 4-11).  However, these numbers need to be interpreted with caution due to 
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the small sample sizes, especially in Newham where a just few people in different 
groups would skew the figures significantly.  
 
Table 4-11: Proportions of individuals in which mucosal lesions where detected in each borough. 
 
 Number of Patients Number of Lesions Lesions per Person 
All Detected Lesions Total 604 Total 1438  
Male 217 (36%) 544 (38%) 2.5 
Female 387 (64%) 894 (62%) 2.3 
 
Newham Individuals with Lesions Total 141 Total 279  
Male 75 (53%) 165 (59%) 2.5 
Female 66 (47%) 114 (41%) 1.5 
 
Tower Hamlets Individuals with Lesions Total 463 Total 1159  
Male 142 (31%) 379 (33%) 2.7 
Female 321 (69%) 780 (67%) 2.4 
 
 
4-3.12  Oral Cancer Risk Factors and Lesion Detection 
A multiple logistic regression analysis was performed to determine any relationship 
between the presence of OMLs in the screened population and their risk factors 
for OSCC (Table 4-12). Individuals in the screened population who used paan 
were 3.43 times (CI: 1.18 - 5.31) more likely to have any OMLs than those who did 
not when controlling for the other risk factors of smoking, alcohol and age. 
Smokers were 2.52 times (CI: 1.02 - 4.54) more likely to present with OMLs than 
non-smokers controlling for paan and alcohol usage and age effects which would 
be expected as smoking is known to induce keratosis of the oral mucosa either by 
direct effect of heat or chemical irritation.  
 
There was no statistically significant relationship with use of alcohol and the 
presence of all OMLs or with increasing age. 
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Table 4-12: Multiple logistic regression analysis showing the relationship between the presence of 
oral mucosal lesions and risk factors for oral cancer, in the screened population. 
  
95% 
Confidence 
Interval 
 
Odds 
Ratio 
Low High 
Significance 
Level 
(p value) 
     All Lesions (Total 1438) 
Paan 3.43 1.18 5.31 0.033 
Smoking 2.52 1.02 4.54 0.041 
Alcohol 1.04 0.73 1.91 0.268 
Age 1.07 0.94 1.22 0.136 
     Benign Lesions (Total 782) 
Paan 1.02 0.79 1.19 0.491 
Smoking 1.79 0.99 7.29 0.191 
Alcohol 1.06 0.91 1.46 0.103 
Age 1.12 0.97 1.19 0.144 
     Complex Lesions (Total 656) 
Paan 5.82 1.98 8.43 0.002 
Smoking 3.59 1.12 4.47 0.027 
Alcohol 1.14 0.92 1.71 0.092 
Age 1.02 0.98 1.51 0.195 
 
 
 
For benign lesions where the dentist is clinically certain there can be no 
malignancy there were no statistically significant relationships between any of the 
risk factors and the presence of these benign OMLs.  
 
Complex lesions show the most prominent relationships between the risk factors 
and the presence of these difficult to diagnose OMLs. The use of paan is highly 
correlated with a 5.82 times (95% CI: 1.98 – 8.43) increase in complex OMLs 
controlling for smoking, alcohol and age related changes. Smoking is associated 
with a 3.59 times (95% CI: 1.12 – 4.47) elevated chance of presenting with a 
complex OML. As with the other groups there is no detectable relationship 
between alcohol usage and OML prevalence in the population or any age related 
changes in the multivariate regression analysis (Table 4-12). 
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4-3.13  Multiple Detected Lesions 
In total 1438 OMLs were detected in the screened population of 1111 people. 
These lesions were all detected in just 604 of these individuals of which 188 (31%) 
had just 1 OML and the other 408 (69%) presented with multiple lesions (Table 4-
13). The patients referred with suspected cancer totalled 66, consisting of 11 
(17%) with 1 OML and 55 (83%) with multiple lesions. 656 OMLs were complex 
lesions and presented in 225 patients with again the majority of patients having 
multiple lesions (84%). The presence of 782 benign lesions in 379 patients was 
more evenly split with 40% presenting with 1 OML and 60% multiple OMLs. The 
presence of multiple OMLs in this population groups was also noted by Pearson 
et. al. (2001) 23 although the clinical significance was not discussed. 
 
Table 4-13: The numbers of patients with one or multiple mucosal lesions in total and in the 
referred population as well as those with complex and benign lesions. 
 
Total number of lesions  1438 
Number of patients with any detected lesions 604 
Patients with 1 lesion 188 31% 
Patients with >1 lesions 416 69% 
 
Referred lesions in total 131 
Number of referred patients 66 
Refereed patients with 1 lesion 11 17% 
Referred patients with >1 lesions 55 83% 
   
Complex lesions in total 656 
Number of patients with complex lesions 225 
Patients with 1 lesion 35 16% 
Patients with >1 lesions 190 84% 
  
Benign lesions in total 782 
Number of patients with benign lesions 379 
Patients with 1 lesion 153 40% 
Patients with >1 lesions 226 60% 
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4-4.01  DISCUSSION  
 
4-4.02  The High Prevalence of OMLs in the Screened Population 
The presence of large numbers and a wide variety of OMLs in the screened 
population for OSCC is likely to be the cause of misinterpretation and resultant 
reduced sensitivity of screening by direct visual examination. 
In total 1438 OMLs were detected in 604 (54%) individuals in the screened 
population of 1111 individuals (Table 4-11). This is considerably higher than the 
40% prevalence reported by Pearson et. al. (2001) 23 in a similar population 
although this can be explained by the targeting of high-risk individuals rather than 
simply observing patients in a general medical practice waiting room. Also our 
reporting criteria included common lesions such as frictional keratosis (36%) and 
paan staining (36%) (Table 4-06) which appear to be not often reported in other 
studies 23-25. This could be because they are so widespread, in this population, as 
to be considered normal variations for a population with high levels of areca nut 
compound and tobacco usage. Additionally, paan staining is not a specific clinical 
lesion in the conventional terminology so maybe overlooked when assessing 
OMLs. These lesions are clinically important because they complicate the 
assessment of OSCC by direct visual examination. Frictional keratosis presents as 
a white patch which can only be excluded from a diagnosis of leukoplakia by a 
careful history and examination to determine the specific cause of frictional 
trauma. Therefore, if no clear cause can be elicited, keratosis, must be classified 
as leukoplakia and in a high-risk individual, biopsied to exclude dysplasia 15. Paan 
staining by definition occurs in high-risk individuals due to the use of areca nut 
containing compounds and its red-brown discolouration of the mucosa may mask 
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or alter the appearance of other OMLs, necessitating careful drying, washing and 
debridement of the mucosal surface for adequate visual examination. Paan 
staining and frictional keratosis are therefore significant issues that directly affect 
OSCC detection by visual examination and cannot be ignored when evaluating the 
role of OMLs in screening efficacy for OSCC.   
 
As well as the high prevalence of OMLs, 32 different types of mucosal lesion were 
detected in the screened population (Table 4-06). 134 lesions were conventionally 
described as PMDs (9.3%) including leukoplakia representing (4.1%), OSF (0.5%), 
erythroleukoplakia (0.8%) and erythroplakia (0.3%). Other rare OMLs such as 
Fordyce spots and herpetiform aphthous ulceration were also detected which also 
serve to complicate the assessment of the oral mucosa.  Therefore, the high 
prevalence and wide variety of OMLs in the screened population confirms the 
difficulty reported by examiners in screening for OSCC by direct visual 
examination the Tower Hamlets and Newham populations.  
 
4-4.03  The Value of Classifying OMLs as Complex or Benign 
OMLs have conventionally been reported in the literature as benign or PMDs or 
OSCC. PMDs have a broad definition of “all clinical presentations that carry a risk 
of cancer” 15. Discussions are often limited to leukoplakia and erythroplakia such 
as in the WHO group review by Napier et. al. (2008) 29 although the broader 
description may be more helpful clinically especially in high-risk population where 
non-leukoplakia PMDs, such as OSF, are common. This confusion may have 
arisen because the definition of PMDs as “all clinical presentations that carry a risk 
of cancer” is not specifically stated in the report by Warnakulauriya et. al. (2007) 
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unlike their clear definition of leukoplakia. The PMD definition occurs in a 
discussion regarding the lack of value in the previous WHO terminology 
differentiating between ‘lesions’ and ‘conditions’.  
 
Of 1438 oral mucosal lesions detected in the screened population 54% were 
clinically diagnosed as benign and no patients with these lesions were referred 
(Figure 4-03). This implies the clinicians can readily exclude malignancy even if 
risk factors are prevalent which is consistent with the high specificity reported for 
direct visual assessment for OSCC 62. Of the 46% of lesions that were not 
definitively benign only a proportion were referred (Figure 4-03, Table 4-07 and 
Table 4-08) as either conventionally described PMDs or suspected malignancy. 
The number of clinically ‘not-benign but also not definitively malignancy’ OMLs 
which also are not usually described as PMDs indicates the need for another term 
such as complex oral mucosal lesions. An important example of an OML that falls 
between the current classification is paan staining or paan associated mucositis 
whereby it’s presence alone  indicates risk factors for OSCC and the staining may 
also obscure malignant mucosal changes. Therefore, complex lesions would be a 
screening-specific term used in direct visual assessment of the oral mucosa 
relating to any abnormality that was not definitively benign. Complex lesions would 
include PMDs and any other mucosal abnormality that the screening dentist could 
not assign a benign diagnosis to and therefore, in high-risk individuals, could not 
be certain was not malignancy. Complex is a better description than ‘suspicious’ 
for a lesion as it indicates the uncertainty of the visual assessment process without 
directly indicating the lesion is malignant or potentially malignant. Therefore, 
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complex lesions could be watched or acted on whilst all suspicious lesions require 
action. 
 
Only 17 of 51 (33%) screening diagnosis could be considered accurate when 
definitive diagnosis is known (Table 4-07 and 4-08). This is predominantly 
because it is impossible to differentiate benign hyperkeratosis in clinically evident 
leukoplakia from those lesions with dysplasia on the basis of a direct visual 
examination. Therefore, detection of leukoplakia by direct visual examination will 
inevitably have very low sensitivity and specificity without adjuncts to aid 
diagnosis. The screening diagnoses were most accurate for the more clinically 
distinct PMDs such as OSF where all 6 cases were accurately reported and LP or 
lichenoid reactions where all 4 patients were also accurately reported. Of the 
patients eventually discharged from further follow-up, indicating no significant risk 
of malignancy, there was range of screening clinical diagnosis including 
leukoplakia, erythroleukoplakia and even erythroplakia confirming the difficulty a 
screening dentist has in making a clinical diagnosis with PMDs. 
 
Amongst the complex clinical lesions detected, Figure 4-04 shows that 100% of 
erythroleukoplakias, erythroplakias and ulcers suspected to be OSCC were 
referred to the tertiary referral centre. 93% of detected leukoplakias were referred 
due to the presence of significant risk factors such as tobacco and paan usage 
with the remainder detected in low risk individuals and therefore classified as 
routine referrals and inappropriate for a suspected cancer pathway. 67% of 
lichenoid reactions and 12% of reticular LP were also referred but always when 
present in conjunction with other lesions more indicative of OSCC, such as 
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erythroleukoplakia. Six out of 7 patients with OSF were referred because of the 
presence of associated lesions of concern and the other was also already under 
the care of the hospital for their condition. Paan staining itself was not an 
indication for referral but 11% of individuals also had other referable lesions. 
Together, this suggests that the group of complex clinical lesions where the 
dentist’s clinical judgment is required to determine whether referral is appropriate 
comprises leukoplakia, lichenoid reactions, LP, OSF and paan staining either 
because the lesion may itself be malignant or because it maybe associated with 
other PMDs. These are the lesions that complicate referral for OSCC screening 
dentists and therefore are most likely responsible for the low sensitivity and PPV of 
direct visual screening for OSCC. 
 
As well as the clinical diagnosis the other factor in the decision to classify lesions 
as complex or benign is their location in the oral cavity. Mucosal lesions were 
detected throughout the oral cavity (Table 4-09) with the largest proportion (48%) 
on the buccal mucosa including the buccal sulcus. This is consistent with a 
significant proportion of the screened population using paan, which results in 
traumatic keratosis at the site of usage, and therefore the buccal area was also the 
largest single site for the complex (36%) and referred (35%) OMLs. The buccal 
mucosa is also often the site of frictional keratosis related to the occlusion and 
thus was also the single commonest site for benign mucosal lesions. Pearson et. 
al. (2001) 23 also reported the majority of OMLs were detected on the buccal 
mucosa in their study of Bangladeshi medical care users, confirming the likely 
aetiology. There were no clinically benign lesions reported on the FOM or ventral 
tongue, which are conventionally high-risk sites for OSCC (Figure 4-05). This 
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would indicate the dentists were unable to exclude malignancy in any lesions at 
these sites whilst conversely there were no referred lesions and very few complex 
lesions on the dorsum of the tongue consistent with this being a very rare site for 
OSCC to develop.  
 
Taken together this data suggests that the screening diagnosis of a benign or 
complex lesion specifically relates to both the screening dentists clinical diagnosis 
and the high-risk site of the OML suggesting this terminology is more accurate in 
reflecting the clinical reality of OSCC screening by visual assessment of the oral 
mucosa than the use of the term ‘potentially malignant disorder’.   
 
 
4-4.04  Significance of the Multiple OMLs in the Screened Patients 
 
It has been reported in previous studies of the Bangladeshi population of Tower 
Hamlets that patients often present with multiple OMLs 23 but the significance of 
this has not been evaluated. The screening dentists in this study also reported that 
difficulties in diagnosing patients with suspicious lesions occurred due to the 
presence of multiple oral mucosal abnormalities. Therefore, it would be expected 
to see more patients in the referred population with multiple OMLs than the 
general screened population. The proportions of patients presenting with 1 OML or 
multiple OMLs are significantly different between the referred group and the total 
group of people with OMLs (Figure 4-06). Comparison of proportions of patients 
with multiple mucosal lesions shows the composition of the referred patient’s 
group is also different to the group of patient’s with benign lesions but similar to 
the complex lesions group. This could simply be because the referred patients, by 
definition, are a sub-group of the complex lesions group but as they only comprise 
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about 10% (66 out of 656) of this group, the indication is of some correlation 
between multiple lesions and referral. This is supported by the benign lesion group 
(where there were no referrals) having statistically significantly fewer patients with 
multiple lesions. The relationship is complex because any one lesion can initiate a 
referral, if suspicious enough to the clinician, but it would also seem reasonable 
that more OMLs would increase the screening clinician’s level of uncertainty and 
concern, especially if the lesions are not obviously benign. To add some degree of 
triangulation validity to this analysis, as well as the benign lesions group being 
significantly different in proportion of patient’s with multiple OMLs, to the referred 
patient group and the complex lesions group, it is statistically similar to the whole 
population of patients with OMLs (Figure 4-06). 
 
Overall it would appear that the screening dentists were referring higher 
proportions of patients with multiple OMLs, specifically if they were complex 
OMLs. This could indicate the dentists were struggling to make a definitive 
diagnosis of no OSCC by visual assessment of the oral mucosa alone, when there 
were multiple complex OMLs present. Multiple benign OMLs did not appear to 
cause this diagnostic dilemma. 
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Figure 4-06: Chi-squared comparison of proportions of patients with multiple mucosal lesions 
shows the composition of the referred patients group is similar to the complex lesions group and 
different to all other groups. The benign lesions group is significantly different in proportion of 
patients with multiple lesions to the referred patient group and the complex lesions group but 
similar to the whole population of patients with multiple OMLs.     
 
 
4-4.05  Oral Cancer Risk Factor Correlation with Lesion Detection 
Individuals in the screened population who used paan were 3.43 times (CI: 1.18 - 
5.31) more likely to have any OMLs than those who did not when controlling for 
the other risk factors of smoking, alcohol and age (Table 4-12). This would be 
consistent with paan usage having substantial staining effects on the oral mucosa 
presenting as visibly detectable OMLs most notably at the site of paan usage. 
Smokers were 2.52 times (CI: 1.02 - 4.54) more likely to present with OMLs than 
non-smokers controlling for paan and alcohol usage and age effects which would 
be expected as smoking is known to induce keratosis of the oral mucosa either by 
direct effect of heat or chemical irritation. Use of tobacco and areca nut 
compounds resulting in increasing numbers of OMLs is consistent with evidence 
that these risk habits are directly related to the presence of leukoplakia as shown 
by Gupta et. al (1992) 124 in a large scale intervention study where stopping 
tobacco usage also drastically reduced the incidence of leukoplakia. 
 196 
There was no statistically significant relationship with use of alcohol and the 
presence of all OMLs. An explanation could be the small sample size for alcohol 
users as only 12% of those screened in Tower Hamlets admitted drinking alcohol. 
It is also possible that alcohol use is infrequent and minimal, in this population, as 
no attempt was made to quantify units or regularity of use. Alternatively alcohol 
use may not result in visible OMLs in the same way as paan or smoking as there 
is no frictional or heat component to alcohol in the oral cavity.  
 
Age has previously been linked with the presence of OMLs in the Bangladeshi 
population 23 yet our multiple logistic regression analysis showed no association 
(Table 4-12). The lack of a relationship in the screened population maybe related 
to the screened population’s relatively low mean age 42.3 (SD 15.9 years) for 
Tower Hamlets (Table 3-03). This would imply relatively fewer older people and 
the resultant small sample size would directly affect the ability to show a 
statistically significant relationship with the older age ranges. It is also known that 
logistic regression algorithms are systematically inaccurate for odds ratios when 
the sample size is less than 500 although conversely the degree of inaccuracy is 
often much lower than the standard error of the estimate and therefore potentially 
insignificant 125. The other possibility is that age presents as a compound risk with 
increasing time of the other behavioural risk factors and the multiple logistic 
regression analysis methodology controls for the other risk factors thereby 
negating this effect. To evaluate this, a univariate linear regression for one 
continuous exposure variable was carried out on the 1111 screened individuals 
with the single outcome variable being the presence of any OMLs and no controls 
for any of the other risk factors (Table 4-14). 
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Table 4-14: Linear regression analysis to determine the relationship between age and the presence 
of OMLs in the screened population. 
 
95% 
Confidence 
Interval 
 
Odds 
Ratio 
Low High 
Significance 
Level 
(p value) 
     All Lesions (Total 1438) 
Age 1.01 1.00 1.03 0.011 
     Benign Lesions (Total 782) 
Age 1.11 0.97 1.17 0.217 
     Complex Lesions (Total 656) 
Age 1.04 1.01 1.14 0.041 
 
 
 
The interpretation of the linear regression analysis would be that for every one 
year increase in age, the odds of developing a OMLs increase by a factor of 1.01 
(95% CI: 1.00 -1.03) or by about 1% each year. The relationship shown by linear 
regression but not by multiple regression controlling for paan usage and smoking 
suggests age presents a cumulative effect of the other risk factors but in itself is 
not a risk factor for the development of OMLs. Older patients essentially have 
more time for pathological features to develop from paan usage and smoking and 
the incidence of OMLs rises because of an inability to repair this pathological 
damage.  
 
For benign lesions where the dentist is clinically certain there can be no 
malignancy there were no statistically significant relationships between risk factors 
and the presence of OMLs. This is consistent with all paan related lesions being of 
some concern to the dentist and therefore not classified as benign hence the lack 
of a relationship with paan usage unlike for all OMLs together. The bulk of the 
benign lesions were frictional keratosis (71%) (Table 4-06) and they are 
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predominantly on the buccal mucosa (Table 4-09) indicating an occlusal trauma 
aetiology. This would explain the lack of a relationship with smoking and it is also 
feasible that smoking being a risk factor for OSCC caused the dentist to classify 
any lesions in smokers as complex for that reason alone. 
 
Complex lesions show the most prominent relationships between the risk factors 
and the presence of these difficult to diagnose OMLs. The paan usage related 
increase is highly statistically significant with a 5.82 times (95% CI: 1.98 – 8.43) 
increase in complex OMLs controlling for smoking, alcohol and age related 
changes. This might be expected because of the visible nature of paan related 
staining of the oral mucosa alerting the dentist to the OSCC risk. Smoking is 
associated with a 3.59 times (95% CI: 1.12 – 4.47) elevated chance of presenting 
with a complex OML whilst controlling for paan or alcohol usage and age related 
changes. As with the other groups there is no detectable relationship between 
alcohol usage and OML prevalence in the population and any age related changes 
may again be being masked by the statistical approach. Linear logistic regression 
analysis of the complex lesion sub-population confirms that age is correlated with 
the presence of OMLs (Table 4-14) but the effect is again likely to be related to the 
other risk factors as it is not apparent when controlling for paan, smoking and 
alcohol usage (Table 4-12). Also the age effect is more evident than with the total 
population of OMLs as the odds ratio is 1.04 (95% CI: 1.01 – 1.14) suggesting a 
4% increase in OMLs per year compared to 1% for all OMLs (Table 4-14). This 
would suggest the risk factors have a more pronounced age effect on people with 
complex lesions than benign or all OMLs supporting the increased risk status of 
this group determined clinically by the dentists. 
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4-5.01  CONCLUSION 
 
 
OMLs are highly prevalent amongst patients targeted for high risk screening in the 
South Asian populations of Tower Hamlets and Newham. The OMLs detected can 
be classified as clearly benign or more complex and problematic lesions which 
may adversely affect the screening dentist’s ability to diagnose suspected OSCC 
accurately. The difficult complex lesions are predominantly leukoplakias as the 
more distinct clinical presentation of PMDs such as OSF and LP is more readily 
diagnosed. The presence of multiple complex OMLs in individual patients further 
hinders the dentist’s ability to screen accurately for OSCC potentially resulting in 
more false positive outcomes. Furthermore, the lifestyle risk factors for OSCC that 
are prevalent in the South Asian population, paan usage and smoking, increase 
the prevalence of these complex OMLs in a time dependent manner.  
 
Taken together this indicates that targeted screening for OSCC in South Asian 
populations by direct visual assessment is always likely to result in high levels of 
false positives because of the presence of other OMLs. Therefore, an effective 
screening protocol for South Asian populations in the UK could not be performed 
by direct visual assessment alone necessitating diagnostic aids to increase 
screening sensitivity. 
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CHAPTER 
FIVE 
 
 
IMMUNOHISTOCHEMICAL ANALYSIS OF KERATIN EXPRESSION IN FRESH 
FROZEN TISSUE SPECIMENS OF ORAL SUBMUCOUS FIBROSIS 
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Chapter 5 
 
 
Immunohistochemical Analysis of Keratin Expression in Fresh 
Frozen Tissue Specimens of Oral Submucous Fibrosis 
 
 
 
5-1.01  INTRODUCTION 
From experience of screening in the Tower Hamlets and Newham South Asian 
populations we have observed two major issues that need resolving before a 
viable targeted screening programme can be contemplated. Firstly the issue of 
non-attendance of screen positive individuals at referral, resulting in an inability to 
accurately evaluate screening outcomes and the potentially more important, but 
completely unquantifiable, effect on the screened individual. Despite all possible 
measures to prevent this 21 out of 86 (24%) of all screen positive individuals from 
the screened population did not comply with referral which may be an inherent 
property of this population as referral compliance in UK studies is usually reported 
approaching 100% yet South Asian based studies are consistent with our findings 
62, 109
. The second major issue is the high prevalence of OMLs in this population 
and in particular those complex lesions that cannot clinically be diagnosed as 
benign and the consequential difficulty in determining which lesions require further 
investigation for malignancy. These two issues are clearly inter-related as the 
difficulty in diagnosis leads to more false positive outcomes from screening activity 
with resultant larger numbers of screen positive individuals referred and 
subsequently failing to attend for definitive diagnosis. The simplest solution is to 
undertake the definitive diagnosis at the time of screening.  
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5-1.02  Definitive Diagnosis of Oral Mucosal Lesions 
The standard process for definitive diagnosis of OMLs is a combination of gross 
(macroscopic) examination followed by histologic (microscopic) examination of a 
tissue section which may be aided by evaluation of the molecular properties of the 
lesion by immunohistochemistry of the tissue section. During cancer resection 
surgery these stages are often carried out in an immediate manner utilising frozen 
section histology to evaluate resection margins before surgical reconstruction is 
attempted. 
 
A variant of this ‘intra-operative pathology support’ approach would be relatively 
straightforward on a mobile dental unit which could house facilities to immediately 
biopsy and snap freeze samples that would be couriered to a pathology laboratory 
for sectioning, staining and diagnosis. The screen positive patient could have a 
definitive diagnosis within a few hours, as to whether they actually had oral cancer 
or not. 
 
PMDs are more problematic as although histology is valuable for diagnosis it is 
their potential to become OSCC that is the most important concern. Our screening 
outcomes suggest some PMDs, such as LP and lichenoid reactions, can be 
readily diagnosed by direct visual examination and this would be enough to 
indicate the patient with relevant risk factors cannot be discharged from further 
follow-up, which is the most appropriate soft gold standard for a positive screening 
outcome in the UK. Leukoplakia was a more difficult diagnostic decision for the 
screening dentist, especially with the paan staining commonly found in high-risk 
South Asian populations such that the majority of lesions referred as leukoplakia 
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were actually benign hyperkeratosis (Table 4-07 and Table 4-08). The presence of 
dysplastic change is the most widely used and reliable indicator of malignant 
potential in leukoplakia 33 and this can be assessed on fresh frozen sections in a 
similar manner to that used to determine clear resection margins. For the soft gold 
standard outcome the presence or absence of dysplasia would be appropriate for 
a positive result. From our experience an average of 2-3 individuals were 
screened positive on each screening day and would require intra-operative 
pathology support for definitive diagnosis which may be feasible within existing 
healthcare services.  
 
In relation to South Asian populations, of particular concern is OSF because of the 
significant potential for malignant conversion (7-26%) 39 as well as the clinical 
complications associated with the fibrosis itself. OSF presents a specific problem 
in screening for OSCC because of its direct association with areca nut compounds 
41
 found in paan. However, OSF only occurs in a small proportion of areca 
compound users, such as the 7 out of 568 (1.2%), reported in our sample, 
suggesting that despite the association with areca it’s specific aetiology is complex 
and not clearly understood. Paan staining itself was a significant issue reported by 
the dentists when attempting direct visual assessment of the oral mucosa during 
the screening programme. Therefore, histological methods to aid diagnosis of OSF 
would be valuable for improving the sensitivity of OSCC screening in high-risk 
South Asian populations. 
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5-1.03  Immunohistochemistry 
Immunohistochemistry (IHC) is the process of detecting antigens in the cells of a 
tissue section by utilising the specificity of antibody binding to those antigens 
(Figure 5-01). IHC shows exactly where the antigen is located within the tissue 
examined. Its major disadvantage is that, unlike immunoblotting techniques where 
staining is checked against a molecular weight ladder, it is impossible to show in 
IHC that the staining definitively corresponds to the protein of interest. Therefore, 
the antibodies used must be well-validated in Western Blots or similar procedures 
to validate IHC staining patterns.  
 
 
Figure 5-01: Two layer indirect immunohistochemical staining for antigen A, using a primary anti-A 
antibody and a secondary antibody raised against the primary. The secondary is also labelled with 
biotin which binds streptavidin. The streptavidin is conjugated with Horse Radish Peroxidase (HRP) 
which oxidises 3,3'-Diaminobenzidine (DAB) to a visible brown colour. 
 
 
Various different systems exist for IHC with the most common based on the avidin-
biotin system 126. The primary antibody is raised against the antigen of interest 
(e.g. ‘A’ in Figure 5-01) in a species that will not cross-react with human, such as 
rabbit. The primary then binds specifically to antigen A and any excess is washed 
away leaving only specific bound antigen–antibody complex. A secondary 
antibody raised against the species of the primary (i.e. rabbit) then binds the 
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primary-antigen A complex. The secondary is labelled with biotin reporter 
molecules which have a very high affinity for streptavidin. Streptavidin itself is 
conjugated with the enzyme horse radish peroxidise (HRP). HRP can be made 
visible using a substrate that, when oxidized by HRP using hydrogen peroxide as 
the oxidizing agent, produces a characteristic colour. 3,3'-Diaminobenzidine (DAB) 
is one such substrate that produces a clear brown colouration of the specifically 
stained areas of tissue. As streptavidin has four binding sites for biotin and 
multiple biotin molecules label the secondary antibody this amplification system 
allows for maximum sensitivity of detection. 
 
5-1.04  Fresh Frozen and Formalin Fixed Tissue Sections  
Fresh frozen tissue specimens ideally require a source of extreme cold for snap 
freezing to preserve cytoarchitecture and molecular markers as well as allowing 
cryosectioning for IHC. For this reason fresh frozen sections are considerably 
more difficult to handle than formalin fixed paraffin embedded tissue where the 
fixation process minimises degradation of the tissue. Unfortunately the fixation 
process is also known to mask antigens and interfere with antibody binding. This is 
thought to be due to formaldehyde associated methylene bridge cross-linking 
affecting the tertiary and quaternary structures of proteins 127. To permit antibody 
binding a process of antigen retrieval is usually required and commonly involves 
high temperature and a citrate or ethylenediaminetetraacetic acid (EDTA) antigen 
retrieval buffer. The antigen retrieval process is known to compromise tissue 
morphology 126 and in combination with formalin fixation is a lengthy procedure 
unsuitable for an intra-operative pathology support services.    
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5-1.05  Normal Oral Mucosa 
The oral cavity is lined by a mucous membrane consisting of epithelium overlying 
a collagenous connective tissue lamina propria. The oral mucosa predominantly 
serves as a lining and protective barrier to the external environment. Histologically 
and functionally oral mucosa is classified as masticatory, lining or specialised. 
Lining mucosa makes up 60% of all oral mucosa and covers the labial and lingual 
sulcus, floor of mouth, soft palate and buccal mucosa. It is flexible to allow 
unrestricted function of the underlying musculature and comprises non-keratinised 
oral epithelium overlying a loose lamina propria and fatty or glandular submucosa. 
The masticatory mucosa of the hard palate and gingivae comprises 25% of the 
oral mucosa and is designed to withstand the abrasion and pounding of a food 
bolus during mastication. The epithelium of masticatory mucosa is keratinised and 
tightly bound to a dense connective tissue by large numbers of deep rete ridges 
and the lamina propria itself is attached to bone with no intervening submucosa. 
Specialised oral mucosa involved in taste sensation is found on the dorsum of the 
tongue and the lip mucosa also has an important sensory function. 
 
5-1.06  Oral Epithelium 
The oral epithelium is separated from the lamina propria by a 1-2µm thick 
basement membrane (BM) and constitutes the primary barrier to the external 
environment. Oral epithelium is a stratified squamous structure made up of layers 
of tightly adhered keratinocytes. The surface layer is constantly shed as a 
protective mechanism necessitating that the epithelium maintains its structural 
integrity by a continuous process of keratinocyte renewal whereby cells produced 
in the deepest layers migrate towards the surface whilst undergoing a process of 
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terminal differentiation, to replace those that are shed. Therefore, two distinct 
populations of epithelial cells can be described in the epithelium: a progenitor 
population predominantly located in the basal layer which undergoes cell division 
to produce new keratinocytes and a maturing cell population undergoing 
sequential terminal differentiation to replenish the surface layer. The progenitor 
population comprises a small number of adult stem cells and a larger population of 
transit-amplifying (TA) cells. Stem cells possess unlimited self-renewal capacity 
but rarely undergo cell division. A stem cell can either divide symmetrically to 
produce two identical stem cells or divide asymmetrically to regenerate and 
produce a TA cell 128. The TA cells migrate laterally to populate the basal layer and 
undergo limited rounds of rapid cell division to increase the TA pool of cells, and 
then become committed to undergo terminal differentiation in the suprabasal 
layers. This mechanism allows a large number of TA cells to be produced from a 
single stem cell division thus protecting the stem cells from acquiring genetic 
lesions because DNA is most at risk from environmental mutagenic agents whilst 
cells are actively dividing. The maturing cell population follows two distinct terminal 
differentiation lineages which results in either a keratinised or non-keratinised oral 
epithelium.  
 
5-1.07  Keratinised and Non-Keratinised Epithelium 
Keratinisation produces a tough, impermeable surface layer to the oral epithelium 
that is consequently less flexible than non-keratinised epithelium. Keratinised oral 
epithelium comprises cuboidal basal cells adjacent to the basement membrane 
and below several layers of larger elliptical keratinocytes in the prickle cell layer. 
The basal and prickle cell layers constitute over half the thickness of keratinised 
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epithelium and lie beneath the granular layer of flattened keratinocytes containing 
keratohyalin granules. The surface layer or stratum corneum consists of flattened 
squames which have no cellular organelles and are composed entirely of 
impermeable cross-linked keratin filaments (Figure 5-02). This differentiation 
lineage is referred to as ortho-keratinisation whilst a stratum corneum of flattened 
keratinocytes with pyknotic nuclei occurs in para-keratinisation and is a normal 
variation.   
 
    
 
Figure 5-02: Schematic representation of the appearance of keratinised oral epithelium. 
 
Non-keratinised oral epithelium is usually thicker than keratinised epithelium with 
the buccal epithelium often over 500µm from BM to surface. The basal and prickle 
cells resemble those of keratinised epithelium whilst the outer layers are arbitrarily 
divided into an intermediate zone and a surface zone with no significant difference 
in the appearance of the keratinocytes (Figure 5-03). 
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Figure 5-03: Schematic representation of the appearance of non-keratinised oral epithelium. 
 
 
5-1.08  Non-keratinocytes in the Epithelium 
Up to 10% of the cell population in oral epithelium are non-keratinocytes. In H+E 
sections these appear as ‘clear cells’ having a clear halo around their nuclei due to 
histologic processing resulting in contraction of the cytoplasm as it lacks the 
insoluble keratin cytoskeleton of the keratinocytes. Non-keratinocytes comprise 
pigment producing melanocytes and sensory Merkel cells in the basal layer of the 
epithelium as well as a few inflammatory Langerhans’ cells and lymphocytes that 
migrate in and out of the normal epithelium. 
 
5-1.09  The Lamina Propria 
The lamina propria consists of cells, blood vessels, neural components and fibres 
embedded in an amorphous extracellular matrix. The lamina propria is divided into 
two layers: the superficial papillary layer associated with the epithelial rete ridges 
and the reticular layer between the papillary layer and the deeper structures. The 
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reticular layer contains thick bundles of collagen fibres arranged parallel to the 
surface plane whilst the papillary layer is made up of finer loosely arranged 
collagen fibres and capillary loops. The principal cells found throughout the lamina 
propria are fibroblasts which are involved in the production and turnover of 
collagen, elastin and fibronectin as well as the proteoglycan rich extracellular 
matrix. Other cell types in the lamina propria include those involved in 
inflammation and host responses such as histiocytes, macrophages, neutrophil 
polymorphs, lymphocytes, plasma cells and mast cells. Endothelial cells are found 
lining vascular channels throughout the lamina propria. 
 
5-1.10  OSF Histological Features 
The characteristic pathological change in OSF is progressive collagenous fibrosis 
and hyalanisation of the sub-epithelial connective tissue and histological 
classification of OSF severity is based entirely on the extent of fibrosis and degree 
of inflammatory infiltration 129. (Figure 5-04) 
 
Figure 5-04: The histological presentation of OSF. (a) Early –  subepithelial inflammatory infiltrate 
(neutrophil polymorphs, lymphocytes and eosinophils) with dilated and congested vessels 
producing a marked oedema but no significant fibrosis of the connective tissue. (b) Intermediate – 
subepithelial fibrosis with early hylanisation characterised by thickened collagen bundles and 
moderate numbers of fibroblasts and chronic inflammatory cells (lymphocytes and plasma cells). 
(c) Advanced – extensive hyalinsation of the subepithelial connective tissue with fibrosis extending 
into the underlying muscle or adipose tissue and little inflammatory infiltrate or oedema due to 
decreased vascularity of the connective tissue. (Adapted from Utsunomiya et al. 2005 16)      
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5-1.11  OSF Related Epithelial Changes 
Although OSF is believed to be a connective tissue disorder certain epithelial 
changes have been noted ever since the first histological evaluations. Dysplasia 
has been reported in 26% of OSF lesions 130, which is consistent with the reported 
rates of malignant transformation to OSCC of 7-26% 39. Keratinising metaplasia is 
present in 67% of cases 131 and is believed to be due to direct mechanical trauma 
from the coarse fibres of the areca nut. Thinning of the epithelium occurs in 87% of 
OSF lesions 131 and was attributed to epithelial atrophy as a result of reduced 
submucosal vasculature and consequent lack of nutrient provision. More recently 
Rajendran et al. (2004) 132 have shown there is no increased keratinocyte cell 
death, either by apoptosis or necrosis, which is a prerequisite for epithelial atrophy 
and therefore suggested that reduced keratinocyte proliferation and epithelial 
hypoplasia as the mechanism for epithelial thinning in OSF.  The other epithelial 
abnormality often described in OSF histological sections is pigment incontinence 
from melanocytes embedded in the basal layer of the epithelium.  
 
Despite these consistent epithelial abnormalities reported in OSF, it is 
conventionally regarded as a connective tissue disorder with the epithelial 
changes a consequence of the underlying pathology. Even malignant 
transformation, the most significant and epithelial complication of OSF, is 
considered to occur because of the build-up of carcinogenic stimuli within the 
avascular sub-epithelial connective tissue. From the literature on other oral 
mucosal lesions and cutaneous fibrotic disorders it is apparent that gross epithelial 
changes often involve alterations within the individual keratinocytes and these 
keratinocytes are intimately involved in interactions with their surroundings 133. 
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Understandably, there is no data in the literature on these epithelial interactions in 
OSF.  
 
5-1.12  Keratins 
Keratinocytes display two structures that distinguish them as epithelial, one is the 
intercellular desmosome responsible for cellular cohesion and the other is their 
cytoskeletal filaments. The keratinocyte cytoskeleton comprises a class of 
intermediate filament forming proteins termed keratins, that as well as providing 
mechanical support for the cell are involved in: cytoarchitecture, stress responses, 
regulation of signaling pathways towards apoptosis and protein synthesis, and 
organelle/vesicle distribution 18.  
 
5-1.13  The Moll Nomenclature  
Moll et. al (1982) 134 provided the first attempt at a comprehensive keratin 
nomenclature by grouping the basic-neutral type II keratins as K1-8 and the acidic 
type I keratins as K9-19. The subsequent discovery and characterisation of further 
type I and type II keratins and the “hard” hair and nail keratins necessitated a new 
systematic nomenclature which could incorporate the 54 functional keratin genes 
demonstrated by analysis of the complete human genome. 28 type I and 26 type II 
keratin genes form two clusters of 27 genes on chromosomes 17q21.2 and 
12q13.13 with the gene for type I K18 being located in the type II keratin gene 
domain of chromosome 12 135 (Figure 5-05). 
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Figure 5-05: Human keratin gene domains. (A) type I keratins and (B) type I., (Red) epithelial 
keratin genes, (Black) hair follicle specific epithelial keratin genes, (Blue) hair keratin genes and 
(Green) keratin psuedogenes. 1 KRT18 is a type I keratin gene.  
(From: Schweizer et  al 2006 17)  
 
 
5-1.14  The New Consensus Nomenclature 
In 2006 Schweizer et. al. 17 reported a new consensus nomenclature for keratins 
updating the Moll designations whilst retaining the HGNC gene designation 
scheme (Table 5-01, 5-02 and 5-03). This classification also does away with the 
alternative name ‘cytokeratin’ with preference for just ‘keratin’.  
 
 
Table 5-01: Numbering scheme of keratin groups (From: Schweizer et al. 2006 17) 
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Table 5-02: The Moll classification and the new consensus nomenclature of Type I keratins. 
(Adapted from: Schweizer et al. 2006 17) 
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Table 5-03: The Moll classification and the new consensus nomenclature of Type II keratins. 
(Adapted from: Schweizer et al. 2006 17) 
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5-1.15  Keratin Filament Structure 
All intermediate filaments, of which keratins comprise the largest family, have the 
same tripartite domain structure. A central α-helical “rod” domain is flanked by 
poorly-structured ‘head’ and ‘tail’ regions at the N- and C- terminus, respectively 
(Figure 5-06). The size and amino acid sequence of the head and tail domains 
varies considerably amongst the intermediate filaments and confers each its 
specific properties and expression pattern. The central rod domain comprises four 
α-helical sub-domains interrupted by non-helical linker regions and makes up over 
50% of the keratin protein which is involved in filament assembly. The α-helix 
occurs because of a heptad repeat of amino acid residues and has a specific 
arrangement of hydrophobic residues that forms a hydrophobic stripe running 
around the right-handed α-helix in a left-handed manner. This allows two helices 
to associate to produce the coiled-coil dimer building block of the intermediate 
filament (Figure 5-07). 
  
 
Figure 5-06: Schematic representation of intermediate filament protein structure showing the 
central α-helical rod domain flanked by non-helical “head” and “tail”. In the rod domain a heptad 
repeat is interrupted at three conserved location by linker sequences L1, L12 and L2 producing 
subdomains 1A, 1B, 2A, 2B. The ends of the rod domain (shown in red) contain highly conserved 
15-20 amino acid sequences. (Adapted from: Gu and Coulombe 2007 18)   
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Figure 5-07: The dimer structure of an intermediate filament comprising a pair of parallel chains 
lying in axial register along the central rod domain. (Adapted from: Parry et al. 2007 19) 
 
  
In vivo keratins initially heterodimerise in the specific type I and type II pairs that 
are expressed in each cell. However, keratins have been described as 
promiscuous heterodimers 19 as more than one type I chain may be able to 
interact with the same type II chain and vice versa e.g. K5 with either K14 or K15 
in the basal keratinocytes of stratified squamous epithelium. The dimers then 
undergo a rapid aggregation into tetramers in a half staggered anti-parallel 
arrangement with overlap of their 1B segments (Figure 5-08).  
 
 
Figure 5-08: (A) Parallel arrangement of keratin type I and type II chains to form a heterodimer. (B) 
Assembly of keratin heterodimers in a staggered anti-parallel manner to form tetramers. 
 
 
Tetramers assemble to form unit length filaments (ULFs) which elongate by 
reorganisation of their heterodimeric building blocks before annealing 
longitudinally to form immature intermediate filaments. A final radial compaction 
step occurs to pack the strands together more closely in the mature intermediate 
filament which is approximately 10nm in diameter and several µm long 19 (Figure 
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5-09). The mature keratin filaments assemble to form the cytoskeleton of the cell 
which needs to be a dynamic structure able to respond to external stimuli by 
disassembly and turnover. The keratin cytoskeleton has a highly dynamic 
composition in vivo because intermediate filaments are able to exchange subunits 
along their entire length unlike the other structural components, actin and 
microtubules, which only allow subunit exchange at their ends. 
 
 
Figure 5-09: Schematic of the current understanding of keratin intermediate filament assembly. 
(From: www.interfil.org) 
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5-1.16  Keratin Expression 
Keratinocytes express matched pairs of type I and type II keratin polypeptides in a 
tissue- and differentiation-specific manner 134. For example, oral stratified 
squamous epithelium expresses keratins K5 and K14/K15 in the basal layer but 
not in the more differentiated suprabasal layers. Similarly, anatomical site 
specificity is shown by the keratinising epithelium of the gingivae expressing K1/10 
in the suprabasal layers in addition to K4/13 and K6/16 which are also expressed 
in the non-keratinising buccal epithelium (Figure 5-10). 
 
 
Figure 5-10: Schematic representation of differentiation specific keratin expression in normal oral 
epithelium. 
 
 
5-1.17  Pathological Keratin Expression 
Keratin gene expression is extremely sensitive to changes in cytokine signalling 
which results in alterations of the keratinocyte phenotype that can be detected by 
immunohistochemistry with anti-keratin antibodies. The activated keratinocyte 
phenotype of cutaneous wound healing is one example that presents as 
upregulation of K6/16 and K17 in the suprabasal keratinocytes with down-
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regulation of K1/10 136. The mechanisms involved and roles of these 
hyperproliferation related keratins are only recently beginning to be understood 
and may include provision of a more flexible cytoskeletal framework for 
keratinocyte migration 137 as well as a direct control function in the healing process 
138
. Altered keratinocyte phenotypes have also been reported in a wide array of 
benign and malignant oral epithelial diseases including lichen planus, 
hyperkeratosis, squamous cell carcinomas and odontogenic cysts 139, 140 indicating 
keratin gene expression is also responsive to pathological signalling.  
 
Changes in keratin expression are widely used as detectable markers of 
underlying pathology by antibody binding in IHC. This is facilitated by keratins 
being immensely stable in comparison to other more volatile proteins that also 
respond to pathological stimulus e.g. the heat shock proteins that act as molecular 
chaperones in many protein-protein interactions necessary for protein structural 
conformation 141 and therefore potentially also antibody binding. Therefore, the 
traumatic tissue biopsy process itself is less likely to directly influence keratin 
protein expression observed by IHC, if samples are snap frozen or rapidly formalin 
fixed, implying that any change in keratin expression is representative of the 
underlying pathology and not of the sampling procedure.  
 
5-1.18  Keratin Expression in OSF 
With the epithelial abnormalities consistently observed in OSF and keratins being 
known to respond to pathological signalling in other oral PMDs, an altered keratin 
expression pattern in OSF may be detectable. There is some evidence of this in 
the literature. Vaidya et. al. (1998) 142 studied the expression of keratins in buccal 
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mucosa from seven OSF patients by immunoblotting. They reported loss of K5 in 
five of seven samples, and K14 downregulation in two samples whilst K8 was only 
expressed in three of the seven samples.  
 
In 2006 the same group reported an IHC study utilising formalin fixed paraffin 
embedded tissue sections where the intensity of staining was assessed to 
determine differences in keratin expression 143. In this study K5 expression was 
observed in 48 (96%) out of 50 OSF samples throughout the basal epithelium and 
abnormally the suprabasal epithelium. Its usual basal specific type I partner K14 
was expressed in just one (2%) of 50 OSF samples and they did not report on 
K15, the other type 1 keratin, which is known to partner K5 when K14 is 
downregulated 144.  
 
Ranganathan et. al. (2006) 143 also showed K8 staining (basal and suprabasal) in 
five (10%) of 50 OSF samples and as K8 is usually a simple epithelium specific 
keratin any expression in the stratified squamous epithelium of the oral mucosa is 
abnormal. Of the possible type 1 partners 145 only K18 was reported where basal 
specific staining was seen in five (12%) of 50 OSF samples. 
 
Other specific keratin expression patterns reported by Ranganathan et. al. (2006) 
143
 were K4 in one (2%) of 50 OSF samples and again its usual partner K13 was 
not reported. K4/13 in the literature are reported as a differentiation specific 
keratins in non-keratinised oral epithelium 139 being supplanted by K1/10 in 
keratinised normal oral epithelium 146. Ranganathan et. al. (2006) showed K1 
expression in 16 (32%) of their OSF samples but did not report in K10 expression. 
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These aberrant results maybe related to the original site of biopsy in OSF patients 
being keratinised or non-keratinised mucosa but this detail is not reported in the 
study.  
 
Keratin expression in normal epithelium has been well characterised in the 
literature 17, 133, 134, 146, 147 so normal tissue samples were used as controls by 
Ranganathan et. al. (2006) 143. However, they observed significantly different 
staining patterns from that reported in the literature. Differentiation specific K4 
expression was observed in nine (90%) of ten samples throughout the basal as 
well as the suprabasal epithelium. The other differentiation specific keratin studied 
was K1 and this was observed predominantly suprabasally in four (40%) of ten 
normal samples. The conventionally basal expression of K5/14, because they are 
known to be down-regulated in normal differentiation was also not observed in this 
study. K5 staining was reported as basal and suprabasal in all ten (100%) of 
normal samples and K14 was seen in just two (20%) of normal tissues but again 
throughout suprabasal as well as basal epithelium. As expected the simple 
epithelia specific K8 was not seen in any normal samples but its type 1 partner 
K18, also reported in the literature as simple epithelia specific in normal tissue, 
was observed throughout the basal and suprabasal epithelium of five (50%) of ten 
normal samples. To explain these abnormalities Ranganathan et. al. (2006) 
reported that their ‘normal’ tissue samples were taken from “patients who had 
come for tooth extraction and did not have good oral hygiene…therefore…it is 
possible these tissues were not fully normal”.  
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Taken together there is some evidence that OSF epithelium expresses keratins in 
an abnormal fashion and this would be best categorised by IHC of fresh frozen 
tissue specimens to eliminate the effect of antigen masking. 
 
5-1.19  An Altered Keratinocyte Phenotype in OSF Epithelium? 
In summary, we hypothesise that an altered keratinocyte phenotype occurs in OSF 
affected epithelium. Our aim was to determine the keratinocyte phenotype of OSF 
affected epithelium by the expression of keratins. The overall keratin expression 
profile can then be compared to the changes seen in other OMLs such as LP, 
dysplasia and hyperkeratosis and conserved changes may provide an insight into 
the pathogenesis and management of OSF. Characterisation of the keratinocyte 
phenotype in OSF may also provide specific immunohistological parameters for 
definitive diagnosis of the condition.  
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5-2.01  MATERIALS AND METHODS 
 
5-2.02  Tissue Samples and Preparation  
Samples of site-matched normal (6 patients) and OSF tissue (28 patients) were 
collected from a Sri Lankan population in the University of Peradeniya and the 
import of tissue samples was compliant with the Human Tissue Act 2004.  Four 
normal samples and 22 OSF biopsies were obtained from normally non-
keratinising buccal mucosa and the remainder from keratinised sites such as the 
tongue and gingivae (Table 5-04). OSF was diagnosed by clinical presentation 
and confirmed by histological evaluation of formalin fixed paraffin embedded tissue 
sections. OSF lesions were graded for severity using conventional histological 
parameters 16, 129 by Professor W. M. Tilakaratne, Centre for Clinical and 
Diagnostic Oral Sciences, Queen Mary School of Medicine and Dentistry, 
University of London. Biopsy specimens were snap frozen and stored in sealed 
containers at -80oC until required. Tissue blocks were mounted on cork discs in 
OCT cryo-mounting medium (VWR, Pennsylvania, USA) and serial 6µm sections 
cut in a cryostat at -25oC (Bright Instruments, Cambridge UK). Sections were thaw 
mounted on Superfrost + coated slides (Menzel-Glaser, Germany) and stored in 
sealed microscope slide boxes at -80oC until required for staining. 
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Table 5-04: Tissue samples used in this study. (OSF samples were graded for severity by 
histological parameters and also for the presence of dysplasia which when present was mild 
dysplasia in all cases). 
 
OSF Histological Grade Sample Biopsy Site 
Early Intermediate Advanced 
Dysplasia 
OSF 1 Buccal   + - 
OSF 2 Tongue  +  + 
OSF 3 Buccal  +  - 
OSF 4 Buccal  +  - 
OSF 5 Buccal   + + 
OSF 6 Buccal   + - 
OSF 7 Lip  +  + 
OSF 8 Buccal  +  + 
OSF 9 Lip  +  - 
OSF 10 Buccal   + + 
OSF 11 Lip   + - 
OSF12 Buccal  +  - 
OSF 21 Buccal  +  - 
OSF 22 Buccal +   - 
OSF 23 Buccal +   - 
OSF 24 Buccal +   - 
OSF 25 Tongue  +  - 
OSF 26 Buccal +   - 
OSF 27 Buccal  +  - 
OSF 28 Buccal   + - 
OSF 29 Buccal  +  + 
OSF 30 Buccal +   - 
OSF 32 Buccal  +  - 
OSF 33 Buccal  +  + 
OSF 35 Lip  +  - 
OSF 41 Buccal  +  + 
OSF 42 Buccal   + - 
OSF 61 Buccal +   - 
N0 Tongue 
N1 Buccal 
N2 Buccal 
N6 Buccal 
N13 Buccal 
NA Gingivae 
 
 
5-2.03  Antibodies and Immunohistochemistry 
Twenty-two different monoclonal mouse antibodies (mAbs) (Table 5-05) were 
obtained, either from commercial sources or raised in house by culturing the 
respective hybridomas in Dulbecco’s modified Eagle’s medium with 10% foetal calf 
serum and the supernatants from confluent cultures stored, refrigerated, in 0.2% 
(w/v) sodium azide. In house mAbs were gifts from Professor I. M. Leigh, Centre 
for Cutaneous Research, Queen Mary School of Medicine and Dentistry, 
University of London.  
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Table 5-05: Mouse monoclonal antibodies used in this study.  
 
Clone Specificity Working Dilution Supplier 
LHK1 K1 1:500 in house 
LHK2e K2 1:1 in house 
6B10 K4 1:10 Sigma-Aldrich, USA 
LHK6B K6 1:100 in house 
LP5K K7 1:1 in house 
LE41 K8 1:1 in house 
Ks9.20+Ks9.28 K9 1:10 Progen, Germany 
DE-K10 K10 1:50 Neomarkers, USA 
RKSE60 K10 1:10 Biogenesis, UK 
LHP2 K10 1:1 in house 
1C7 K13 1:1 in house 
1C7+2D7 K13 1:10 Neomarkers, USA 
LL001 K14 1:500 In house 
LHK15 K15 1:500 In house 
LL025 K16 1:500 In house 
E3 K17 1:10 Dako, Denmark. 
LP34 K6+K18 1:500 in house 
LE61** K18 1:100 in house 
LE65** K18 1:10 in house 
CY-90 K18 1:10 Sigma-Aldrich, USA 
LP2K K19 1:100 in house 
RCK108 K19 1:100 Dako, Denmark. 
**Data using recombinant polypeptides has shown these antibodies bind complexes of K8/18 rather than individual 
polypeptides. 148, 149 
 
Three layer indirect immunohistochemical staining was performed on frozen tissue 
sections utilising the DAKO LSAB+ kit (Dako, Cambridgeshire UK). Sections were 
first air dried for 20 minutes after removal from -80oC storage and blocked with 5% 
normal goat serum (Vector Labs, USA) in PBS for 30 minutes at room 
temperature. This and subsequent incubation stages were carried out at room 
temperature in a humid chamber with utmost care taken to prevent the sections 
drying out. After washing in 3 changes of PBS for 5 minutes each the sections 
were incubated in primary antibody diluted in PBS for 1 hour before washing again 
(3 changes of PBS for 5 minutes each) and adding the biotinylated multilink 
secondary for 30 minutes. Another wash stage followed and the streptavidin 
complex added for 30 minutes. This was then washed away and colour developed 
using 3, 3’-diaminobenzidine (DAB) (Vector Labs, California USA). 
Counterstaining of cell nuclei was with Mayers haematoxylin (Sigma-Aldrich, USA) 
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and the tissues mounted in Vectamount (Vector Labs, USA) under glass 
coverslips. Where available immunohistochemical staining was performed with 
several different mAbs raised against the same keratin polypeptide, to determine 
reproducibility of the staining pattern. 
 
5-2.04  Control of Variables 
For this experimental design the dependant variable, in which we were interested, 
was keratin expression within the epithelium. Control of extraneous variables 
involved use of a standardised staining protocols. The monoclonal antibodies 
utilised were generally well characterised with either extensive usage within the 
Centre for Cutaneous Research and the Centre for Clinical and Diagnostic Oral 
Sciences of Queen Mary School of Medicine and Dentistry, University of London 
or commercially available and having been previously used in publications within 
peer reviewed journals. Staining protocols were optimised for each antibody either 
from departmental experience in their use or by repeat staining runs on normal 
tissues or cells which expressed the relevant keratin e.g. MCF7 cells for K8/18 and 
K19. In addition the keratin expression pattern of normal oral epithelium, has been 
published in a number of peer reviewed articles with, in general, consistent keratin 
expression patterns amongst studies utilising the same antibody clone on frozen 
tissue sections 133, 144, 147, 150, 151. 
 
Each staining run included procedural controls such as the substitution of primary 
mAb for PBS and the staining of normal epithelial samples or cells with known 
keratin expression patterns.  
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5-2.05  Data Analysis 
The staining data were analysed by visual assessment and quantified by image 
analysis. Slides were photographed on a Microphot-FXA microscope with Coolpix 
990 camera (Nikon, Japan) and the images assembled using Adobe Photoshop 
CS2 v9.0.2 (Adobe Systems Inc., USA).  
 
5-2.06  Visual Assessment 
Each slide was visually assessed, initially, independently by 2 observers and 
agreement was reached by consensus where initial assessment differed. 
Representative sections of slides showing positive staining were graded on a three 
point equally weighted scale (+, ++ or +++) for staining in the basal layer and the 
suprabasal compartment of the epithelium at 150x magnification. Reference slides 
with (+) representing 0-33% stained surface area, (++) 34-66% and (+++) 67-
100% stained surface area were provided. No attempt was made to quantify 
intensity of DAB staining.  
 
A Cumulative Staining Quotient (CSQ) for OSF and normal samples was 
calculated using the formula: 
Cumulative Staining Quotient   =   number of (+) in all samples   x   100 
       (CSQ)               number of samples 
The CSQ therefore semi-quantifies the visual assessment grading and shows 
gross differences in staining pattern between the whole population of OSF 
samples and normal samples. Results were further subdivided into samples from 
normally keratinised or non-keratinised biopsy sites as OSF pathology is known to 
be associated with inappropriate hyper-keratinisation of the epithelium and 
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anatomically normal keratinisation may conceal any pathological effects on keratin 
expression.  
 
5-2.07  Pixel Analysis 
Due to the inherent subjectivity of the visual assessment approach a more 
quantitative approach by image analysis was also completed for each slide 
showing a different staining pattern in normal and OSF samples. Pixel analysis 
was performed on the photographed digital images, using a modification of the 
approach described by Elie (2003) 152. Photographs were taken at 100x 
magnification with identical optical and digital zoom camera settings. In Photoshop 
the epithelium was carefully selected from the tissue section using the ‘lasso tool’ 
and the total pixel count in the selected area recorded from the Histogram palette 
(Figure 5-11). For keratinised samples the superficial keratin layer was not 
selected as part of the epithelium as it is often poorly retained in frozen sections 
and the dense keratinisation in these squames may obscure antibody binding sites 
133
. A new image was created by cutting and pasting the selected epithelium and 
from this the basal and suprabasal compartments carefully delineated by the lasso 
tool to give the pixel count for each segment of the epithelium. To separate brown 
DAB staining from the blue haematoxylin counterstain a colour range selection 
was performed using the same sampled colour with RGB values of 160, 100 and 
100 respectively as shown in the ‘colour palette’ of the software. The range of 
colours selected was set to 100 on the ‘fuzziness slider’ which selects other parts 
of the image by the degree their colour is related to the sample colour. To confirm 
that all DAB stained sections of the image were selected, these pixels were cut 
from the image to leave just the counterstained areas. Any DAB stained areas 
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remaining when the selected pixels were removed, for example with very dark 
brown staining, were manually selected and employed for the evaluation using the 
‘plus eyedropper’ tool of the software. The DAB pixel count in the basal and 
suprabasal compartments of the epithelium was recorded and calculated as a 
percentage of the total basal or suprabasal pixel count (that will include DAB and 
haematoxylin). Quantification in this manner permitted use of the Mann Whitney U 
test to determine statistically significant differences in the DAB staining between 
normal and OSF samples. 
 
 
Figure 5-11: Quantitative analysis of DAB immunostained and haematoxylin counterstained tissue 
images. (a) Original images imported into Adobe Photoshop CS2 v9.0.2 (Adobe Systems Inc., 
USA), (b) with epithelium delineated and (c) DAB staining specifically selected  or (d) haematoxylin 
counterstain selected by adjustment of ‘colour selection’ properties. (e) the pixel count of the 
selected area is given in the ‘histogram palette’. (From: Lalli et. al. (2008) 20) 
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5-3.01  RESULTS 
5-3.02  Suprabasal Keratins (K1/K10, K2, K4/K13, K6/16 and K9) 
  
 
Figure 5-12: Immunohistochemical staining of normal oral (a, c, e and g) and OSF lesional (b, d, f, 
and h) epithelium for the suprabasal keratins. K16 (a and b), K6 (c and d), K1 (e and f) and K13 (g 
and h). Bar = 50µm.(Adapted from Lalli et. al. (2008) 20) 
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5-3.03  Keratins 6/16 
K16 staining was entirely suprabasal with similar expression in all OSF and normal 
samples (Figure 5-12: images a and b) confirmed by a suprabasal CSQ of 92% 
and 94%, respectively (Table 5-06). K6 was also strongly suprabasal (CSQ 94%) 
in normal epithelia with no expression in the basal layer (CSQ 0%) (Figure 5-12: 
image c) whilst in OSF, K6 was detectable in both the basal (CSQ 70%) and 
suprabasal layers (CSQ 87%) (Figure 5-12: image d). The increase in basal K6 
expression in OSF compared to normal was highly significant (p<0.001) whilst 
suprabasal K6 expression was unaffected by OSF (p>0.05) (Figure 5-13). In 
summary, it appears that K16 expression is unaffected by OSF pathology but its 
type II partner K6 is upregulated in basal keratinocytes.  
 
Table 5-06: Cumulative Staining Quotient (CSQ) of immunostaining in normal and OSF samples. 
Results for biopsy samples from normally keratinised and non-keratinised samples are shown 
where a difference was observed. 
 
Cumulative Staining Quotient (%) 
Basal Suprabasal  
Keratin 
Normal OSF Normal OSF 
K1 (all biopsy sites) 0 0 33 65 
K1 (non-keratinised sites only) 0 0 17 65 
K1 (keratinised sites only) 0 0 67 67 
K10 (all biopsy sites) 0 0 33 69 
K10 (non-keratinised sites only) 0 0 17 62 
K10 (keratinised sites only) 0 0 67 67 
K6 0 70 94 87 
K16 0 0 94 92 
K4 0 0 94 95 
K13 0 0 94 96 
K2 0 0 11 1 
K14 100 100 100 96 
K15 100 99 0 0 
K17 61 58 17 44 
K19 (all samples) 22 0 0 0 
K19 (non keratinised sites only) 33 0 0 0 
K19 (keratinised sites only) 0 0 0 0 
 
 233 
 
Figure 5-13: Increased K6 expression in the basal layer of OSF epithelium compared to normal 
(p<0.001) whereas suprabasal K6 expression is unchanged. 
 
5-3.04  Keratins 1/10 
The expression of K1 and K10 was entirely suprabasal and comparable in all 
samples indicating this keratin pair is co-expressed in suprabasal keratinocytes. In 
normal epithelia K1/10 was expressed strongest in samples from keratinised 
biopsy sites with a CSQ of 67% for both keratins whilst the non-keratinised buccal 
epithelia displayed more limited staining represented by a CSQ of 17% (Figure 5-
12 image e and Table 5-06). All OSF tissues, from both keratinised and non-
keratinised biopsy sites, were strongly K1/10 positive with CSQs of 65% for K1 
and 69% for K10 (Figure 5-12: image f and Table 5-06). There was no difference 
between OSF samples from keratinised and non-keratinised sites e.g. CSQs of 
65% and 67% for K1 in non-keratinsed and keratinised samples, respectively 
(Table 5-06). For non-keratinised biopsy sites, increased K1/10 expression in OSF 
compared to normal was highly significant (p<0.001) whilst normally keratinised 
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sites appear qualitatively unaffected with a CSQ of 67% for both K1 and K10 
although the number of relevant samples is too low for meaningful statistical 
analysis (Figure 5-14 and Table 5-06). Overall, it appears that the 
hyperkeratinisation associated K1/10 are upregulated in OSF to a level 
comparable with naturally keratinised oral epithelium.  
 
 
Figure 5-14: Increased suprabasal K1 expression in OSF affected oral epithelium originally from 
non-keratinised sites of the oral cavity, compared to normal epithelium. 
 
5-3.05  Keratin 2  
K2 was detected in a few upper suprabasal keratinocytes in the 2 out of 6 normal 
tissues, which originated from the keratinised surfaces of the tongue and gingivae 
with no expression in the normally non-keratinised buccal mucosa samples. One 
out of 28 OSF samples was weakly positive with similar expression pattern to that 
seen in the two normal oral keratinised samples. This OSF sample originated from 
the tongue and therefore none of the other five OSF samples from keratinised 
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biopsy sites were positive indicating a potential reduction in K2 expression 
although the number of relevant samples was limited (Table 5-06). 
 
5-3.06  Keratins 4/13 
All OSF and normal tissue samples stained strongly throughout the suprabasal 
epithelium for K4/13 with CSQs around 95% (Figure 5-12: image g and h and 
Table 5-06). OSF pathology therefore appears not to influence the expression of 
these suprabasal keratins.   
 
5-3.07  Keratin 9 
No expression was detected in normal or OSF affected oral epithelium which is 
consistent with K9 being a palmo-plantar epidermis specific keratin. 
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5-3.08  Basal Keratins (K14, K15, K17 and K19) 
 
Figure 5-15: Immunohistochemical staining of normal oral (a, c, e, g and i) and OSF lesional (b, d, 
f, h and j) epithelium for the basal keratins. K17 (a and b showing isolated basal and suprabasal 
staining whilst c and d show both basal and suprabasal staining patterns), K19 (e and f), K14 (g 
and h) and K15 (i and j). Bar = 50µm. (Adapted from Lalli et. al. (2008) 20) 
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5-3.09  Keratin 17 
K17 was detected in the basal layer of all normal samples but staining in 
suprabasal keratinocytes was only present in 50% of cases and generally confined 
to the lower suprabasal layers (Figure 5-15: images a and c). All OSF samples 
expressed K17 and although the staining varied considerably in intensity and 
distribution (Figure 5-15: images b and d) there was increased K17 in the 
suprabasal layers with CSQs of 17% in normal and 44% in OSF. Basal K17 
expression appeared unaffected with CSQs of 61% in normal and 58% in OSF 
(Table 5-06). 
 
5-3.10  Suprabasal K17 Expression Correlates with OSF Severity 
Quantification by pixel analysis confirms this global picture of unchanged basal 
expression (p>0.5) and increased suprabasal expression (p<0.01) (Figure 5-16). 
This image analysis data correlated with histological severity shows there is no 
significant difference between normal levels of suprabasal expression and early 
OSF lesions (p>0.05) but with intermediate OSF there is a moderately significant 
increase (p<0.05) and there is a highly significant (p<0.01) increase in suprabasal 
K17 expression in the advanced OSF samples (Table 5-07 and Figure 5-17). 
 238 
 
Figure 5-16: Increased suprabasal K17 expression in OSF epithelium compared to normal 
epithelium (p<0.01) whereas basal K17 expression is unchanged.  
 
 
 
 
 
 
Figure 5-17: Suprabasal expression of K17 in OSF epithelium shown by image analysis of DAB 
immunostaining and correlated with histological grading of disease severity. No statistically 
significant difference is measurable between early lesions and normal epithelium but increased 
K17 is evident with intermediate pathology and advanced lesions display highly significant (p<0.01) 
K17 suprabasal increased expression.(From: Lalli et. al (2008) 20) 
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Table 5-07: Analysis by Mann Whitney U Test of normal against OSF populations for keratin 
expression and correlation with disease severity. 
 
Brown (DAB) Coloured Pixels as a Percentage of All Pixels in The Epithelial Compartment 
K17 
 EAR INT ADV EAR INT ADV 
Sample 
  
  B SB B B B SB SB SB 
OSF 1 0 27 - - 0 - - 27 
OSF 2 22 36 - 22 - - 36 - 
OSF 3 28 25 - 28 - - 25 - 
OSF 4 44 11 - 44 - - 11 - 
OSF 5 36 12 - - 36 - - 12 
OSF 6 81 66 - - 81 - - 66 
OSF 7 56 35 - 56 - - 35 - 
OSF 8 47 18 - 47 - - 18 - 
OSF 9 34 11 - 34 - - 11 - 
OSF 10 41 43 - - 41 - - 43 
OSF 11 2 19 - - 2 - - 19 
OSF12 39 57 - 39 - - 57 - 
OSF 21 87 0 - 87 - - 0 - 
OSF 22 47 62 47 - - 62 - - 
OSF 23 54 0 54 - - 0 - - 
OSF 24 12 39 12 - - 39 - - 
OSF 25 52 47 - 52 -  47 - 
OSF 26 60 46 60 - - 46  - 
OSF 27 39 55 - 39 - - 55 - 
OSF 28 3 48 - - 3 - - 48 
OSF 29 60 37 - 60 - - 37 - 
OSF 30 44 0 44 - - 0  - 
OSF 32 16 27 - 16 - - 27 - 
OSF 33 0 68 - 0 - - 68 - 
OSF 35 42 0 - 42 - - 0 - 
OSF 41 100 6 - 100 - - 6 - 
OSF 42 40 53 - - 40 - - 53 
OSF 61 39 58 39 - - 58 - - 
N0 14 0 14 14 14 0 0 0 
N1 57 14 57 57 57 14 14 14 
N2 11 0 11 11 11 0 0 0 
N6 100 16 100 100 100 16 16 16 
N13 45 0 45 45 45 0 0 0 
NA 31 9 31 31 31 9 9 9 
U Statistic 85.5 141.0 20.0 48.5 28.0 27.0 74.0 40.0 
P Value 
  
0.947 
P >0.05 
0.00796 
P <0.01 
0.818 
P >0.05 
0.791 
P >0.05 
0.445 
P >0.05 
0.180 
P >0.05 
0.0233 
P <0.05 
0.00466 
P <0.01 
SB     Suprabasal Epithelial Compartment 
B       Basal Epithelial Compartment 
EAR  OSF Histological Severity Grading - Early 
INT    OSF Histological Severity Grading - Intermediate 
ADV   OSF Histological Severity Grading – Advanced 
 
 
5-3.11  Loss of Basal K17 Expression in OSF 
The two extremes of the variable K17 expression pattern were assessed, that is 
those samples with entirely basal or suprabasal K17 expression, which showed 
that all samples with entirely basal staining were not advanced OSF lesions whilst 
all samples with complete loss of basal K17 staining were more advanced lesions 
(Table 5-08). Further indicating that suprabasal K17 expression in OSF maybe 
related to disease severity although loss of K17 basal expression only occurs in a 
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subset of these lesions. No other histological or clinical parameters, e.g. epithelial 
inflammation or atrophy, were assessed for correlation with K17 expression. 
 
Table 5-08: Loss of basal K17 expression in a subset of the more advance OSF cases whilst no 
samples without suprabasal K17 were advanced lesions. 
 
 
 
 
 
 
 
 
 
5-3.12  Keratin 19 
K19 staining was discontinuous and limited to the basal layer of non-keratinised 
normal epithelia (Figure 5-15: image e) with no expression in normal keratinised 
epithelium. There was also no expression in any OSF samples whether from 
keratinised or non-keratinised sites (Figure 5-15: image f). The apparent down-
regulation of K19 in OSF was confirmed by a highly significant reduction in 
staining in the basal layer of non-keratinised epithelia (p<0.001) compared with the 
normal controls (Figure 5-18). 
K17 Staining OSF Histological Grading Sample 
Basal Suprabasal Early Intermediate Advanced 
 
OSF 1 - +   + 
OSF 11 - +   + 
OSF 28 - ++   + 
OSF 33* - ++  +  
 
OSF 4 ++ -  +  
OSF 21 +++ -  +  
OSF 23 ++ - +   
OSF 35 ++ -  +  
OSF 41* +++ -  +  
*Evidence of dysplastic change in the epithelium 
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Figure 5-18: Loss of K19 expression in OSF epithelium compared to non-keratinised normal 
epithelium (p<0.001). 
 
 
5-3.13  Keratin 14/15 
K14 staining was present homogenously throughout the basal and suprabasal 
layers (Figure 5-15: images g and h) whilst K15 was detected in the entire basal 
layer (Figure 5-15: images I and j) of both normal and OSF samples implying the 
disease did not influence expression of these two keratins. 
 
5-3.14  Simple Epithelial Keratins (K7, K8 and K18) 
No staining for K7, K8, K18 or the K8/18 complex was observed in normal or OSF 
samples. This is expected as oral epithelium is a stratified squamous tissue and 
these are simple epithelial keratins where differentiation related stimuli for keratin 
expression is not present. 
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5-3.15  Correlation between Visual Assessment and Pixel Analysis 
There was a high level of correlation between the digital image pixel analysis and 
the visual assessment grading system shown by an overall correlation co-efficient 
value r = 0.90 (p<0.001). All non-staining keratins in basal or suprabasal 
compartments of the epithelium were disregarded (Table 5-09 and Figure 5-19). 
The heterogeneity of K17 staining resulted in the lowest correlation (r = 0.83) 
between pixel analysis and the more subjective visual grading. Conversely, the 
homogenous basal staining of K15 resulted in an almost perfect level of correlation 
(r= 0.99).  
 
 
 
Figure 5-19: Correlation between visual assessment grading and image analysis of DAB 
Immunostaining for K6 in the basal layer of OSF and normal oral epithelium (r = 0.9). Dotted line 
represents image analysis and the solid line visual assessment. 
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Table 5-09: Keratin Immunostaining of normal and OSF epithelia showing the correlation between 
visual assessment of slides and pixel analysis of digital images. 
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5-4.01  DISCUSSION 
Epithelial-mesenchymal interactions play vital roles in keratinocyte differentiation, 
proliferation, migration and invasion 153, 154. Alterations in keratin expression as a 
result of changes in the mesenchyme have also been reported using both in vitro 
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  and in vivo models 156. In OSF an imbalance of collagen metabolism causes 
excessive deposition of collagen leading to abnormal mesenchyme, which could 
affect the overlying epithelium. Two known benign connective tissue disorders of 
the epidermis, hypertrophic and keloid scars, are also characterised by abnormal 
collagen metabolism with considerable similarities to OSF and it is known that the 
pathogenesis of these condiitons involves perturbed epithelial-mesenchymal 
interactions with abnormality of keratinocyte phenotype in the epidermis 133, 136, 157. 
Therefore, we hypothesise that keratinocytes in OSF epithelium could be altered, 
which would implicate them in the disease pathogenesis, as well as their 
predisposition to oral cancer.  
 
5-4.02  Hyperkeratinisation of OSF Epithelium 
In OSF, compared to non-keratinised normal epithelium, there is increased 
suprabasal expression of K1/10 (Figure 5-12: image c) which is a feature of oral 
hyperkeratotic lesions 133. Keratinised normal oral epithelium also shows similar 
expression of K1/10 indicating this to be a specific molecular marker of 
keratinisation 139. The histologically apparent keratosis in many OSF lesions is 
therefore consistent with the increase in K1/10 expression. Increased K1/10 
expression has also been associated with K2 upregulation in oral dysplastic 
lesions which is distinct from the keratinisation seen in oral lichen planus (LP). In 
LP related keratosis, K1/10 upregulation occurs independently of K2 induction 133. 
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OSF lesions thus mirror mirrors LP in that K1/10 expression is upregulated without 
a concomitant increase in K2 despite the presence of dysplasia. LP is an 
autoimmune disorder therefore the similarities in K1/10 and K2 regulation seen in 
OSF may indicate an immunological pathogenesis although it is believed that 
keratinisation in OSF is due to direct mechanical trauma from the coarse fibres of 
the areca nut. LP is histologically characterised by a dense sub-epithelial band of 
lymphocytes, which produces a massive inflammatory infiltrate with resultant high 
levels of pro-inflammatory cytokines that induce abnormal keratinocyte 
differentiation. Whilst inflammatory cells are not overtly evident in OSF lesions the 
dense fibrosis and reduced vasculature of OSF sub-epithelial tissues may allow for 
long term build up of inflammatory cytokines which can then affect the epithelium 
in a similar manner. This should also provide a mechanism for malignant change 
as persistent tissue inflammation is implicated in carcinogenesis 158. 
 
5-4.03  Specific Induction of K6 in the Basal Keratinocytes 
In OSF we observed increased K6 expression in the basal layer of the epithelium 
but no change in the constitutive basal keratins K14 and K15 (Figure 5-12: image 
b and Figure 5-15: image g to j). The influence of OSF pathology on K5 expression 
could not be determined as a well characterised mAb, suitable for frozen sections, 
was not available. Commercially available anti-K5 antibody XM26 (Novocastra, 
Newcastle UK) has been used on formalin-fixed sections but with frozen tissue this 
mAb did not react. This confirms that it may not be possible to compare frozen and 
formalin-fixed samples for keratin staining using the same mAb 159, 160. The only 
previous immunohistological study of keratin expression in OSF used formalin-
fixed samples 143 and this may explain some of the inconsistencies in observed 
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expression patterns such as suprabasal expression of the basal specific K5 and 
lack of K14 expression in 80% of samples. Alternatively, this abnormal staining 
could be a feature of the mAbs employed and it is unclear whether site-matched 
normal and OSF tissues were used in the study. In addition, Ranganathan et. al. 
(2006) 143 did not use antibodies against K6, K17 and K19, the keratins found to 
be the most influenced by OSF pathology. 
 
Induction of K6 expression in the basal layer of OSF epithelium creates a situation 
whereby a type II keratin is switched on without the expression of its normal type I 
partner K16. In non-keratinised epithelium heterogenous basal expression of K6 
but not K16 has been reported previously 151 and only in the rete-ridges, using 
anti-K6 KA12 antibody. Unfortunately, no image of the staining was published so it 
is impossible to critically evaluate the reactivity. None of our normal oral tissues 
expressed K6 in the basal layer which is consistent with the literature using LHK6B 
147
 but the pattern of K6 expression in other PMDs is unknown. Interestingly, 
staining observed with LP34 was entirely suprabasal in both OSF and normal 
tissue and this antibody is commercially marketed for the detection of K6 and K18 
(Cancer Research Technology, London. UK) or K5, K6 and K18 (Acris, 
Hiddenhausen, Germany), suggesting its precise reactivity is yet to be established. 
We have shown with multiple mAbs (LE61, LE65 and CY-90) that K8/K18 complex 
or K18 alone are not detectable in these samples, implying LP34 staining may be 
K6 specific. However, as K6 is present in the basal layer of OSF epithelium 
(Figure 5-12: image 1d), the lack of LP34 reactivity suggests that this mAb may 
not recognise K6 either. If LP34 was reacting with K5 then staining would be 
observed in the basal layer, but this was absent in normal samples indicating that 
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LP34 may also not detect K5. The LP34 staining in normal and OSF epithelium 
could be from cross-reactivity with another, as yet unidentified suprabasal protein, 
in a manner similar to anti-K14 LL001 antibody which stains both basal and 
suprabasal keratinocytes in normal buccal epithelium (Figure 5-15: image g), 
although K14 mRNA expression is restricted to the basal layer 144. Alternatively, it 
is conceivable that the LP34 binding site on K6 may undergo a conformational 
change in K6/16 complexes to unmask the epitope. This does not occur in the 
basal layer of OSF epithelium as K16 is absent, whereas in the suprabasal layers 
both K6 and K16 are expressed, inducing LP34 binding. The conformation-
specific-epitope phenomenon has been reported for a number of keratin 
antibodies 148, 149, 161-163 and requires further investigation as LP34 is widely used in 
diagnostic pathology. Nevertheless, LHK6B staining in the basal layer of oral 
epithelium appears to be a characteristic feature of OSF, in this study. 
Furthermore, as the basal layer predominantly contains proliferating cells and the 
suprabasal cells are derived from basal keratinocytes, anomalous expression of 
K6 in the basal layer is likely to influence subsequent differentiation related cellular 
features such as keratinisation and epithelial atrophy. The literature also reveals 
this K6 expression pattern is also exhibited by normal oral keratinocytes induced 
to differentiate in an organotypical culture 147 although the significance is unclear.  
 
5-4.04  Reduced Expression of K19 and K17 in the Basal Keratinocytes 
The sporadic K19 expression in the basal layer of normal nonkeratinised oral 
epithelia is consistent with that reported in the literature. Decreased K19 
expression in OSF may be symptomatic of the keratinised state of the tissue as 
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K19 expression is known to be incompatible with keratinisation in normal oral 
epithelia 150, 164. 
 
K17 has been described as both an oral epithelial basal cell marker 165 and a 
suprabasal hyperproliferation marker similar to K16 in epidermal wound healing 
151, 166
. Our findings are consistent with the former as expression of K17 is 
predominantly in the basal layer of normal epithelium with sparse suprabasal 
expression in 50% of samples. Table 5-08 shows 4 out of 28 OSF samples in 
which there was no basal expression of K17 and 3 of these were amongst the 
most advanced OSF cases, whilst the other was classified as intermediate with 
evidence of dysplasia. Conversely, 5 out of 28 samples expressed basal but no 
suprabasal K17 and none were advanced cases. Loss of basal K17 appears to be 
a feature of certain advanced OSF pathologies in a particular cytokine 
environment such as the low level of interferon γ found in some OSF lesions 48. 
This premise is consistent with the fact that interferon γ is known to induce K17 in 
keratinocytes 167, 168. Perhaps K17 expression is more sensitive to interferon γ than 
K15 because K15 is also induced by interferon γ 169 but appears to be 
uninfluenced by OSF pathology (Figure 5-15: image I and j). Finally and despite 
the small number of samples, 4 out of 28 OSF tissues (14%) showing loss of K17 
in the basal layer, as well as being biopsied from some of the most advanced 
lesions, is approximately the same number that would be projected to progress to 
OSCC although no direct correlation can be made to this effect.  
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5-4.05 Induction of K17 in the Suprabasal Layers of OSF Epithelium 
Correlates with Disease Severity 
Although K17 expression in the basal layer was absent in a sub-set of the most 
severe cases, overall there was no correlation determinable between the basal 
K17 expression and disease severity. However, expression in the suprabasal 
layers correlated with histological grading of OSF severity whereby the most 
significant K17 increase appeared to occur in the most advanced cases (Figure 5-
17). None of the other keratins influenced by OSF pathology showed any 
significant correlation with disease severity. These observations suggest that 
perturbation in K17 expression is perhaps a primary outcome of OSF pathology 
and the expression of other keratins is influenced by factors in addition to the 
disease pathology such as keratinisation or dysplasia. K17 expression has been 
linked in the literature with the development of OSCC in other in vivo 
immunohistochemical studies 140, 170 as well as in vitro molecular model systems 
171
. However, the clinical significance of this is unknown as there is no clear link 
between histological severity of OSF and its clinical presentation or malignant 
change 16, 129. 
 
5-4.06 Keratinisation in OSF has a Molecular Signature Distinct from 
that in Dysplasia 
OMLs with dysplasia are often keratinised, however, hyperkeratinisation does not 
always lead to dysplasia. Virtually all of our OSF samples showed evidence of 
keratinisation but dysplastic changes were present only in seven samples. There 
are several lines of evidence to suggest that OSF keratinisation may be different 
from that seen in hyperkeratotic lesions or dysplasia. K16 has been reported to be 
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induced in some forms of dysplastic lesion 172 whilst we did not observe any 
change in the expression of this protein in OSF dysplastic epithelium. The 
complete absence of K19 in OSF epithelium observed in this study is in contrast to 
its reported induction in dysplasia 150. Furthermore, in hyperkeratotic lesions and 
dysplasia there is a reported upregulation of keratin K2 133 whilst in OSF 
hyperkeratotic or dysplastic epithelium K2 is not expression. Taken together these 
observations strongly suggest that keratinisation in OSF may have a molecular 
signature distinct from that observed in other hyperkeratotic lesions and dysplasia.  
 
5-4.07  Validity of Visual Assessment for Keratin Immunostaining 
There was a uniformly high level of correlation between pixel analysis and visual 
assessment of keratin staining in normal and OSF tissue (Table 5-09).  This 
suggests the quicker and simpler but more subjective visual grading process is 
sufficiently accurate to obviate the need for the considerably more laborious but 
objective image analysis technique in quantifying keratin staining. However, it was 
noted that the most varied staining patterns observed in our study were with K17 
and this resulted in the lowest level of correlation (r = 0.83) indicating that for 
heterogeneous keratin staining the more objective approach maybe valuable.
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5-5.01  CONCLUSION 
OSF pathology results in an altered keratinocyte phenotype presenting as an 
induction of keratinisation-specific keratins K1 and K10 in the suprabasal layers of 
OSF epithelium. In the basal layer there was increased K6 and decreased K19 
expression. K17 expression in the basal layer was downregulated only in a sub-set 
of the most severe cases whereas in the suprabasal layers K17 expression 
increased with disease severity. This altered keratinocyte phenotype in OSF, 
suggests a potential mechanism for the chronic connective tissue pathology via 
perturbed epithelial-mesenchymal interactions and the specificity of changes may 
provide immunohistological diagnostic criteria for OSF although the specific clinical 
significance of these changes remains to be elucidated. 
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General Discussion and Conclusions 
 
 
 
6-1.01  GENERAL DISCUSSION 
The development of a screening protocol to target high-risk individuals for OSCC 
in the Tower Hamlets and Newham South Asian populations required it to be is 
both feasible within existing healthcare services and acceptable to the 
predominantly South Asian ethnic population involved.  
 
6-1.02  The Value of a Community Advisory Group (CAG)  
Specific behavioural and socio-economic factors affecting the South Asian 
population in the UK, such as tobacco and paan usage and financial deprivation, 
suggest they are at higher risk of OSCC than other groups within the UK. 
Targeting these characteristics in a culturally acceptable manner is feasible by the 
involvement of all relevant stakeholders in a community advisory group. The 
outcomes from the CAG need to be evaluated against the available data to 
prevent competing interests interfering with the primary objective of screening 
high-risk individuals. In our study the CAG wished to organise screening activity to 
enable equitable distribution of screening locations within the population whereas 
the most effective approach was to site screening activity in areas of highest 
footfall of high-risk individuals such as worship or shopping facilities. 
 
In total 1596 individuals were screened between 2006 and 2008 in Tower Hamlets 
and Newham of which 86 were screened positive and referred to the local hospital 
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for definitive diagnosis. Of these 86 individuals, 21 (24%) failed to attend the 
secondary referral centre despite all possible efforts by the screening team and 
hospital service to encourage attendance. Reasons for non-attendance were 
investigated in patients who initially refused to comply with referral but 
subsequently did attend. Causes for initial non-attendance included language 
barriers, non-receipt of appointment letters and difficulty attending the hospital. 
This indicates that the model of screening, on a mobile dental unit in a community 
setting with culturally-matched advocates was able to overcome some specific 
barriers to access that still exist in the hospital setting for these high-risk 
individuals. 
 
6-1.03 UK High-Risk South Asian Screening Outcomes compared to 
the Asian Subcontinent  
Evaluation of our screening outcomes suggests that this screening protocol 
targeting high-risk individuals in a UK based South Asian population is more 
comparable to screening trials reported on the Asian subcontinent than other UK 
screening programmes. Most importantly this is observed in the issue of referral 
compliance where most UK based screening programmes report compliance rates 
approaching 100% contrasting to compliance rates of about 50% on the Indian 
subcontinent 62. The Trivandrum Oral Cancer Screening Study 5 is the only trial 
reported as sufficiently robust for inclusion in a Cochrane review 70 and indicates a 
referral compliance rate of 63%. Our studies referral compliance rate of 76%, 
despite the measures taken to overcome barriers to healthcare service uptake, 
suggests this maybe an inherent property of the South Asian population studied.  
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Another similarity between our outcomes and those reported in the Trivandrum 
study is the proportion of screen positive individuals at 5.9% in Kerala and 86 
(5.4%) out of a total of 1596 screened in Tower Hamlets and Newham. The 
reported screen positive rates for other UK based screening trials are 0.2% 173, 
1.2% 174, 2.7% 175 and 5.5% 176 although study methodologies and populations are 
not comparable.  
 
6-1.04 The Prevalence of OMLs in the High-Risk South Asian 
Population 
Comparison of the prevalence of OMLs in South Asian populations suffers 
noticeably from the heterogeneity of methodology and reporting in the literature. 
The prevalence observed in our study at 54% of screened individuals is 
considerably higher than the 40% previously reported in the Tower Hamlets 
population by Pearson et. al. (2001) 23, although they were not attempting to target 
high-risk individuals. Reports from the Indian subcontinent suggest OML 
prevalence of 2-8% 24, 25, 122, again without targeting high-risk individuals. However 
the reporting of OMLs appears highly inconsistent as smoking related changes are 
the commonest lesions in one Indian population attending a hospital dental 
outpatients department of which 15% smoke 24 but not reported at all in another 
despite 9% of the screened population smoking 25. Therefore, comparison with 
these prevalence figures is undertaken with caution although the high OML 
prevalence we report (54%) is similar to the 63% observed when targeting high-
risk Indian groups such as mine-workers 123.    
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6-1.05  Gold Standard Screening Outcomes 
Despite 1596 individual screenings in a high-risk population for oral cancer there 
were no OSCCs detected. Therefore, it is impossible to assess the sensitivity and 
specificity of screening on the basis of the ideal gold standard for one-off oral 
cancer screening programme, which is histologically confirmed OSCC. In reality 
this gold standard outcome is ethically impossible because it necessitates the 
biopsy of normal tissue to confirm those screened negative are actually disease 
free and determining a histological diagnosis solely for those screened positive 
risks introducing a verification bias. The fact that 24% of screen positive 
individuals referred to the hospital, did not attend for further investigation of their 
suspicious OMLs makes assessment of any gold standard outcome even less 
accurate. Therefore, a more appropriate gold standard outcome is proposed for 
UK based screening programmes taking into account the available healthcare 
services and its ethical obligations, the patient’s risk factors and their OML 
diagnosis, which is also the specialist clinician’s normal decision making process. 
This ‘soft’ gold standard is the outcome of whether a screen positive individual is 
discharged following definitive diagnosis or requires long term follow-up. On this 
basis our screening programme specificity was 98.7% with a PPV of 79% with 
‘sensitivity’ and ‘NPV’ at 100% as would be expected from any definition of a gold 
standard that only assesses the positive screened individuals. For patient safety 
we assume the worst case scenario that all patients who did not comply with 
referral would have been reviewed and not discharged. These figures are 
comparable to the literature on OSCC screening where overall specificity is 97% 
and PPV 70% despite the heterogeneity of study methodologies reported 62. The 
79% PPV indicates that approximately 1 in 5 screen positive individuals were false 
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positives attributable to specific difficulties in assessing the screened population, 
such as differentiating discrete lesions from generalised paan-related staining 
which is consistent with the high prevalence of OMLs in this population. Low PPV 
is also unavoidable for a rare condition such as OSCC. Importantly, high specificity 
indicates very few false negatives amongst the discharged (healthy) population 
suggesting few patients who actually require follow-up would be discharged. 
 
6-1.06  OMLs, Risk Factors and Screening Sensitivity 
Qualitative evidence from the screening dentists suggested the presence of OMLs 
hampered their ability to make accurate diagnosis, in particular the presence of 
paan associated staining of the oral mucosa. The high prevalence of OMLs was 
confirmed by surveying the screened population during their consultation without 
adversely interfering with the primary objective of screening for OSCC. It was 
discovered that 46% of these lesions could not readily be diagnosed as benign 
conditions of no concern for malignancy. These complex lesions included the 
conventional PMDs 15 but also paan related staining of the oral mucosa and were 
predominantly at the high risk sites in the oral cavity (‘gutter area’ and buccal 
sulcus) for OSCC in a population with risk factors including smoking and areca nut 
usage. These complex OMLs, especially when more than one was present, were 
responsible for the high levels of false positives in screening referrals. Additionally, 
there was a direct link between the use of paan or tobacco and the number of 
OMLs detected whilst increasing age compounded the effect of these agents but 
did not itself result in increasing numbers of OMLs.  
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6-1.07  The Need for Diagnostic Aids in Oral Cancer Screening 
From our evaluation of the screening protocol and outcomes two major issues 
needed resolving before a viable targeted screening programme could be 
contemplated. Firstly the issue of non-attendance of screen positive individuals at 
referral resulting in an inability to accurately evaluate screening outcomes and the 
potentially more important, but completely unquantifiable, effect on the screened 
individual. The second major issue is the high prevalence of OMLs in this 
population and in particular the complex lesions that cause difficulty in determining 
which lesions require further investigation for malignancy. These two issues are 
clearly inter-related as the difficulty in diagnosis leads to more false positive 
outcomes from screening activity with larger numbers of screen positive 
individuals referred and subsequently failing to attend for definitive diagnosis and 
treatment as required.  
 
The standard process for definitive diagnosis of OMLs is a combination of gross 
(macroscopic) examination followed by histologic (microscopic) examination of a 
tissue section which may be aided by evaluation of the molecular properties of the 
lesion by immunohistochemistry of the tissue section. A viable intra-operative 
pathology consultation approach would be relatively straightforward on a mobile 
dental unit which could house facilities to immediately biopsy and snap freeze 
samples that would be couriered to a pathology laboratory for sectioning, staining 
and diagnosis. The screen positive patient could therefore have their definitive 
diagnosis within a few hours and potentially not need to attend the hospital. 
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PMDs are more problematic as although histology is valuable for diagnosis it is 
their potential to become OSCC that is the most important concern. Our screening 
outcomes suggest some PMDs, such as LP, can be readily diagnosed by direct 
visual examination and this would be enough to indicate the patient with relevant 
risk factors cannot be discharged from further follow-up. Leukoplakia presents a 
more difficult diagnostic decision for the screening dentist, especially with the paan 
staining commonly found in high-risk South Asian populations such that the 
majority of lesions referred as leukoplakia were actually benign hyperkeratosis. 
The presence of dysplastic change is the most widely used and reliable indicator 
of malignant potential in leukoplakia 33 and this can be assessed by intraoperative 
pathology support on fresh frozen sections. For the soft gold standard screening 
outcome the presence or absence of dysplasia would be appropriate for a positive 
result. From our experience an average of 2-3 individuals were screened positive 
on each screening day and would require intra-operative pathology support for 
definitive diagnosis which may be feasible within existing healthcare services.  
 
6-1.08  OSF and Screening for Oral Cancer 
In relation to South Asian populations, of particular concern is OSF because of the 
significant potential for malignant conversion (7-26%) 39 as well as the clinical 
complications associated with the fibrosis itself. OSF presents a specific problem 
in screening for OSCC because of its direct association with areca nut compounds 
41
 found in paan. However, OSF only occurs in a small proportion of areca 
compound users, such as the 7 out of 568 (1.2%), reported in our sample, 
suggesting that despite the clear association with areca nut the specific aetiology 
is complex and not clearly understood. Paan staining itself was a significant issue 
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reported by the dentists when attempting direct visual assessment of the oral 
mucosa during the screening programme. Therefore, histological methods to aid 
diagnosis of OSF are required to improve the sensitivity of OSCC screening in 
high-risk South Asian populations. 
 
6-1.09  An Altered keratinocyte Phenotype in OSF  
Keratin gene expression is extremely sensitive to pathological changes in cellular 
signalling which results in alterations of the keratinocyte phenotype that can be 
detected by IHC with anti-keratin antibodies. IHC evaluation of the epithelium in 
OSF indicates there are changes in the keratin expression pattern related to the 
OSF pathological process, suggesting that OSF is not a purely connective tissue 
disorder. Our results indicate OSF pathology results in an altered keratinocyte 
phenotype presenting as an induction of keratinisation-specific keratins K1 and 
K10 in the suprabasal layers of OSF epithelium. In the basal layer there was 
increased K6 and decreased K19 expression. K17 expression in the basal layer 
was downregulated only in a sub-set of the most severe cases whereas in the 
suprabasal layers K17 expression appeared to increase with disease severity. 
This altered keratinocyte phenotype in OSF, suggests a potential mechanism for 
the chronic connective tissue pathology via perturbed epithelial-mesenchymal 
interactions and the specificity of changes may provide immunohistological 
diagnostic criteria for OSF although the specific clinical significance of these 
changes remains unclear. 
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6-1.10  Limitations of this Study 
The biggest regret I have is that 21 people who were screened at one of the oral 
cancer screening sessions were told they require further investigation and I can 
only assume they must have taken that to mean they might have OSCC.  These 
21 have never been definitively diagnosed and subsequently cleared or treated. 
The effects on an individual of this knowledge are unquantifiable and in the UK, in 
the 21st century, this is must never be allowed to happen in a cancer screening 
campaign. We have proposed a viable method of preventing this outcome by 
utilising intraoperative pathology support.  Additionally, we can take some comfort 
from the much larger proportion of individuals who attended with an OML and 
were able to be reassured it was not OSCC. This direct positive effect is again 
essentially unquantifiable.  
 
Data collection in the screening component of the study was a source of difficulty, 
specifically how much to collect. Other epidemiological studies, in which I have 
been involved and where a comprehensive data collection process is required, 
take tens of minutes to complete a questionnaire in addition to the oral 
examination. An example would be the Adult Dental Health Survey completed 
every 10 years and published by the Office for National Statistics. This approach 
would be unsuitable for a screening programme where high flow-through of 
patients is necessary and therefore data collection was limited to that which would 
normally be collected to assess OSCC risk. The disadvantage is difficulty in 
interpretation of findings such as the issues we encountered with descriptions of 
tobacco use as distinct from smoking. On the other hand our data set was 
complete which is often not the case when large amounts of information are 
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collected either due to errors by the data collectors or patients being unwilling or 
unable to give so much detailed information. This necessitates the use of 
statistical methods to quantify the errors and as each test requires its own set of 
assumptions this can introduce further errors to the data set which may not be so 
identifiable or quantifiable.       
 
For the IHC component of the study we utilised a sample of Sri Lankan OSF and 
normal tissue samples which may not be directly comparable to UK populations. 
Not enough is known about OSF pathology to ensure that the molecular process is 
identical to that in the UK although the clinical presentation is indistinguishable. 
The Sri Lankan samples were utilised to permit a large enough study to 
demonstrate and evaluate any alterations in keratin expression especially with the 
need to further subdivide the samples by histological grading and the presence of 
dysplasia. In addition, the study published by Ranganathan et. al. (2006) 143 
suggested that their abnormal keratin expression findings in apparently ‘normal’ 
samples were down to the collection process because the tissue was taken from 
patients attending for tooth extraction such that these samples maybe inflamed 
and although non-OSF not entirely ‘normal’. Inflammation can be a pathological 
process and is known to result in changes in molecular markers such as the 
keratins 166. Our Sri Lankan association permitted normal tissue to be sampled 
from non-inflamed buccal, tongue and gingivae with suitable ethical approval as 
was required at the time of harvesting. Also in the interests of homogeneity of 
sample handling and storage the whole population of analysed samples were 
collected from the same clinical facility in Peradeniya. This could be an important 
cause of heterogeneity especially when assessing molecular markers which are 
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responsive to wound healing processes as well as disease pathology. For 
example, with the facilities available at the Centre for Clinical and Diagnostic Oral 
Sciences we can snap freeze tissue in liquid nitrogen (-196oC) and short-term 
store tissue in -80oC freezers with long-term storage in liquid nitrogen, and 
transport samples either on dry ice (-78oC) or liquid nitrogen depending on journey 
duration. Our Sri Lankan partners do not have access to such facilities and 
imported dry ice specifically for this study with the use of domestic freezers (-20oC) 
for storage.   
 
6-1.11  Scope for Further Work 
The most important outcome of this study is whether a further screening 
programme in the Tower Hamlets and Newham population can be justified. The 
burden of oral cancer on the healthcare system remains an enigma for dentists 
who profess to specialise in diseases of the oral cavity because the most serious 
of these diseases should be easily managed, as most oral cancers occur with 
known risk factors and are visually detectable at an early stage. Yet the majority of 
oral cancers are still diagnosed at advanced stages when treatment is either 
ineffective or massively debilitating. The moral argument is therefore clearly that 
dentistry as a profession must eliminate the burden of oral cancer but the question 
of whether this can this be justified within the restricted resource environment of 
the healthcare system remains to be answered. Our study provides a model for 
effectively targeting a high-risk South Asian population conventionally believed to 
be poor users of screening services. Although financial considerations were not 
the primary objective of this study the cost per screening was approximately £24 in 
comparison to £45.50 for the NHS breast screening programme. This indicates 
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there may be scope to implement the necessary intra-operative pathology support 
to be a truly effective and ethical screening programme. 
 
Our model of targeting high-risk populations based on their specific risk factors 
and utilising a mobile dental unit to deliver the screening service may provide a 
platform for further study. This approach could be targeted at other disadvantaged 
minority high risk groups who do not utilise conventional dental services.  
Alternatively, the ability to target a population with a high prevalence of OMLs from 
a mobile dental unit maybe useful in the evaluation of the new technology 
screening aids such as brush biopsy, vital staining or the light based systems. The 
major criticism of these systems appears to be their inability to improve sensitivity 
and specificity, over direct visual examination, when assessing abnormal but not 
clearly malignant lesions 13 i.e. the complex lesions detected during screening. Our 
screening approach would provide the ideal target population to optimise and 
evaluate these diagnostic aids. 
 
The IHC analysis of keratins in fresh frozen OSF samples revealed some evidence 
of changes in keratin expression that may provide pathways for further 
investigation. The study of keratin protein expression and the expression profile of 
K17 in particular may provide markers of disease progression which need to be 
correlated with the clinical presentation and behaviour of the disease. The altered 
keratin expression of K6 in OSF may also facilitate the use of brush biopsy 
cytology samples where the tissue architecture is not available for examination. 
Co-staining for basal specific K15 and K6 may be able to determine which of the 
brush biopsy sample are basal cells (K15 positive) and which samples are 
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suprabasal OSF (K15 and K6 positive). The clinical value of this application is yet 
to be elucidated but markers of disease pathology may lead to improved 
diagnostic ability of these clinically important oral mucosa pathologies. 
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6-2.01  CONCLUSIONS 
Oral cancer appears to be an ideal target for a screening programme because 
most oral cancers develop in visible lesions of the oral mucosa and most occur in 
response to known environmental carcinogens. Therefore unlike the majority of 
other cancers, OSCC can be detected early when treatment is simple and 
effective. A screening protocol to target high-risk individuals for OSCC in the 
Tower Hamlets and Newham South Asian populations is both feasible within 
existing healthcare services and culturally acceptable to the population involved. 
This approach is potentially so effective in overcoming barriers to access that 
positive screened patients then cannot utilise existing healthcare services for the 
follow-up treatment they need. In addition, the high-risk population presents with a 
high prevalence of visible oral mucosal lesions in which cancer can develop such 
that it renders screening by direct visual examination ineffective with a large 
proportion of false positive screening outcomes. An intra-operative pathology 
support service is required so immediate biopsy can be undertaken and a 
definitive diagnosis given without delay. This could be extended with 
immunohistochemical analysis of the fresh frozen sample to aid the diagnosis of 
oral mucosal lesions. Conditions such as paan associated Oral Submucous 
Fibrosis present particular diagnostic and management issues in this population 
and have characteristic keratin expression patterns as a result of the underlying 
pathology, which may be useful diagnostic markers. 
 
Oral cancer screening can be effectively targeted at high-risk South Asian 
populations residing in the UK but ethical and effective screening programmes 
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should utilise intra-operative pathology support services to improve the diagnostic 
ability of the screening clinician. 
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An altered keratinocyte phenotype in oral submucous
fibrosis: correlation of keratin K17 expression with disease
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Oral submucous fibrosis (OSF) is characterized by
abnormal collagen metabolism in the submucosal con-
nective tissue. Its influence on the overlying epithelium
is not known but about 14% of OSF cases undergo
malignant transformation to squamous cell carcinoma
indicating association with abnormality of the epithe-
lium. Here, we have defined the keratin expression
profile, by immunohistochemistry and quantitative im-
age analysis, using a panel of 22 anti-keratin monoclonal
antibodies on 28 OSF samples. We observed an in-
crease of K1 and K10 in the suprabasal layers, induction
of K6 in the basal layer and complete loss of K19 in the
epithelium. Furthermore, there was increased K17
expression in the suprabasal layers, which correlated
with disease severity. In a subset of the most severe
OSF cases (14%), K17 expression was completely lost
in the basal layer which might define them to be at
most risk to undergo malignant transformation. There
was no detectable expression of K8, K18, K7 and K9
and the expression of K4, K13, K14, K15 and K16 did
not change in OSF. We propose that the altered ker-
atin profiles could be useful as histological diagnostic
markers and provide important insights into the
pathogenesis of the disease and its predisposition to
malignancy.
J Oral Pathol Med (2008) 37: 211–220
Keywords: epithelium; immunohistochemistry; keratin;
pre-malignancy
Introduction
Oral submucous ﬁbrosis (OSF) is a chronic debilitating
pre-malignant condition aﬀecting millions of individuals
worldwide. Incidence varies between countries but OSF
is most commonly seen in the Asian subcontinent.
Malignancy develops in about 14% of OSF lesions (1)
and contributes to oral cancer being the eighth most
common cancer worldwide and one of the three com-
monest cancers in South-Central Asia (2). Although the
aetiology of OSF is largely unknown there is a
relationship between the use of areca nut extract and
development of OSF prompting the World Health
Organization to classify areca nut as a group I carcin-
ogen (3). However, OSF pathogenesis is likely to be
multifactorial as only a small proportion of the nut users
actually suﬀer from this condition.
Clinically, OSF is characterized by progressive loss
of elasticity of the oropharyngeal mucosa and atrophy
of the oral epithelium with resultant restricted mouth
opening, reduced tongue mobility and sensitivity to
spicy food. The characteristic histological change in
OSF is progressive collagenous ﬁbrosis and hyaliniza-
tion of the subepithelial connective tissue. As the
disease is considered to be mesenchymal in origin,
research in the literature has focussed on the cellular
and biochemical events that take place in the connec-
tive tissue (4, 5). Despite these advances the patho-
genesis remains to be elucidated. At present nothing is
known about the eﬀects of ﬁbrosis on the overlying
epithelium at the molecular level but histology shows
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the presence of epithelial abnormalities. Dysplasia is a
feature in 26% of OSF lesions (6), which is consistent
with the high rate of malignant transformation. Addi-
tionally, epithelial atrophy occurs in 87% and kerati-
nizing metaplasia in 67% of cases (7). Given these
morphological changes it is plausible that the epithe-
lium may play a role in inducing the connective tissue
changes seen in OSF and is certainly involved in the
malignant changes that occur in a signiﬁcant number
of cases.
Oral epithelium is formed of stratiﬁed layers of
keratinocytes which express matched pairs of type I and
type II keratin polypeptides in a tissue- and diﬀerentia-
tion-speciﬁc manner (8, 9). For example, all stratiﬁed
epithelia express keratins K5 and K14⁄K15 in their basal
layer but the suprabasal layers express diﬀerent pairs. In
non-keratinizing epithelia such as buccal mucosa the
suprabasal keratinocytes express K4 and K13, whereas
the keratinizing epithelia such as gingivae and hard palate
express K1 andK10 as the predominant keratins. Keratin
gene expression is extremely sensitive to pathological
signalling and altered keratinocyte phenotypes have been
described using keratin gene expression both in cutane-
ous and in oral diseases (10, 11).
In this study, we describe an OSF-speciﬁc keratino-
cyte phenotype with a diﬀerent keratin expression
proﬁle from other cutaneous and oral diseases. The
extensive changes in expression were present in the basal
layer and also aﬀected the suprabasal keratinocytes.
These changes in keratin gene expression provide an
insight into the mechanisms of OSF development and its
conversion to oral squamous cell carcinoma.
Materials and methods
Tissue samples
Samples of site-matched normal (six patients) and OSF
tissue (28 patients) were collected with ethical com-
mittee approval for use in this study. Four normal
samples and 22 OSF biopsies were obtained from
normally non-keratinizing buccal mucosa and the
remainder from keratinized sites such as the tongue
and gingivae (Supplementary Table S1 shows the
biopsy site of each sample and is submitted for the
online version of this journal at http://www.blackwell-
synergy.com/). OSF was diagnosed by clinical presen-
tation and conﬁrmed by histological evaluation.
Biopsy specimens were snap frozen and serial 6 lm
sections cut in a cryostat (Bright Instruments, Cam-
bridge, UK).
Antibodies and immunohistochemistry
Twenty-two diﬀerent monoclonal mouse antibodies
(mAbs) were obtained, either from commercial sources
or raised in house by culturing the respective hybrido-
mas (Table 1). Three layer indirect immunohistochem-
ical staining was performed on frozen tissue sections
utilizing the DAKO LSAB+ kit (Dako, Cambridge-
shire, UK). Colour was developed using 3,3¢-diamino-
benzidine (DAB; Vector Labs, Peterborough, UK) with
a haematoxylin counterstain.
Data analysis
The staining data were analysed by visual assessment and
quantitated by image analysis. Each slide was visually
assessed, independently by two observers, and those
showing positive staining were graded on a three-point
equally weighted scale (+, ++ or +++) for staining
in the basal layer and the suprabasal layers. A cumulative
staining quotient (CSQ) was then calculated for each
antibody, in normal and OSF samples (Table 2):
Cumulative staining quotient ðCSQÞ
¼ Number of ðþÞin all samples
Number of samples
 100
Haematoxylin and eosin-stained OSF lesions were
graded as early, intermediate or advanced based on the
extent of ﬁbrosis and degree of inﬂammatory inﬁltrate
(12) and the histopathological ﬁndings correlated with
keratin staining.
Slides were photographed on a Microphot-FXA
microscope with Coolpix 990 camera (Nikon, Tokyo,
Japan) and the images assembled using ADOBEPHOTOSHOP
CS2 v9.0.2 (Adobe Systems Inc., San Jose, CA, USA).
For quantiﬁcation of staining showing a diﬀerent
pattern in normal and OSF samples, pixel analysis was
performed on the digital images, using a modiﬁcation of
the approach described earlier (13). Photographs were
taken at 100· magniﬁcation with identical optical and
digital zoom camera settings. In PHOTOSHOP, the epithe-
lium was carefully selected from the tissue section using
the Lasso tool and the total pixel count in the selected
Table 1 Mouse monoclonal antibodies used for immunohistochem-
ical characterization of keratin expression in oral submucous ﬁbrosis
Clone Speciﬁcity
Working
Dilution Supplier
LHK1 K1 1:500 In house
LHK2e K2 – In house
6B10 K4 1:10 Sigma-Aldrich,
St Louis, MO, USA
LHK6B K6 1:100 In house
LP5 K K7 – In house
LE41 K8 – In house
Ks9.20 + Ks9.28 K9 1:10 Progen, Heidelberg,
Germany
DE-K10 K10 1:50 Neomarkers, Fremont,
CA, USA
RKSE60 K10 1:10 Biogenesis, Poole, UK
LHP2 K10 – In house
1C7 K13 – In house
1C7 + 2D7 K13 1:10 Neomarkers
LL001 K14 1:500 in house
LHK15 K15 1:500 in house
LL025 K16 1:500 in house
E3 K17 1:10 DAKO, Glostrup,
Denmark
LP34 K6 + K18 1:500 In house
LE61 K18 1:100 In house
LE65 K18 1:10 In house
CY-90 K18 1:10 Sigma-Aldrich
LP2 K K19 1:100 In house
RCK108 K19 1:100 DakoCytomation
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area recorded from the Histogram palette (Fig. 3). For
keratinized samples the superﬁcial keratin layer was not
selected as part of the epithelium as it is often poorly
retained in frozen sections and the dense keratinization
in these squames may obscure antibody-binding sites
(11). A new image was created by cutting and pasting
the selected epithelium and from this the basal and
suprabasal compartments carefully delineated by the
Lasso tool to give the pixel count for each segment of
the epithelium. To separate brown DAB staining from
the blue haematoxylin counterstain a colour range
selection was performed using the same sampled colour
with RGB values of 160, 100 and 100, respectively, as
conﬁrmed in the Colour palette of the software. The
range of colours selected was set to 100 on the Fuzziness
slider which selects other parts of the image by the
degree their colour is related to the sample colour. To
conﬁrm that all DAB-stained sections of the image were
selected, these pixels were cut from the image to leave
just the counterstained areas. Any DAB-stained areas
remaining when the selected pixels were removed, for
example, with very dark brown staining, were manually
selected and employed for the evaluation using the Plus
Eyedropper tool of the software. The DAB pixel count
in the basal and the suprabasal compartments of the
epithelium was recorded and calculated as a percentage
of the total basal or suprabasal pixel count (that will
include DAB and haematoxylin). Quantiﬁcation in this
manner permitted use of the Mann–Whitney U-test to
determine statistically signiﬁcant diﬀerences in the DAB
staining between normal and diseased samples. The
validity of the pixel analysis was conﬁrmed by correla-
tion coeﬃcient r = 0.9 (P < 0.001; Fig. 4) with our
visual assessment grading, even with all non-stained
basal or suprabasal compartments of the epithelium
disregarded.
Results
Where available immunohistochemical staining was
performed with several diﬀerent mAbs raised against
the same keratin, to ensure reproducibility of the
staining pattern, and in each case comparable staining
was observed (Table S1).
Suprabasal keratins (K1⁄K10, K2, K4⁄K13, K6⁄K16
and K9)
K16 staining was entirely suprabasal with similar
expression in all OSF and normal samples conﬁrmed
by a CSQ of 92% and 94%, respectively (Fig. 1a,b and
Table 2). K6 was also strongly suprabasal in normal
epithelia with no expression in the basal layer (Fig. 1c)
whilst in OSF K6 was detectable in both the basal and
the suprabasal layers (Fig. 1d). This increase in expres-
sion in the basal layer of OSF epithelium was highly
signiﬁcant (P < 0.001) whilst the suprabasal K6 expres-
sion was unaﬀected (Table S1).
K2 was detected in a few suprabasal keratinocytes in
two of six normal tissues, which originated from the
tongue and gingivae with no normal buccal mucosa
samples positively stained. One of 28 OSF samples was
weakly positive with a suprabasal expression pattern
similar to that seen in normal oral keratinized samples.
This originated from the tongue and none of the other
OSF samples from keratinized biopsy sites was positive
indicating a potential reduction in K2 expression
although the number of relevant samples was limited
(Table S1).
K1 was expressed in the suprabasal layers of two of
four normal buccal epithelia as well as the two biopsies
from keratinized sites in the oral cavity (Table S1 and
Fig. 1e). K10 staining mirrored K1 in all samples. All
OSF tissues from both keratinized and non-keratinized
biopsy sites were strongly K1⁄K10-positive (Fig. 1f).
This increase was highly signiﬁcant (P < 0.001) for
non-keratinized site-matched (buccal) samples whilst
normally keratinized sites appear qualitatively unaf-
fected with a CSQ of 67% for both K1 and K10 in the
suprabasal layers although the number of samples was
limited (Table 2).
All OSF and normal tissue samples stained compa-
rably for K4⁄K13 in the suprabasal layers (Fig. 1g,h)
and none expressed the palmo-plantar epidermis-speciﬁc
K9.
Basal keratins (K14, K15, K17 and K19)
K17 was detected in the basal layer of all normal
samples but additional suprabasal staining was only
present in 50% of cases (Figs 2a,c and 5a). All OSF
samples expressed K17 and although the staining varied
considerably in intensity and distribution (Figs 2b,d and
5a) there was increased K17 in the suprabasal layers
(P < 0.01) and no change in basal expression. When
correlated with histological grading the suprabasal
staining was most signiﬁcantly upregulated in the most
severe samples (P < 0.01; Fig. 6). The intermediate
classiﬁed samples returned weaker evidence of a diﬀer-
ence between normal and OSF (P < 0.05) and for the
Table 2 CSQ of immunostaining in normal and OSF
Keratin
Cumulative staining quotient (%)
Basal Suprabasal
Normal OSF Normal OSF
K1 (all biopsy sites) 0 0 33 65
K1 (non-keratinized sites only) 0 0 17 65
K1 (keratinized sites only) 0 0 67 67
K10a (all biopsy sites) 0 0 33 69
K10a (non-keratinized sites only) 0 0 17 62
K10a (keratinized sites only) 0 0 67 67
K6 0 70 94 87
K16 0 0 94 92
K4 0 0 94 95
K13a 0 0 94 96
K2 0 0 11 1
K14 100 100 100 96
K15 100 99 0 0
K17 61 58 17 44
K19a (all samples) 22 0 0 0
K19a (non-keratinized sites only) 33 0 0 0
K19a (keratinized sites only) 0 0 0 0
aResults for multiple monoclonal antibodies were identical and have
been combined for clarity.
CSQ, cumulative staining quotient; OSF, oral submucous ﬁbrosis
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
Figure 1 Immunohistochemical staining of normal oral (a, c, e and g) and oral submucous ﬁbrosis lesional (b, d, f and h) epithelium for the
suprabasal keratins. K16 (a and b), K6 (c and d), K1 (e and f) and K13 (g and h). Bar = 50 mm.
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(a) (b)
(c) (d)
(e) (f)
(g) (h)
(i) (j)
Figure 2 Immunohistochemical staining of normal oral (a, c, e, g and i) and oral submucous ﬁbrosis lesional (b, d, f, h and j) epithelium for the
basal keratins. K17 [(a) and (b) showing isolated basal and suprabasal staining whilst (c) and (d) show both basal and suprabasal staining patterns],
K19 (e and f), K14 (g and h) and K15 (i and j). Bar = 50mm.
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early OSF there was no signiﬁcant diﬀerence to supra-
basal K17 expression in normal epithelium (P > 0.05).
Basal K17 expression did not appear to correlate with
histological OSF grading.
K19 staining was discontinuous and limited to the
basal layer of non-keratinized normal epithelia (Fig. 2e)
with no expression in normal keratinized epithelium.
There was also no expression of K19 in any OSF
samples whether from keratinized or non-keratinized
sites (Fig. 2f) suggesting a highly signiﬁcant reduction in
site-matched non-keratinized epithelia (P < 0.001;
Fig. 5d) compared with the normal controls.
K14 staining was present homogenously throughout
the basal and suprabasal layers (Fig. 2g,h) whilst K15
was detected in the entire basal layer (Fig. 2i,j) of both
normal and OSF samples implying the disease did not
inﬂuence these two keratins.
Simple epithelial keratins (K7, K8 and K18)
No staining for K7, K8, K18 or the K8⁄K18 complex
was observed in normal or OSF samples.
Discussion
Epithelial–mesenchymal interactions play vital roles in
keratinocyte diﬀerentiation, proliferation, migration and
invasion (14, 15). Alterations in keratin expression as a
result of changes in the mesenchyme have also been
reported using both in vitro (16) and in vivomodels (17). In
OSF an imbalance of collagen metabolism causes exces-
sive deposition of collagen leading to abnormal mesen-
chyme, which could aﬀect the overlying epithelium. Two
known benign connective tissue disorders of the epider-
mis, hypertrophic (HTS) and keloid scars, are also
characterized by abnormal collagen metabolism with
considerable similarities to OSF (18, 19). We and others
have shown that the pathogenesis of HTS and keloids
involves perturbed epithelial–mesenchymal interactions
with abnormality of keratinocyte phenotype in the
epidermis (11, 18, 19). Therefore, we hypothesize that
keratinocytes in OSF epithelium could be altered, which
would implicate them in the disease pathogenesis, as well
as their predisposition to oral cancer.
Hyperkeratinization of OSF epithelium
In OSF, compared to non-keratinized normal epithe-
lium, there is an increased suprabasal expression of
Figure 4 Correlation between visual assessment grading and image
analysis of 3,3¢-diaminobenzidine immunostaining for K6 in the basal
layer of oral submucous ﬁbrosis and normal oral epithelium (r = 0.9).
Dotted line represents image analysis and the solid line represents
visual assessment.
(a)
(e)
(b) (c) (d)
Figure 3 Quantitative analysis of 3,3¢-diaminobenzidine (DAB)-immunostained and haematoxylin-counterstained tissue images. (a) Original
images imported into ADOBE PHOTOSHOP CS2 v9.0.2 (Adobe Systems Inc.), (b) with epithelium delineated and (c) DAB staining speciﬁcally selected
or (d) haematoxylin counterstain selected by adjustment of colour selection’ properties. (e) The pixel count of the selected area is given in the
Histogram palette.
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K1⁄K10 (Fig. 5c) which is a feature of oral hyperkera-
totic lesions (11). Keratinized normal oral epithelium
also shows similar expression of K1⁄K10 indicating this
to be a speciﬁc molecular marker of keratinization (20).
The histologically apparent keratosis in many OSF
lesions is therefore consistent with the increase in
K1⁄K10 expression. Increased K1⁄K10 expression has
also been linked with K2 upregulation in oral dysplastic
lesions which is distinct from the keratinization seen in
oral lichen planus (OLP). In OLP, keratosis K1⁄K10
upregulation occurs independently of K2 induction (11).
OSF mirrors OLP in that K1⁄K10 expression is upreg-
ulated without a concomitant increase in K2 despite the
presence of dysplasia. OLP is an autoimmune disorder
therefore the similarities in K1⁄K10 and K2 regulation
seen in OSF may indicate an immunological pathogen-
esis although it is also believed that keratinization in
OSF is due to direct mechanical trauma from the course
ﬁbres of the areca nut (21). OLP is histologically
characterized by a dense subepithelial band of lympho-
cytes, which produces a massive inﬂammatory inﬁltrate
with resultant high levels of proinﬂammatory cytokines
that induce abnormal keratinocyte diﬀerentiation (11).
Whilst OSF lesions do not show this characteristic
subepithelial inﬁltrate the dense ﬁbrosis and reduced
vasculature of OSF subepithelial tissues may allow for
long-term build-up of inﬂammatory cytokines which can
then aﬀect the epithelium in a similar manner to OLP.
This should also provide a mechanism for malignant
change as persistent tissue inﬂammation is implicated in
carcinogenesis(22).
Speciﬁc induction of K6 in the basal keratinocytes of OSF
epithelium
In OSF, we observed increased K6 expression in the
basal layer of the epithelium but no change in the
constitutive basal keratins K14 and K15 (Figs 2g–j
and 5b). The inﬂuence of OSF pathology on K5
expression could not be determined as a well-character-
ized mAb, suitable for frozen sections, was not
available. Commercially available anti-K5 antibody
XM26 (Novocastra, Newcastle, UK) has been used on
(a) (b)
(c) (d)
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Figure 5 Quantiﬁcation of keratin expression by pixel analysis of 3,3¢-diaminobenzidine staining in oral submucous ﬁbrosis (OSF) and normal
epithelium. (a) IncreasedK17 expression in the suprabasal layers of all 28 OSF samples (keratinized and non-keratinized) compared to six normal and
(b) increasedK6 in the basal layer in the same samples, (c) increased suprabasalK1 and (d) basalK19 reduced expression in 22OSF samples fromnon-
keratinized biopsy sites compared to four non-keratinized normal oral epithelia. OSF samples are shown by dotted bars and normal by hashed bars.
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formalin-ﬁxed sections but with frozen tissue this mAb
did not react. This conﬁrms that it may not be possible
to compare frozen and formalin-ﬁxed samples for
keratin staining using the same mAb (23, 24). The only
previous immunohistological study of keratin expres-
sion in OSF used formalin-ﬁxed samples (25) and this
may explain some of their anomalous expression
patterns such as suprabasal expression of the basal-
speciﬁc K5 and lack of K14 expression in 80% of
samples. Alternatively, this abnormal staining could be
a feature of the mAbs employed and it is unclear
whether site-matched normal and OSF tissues were used
in their study. Furthermore, they did not use antibodies
against K6, K17 and K19, the keratins we found to be
the most inﬂuenced by OSF pathology.
Induction of K6 expression in the basal layer of OSF
epithelium creates a situation whereby a type II keratin
is switched on without the expression of its normal type
I partner K16. In non-keratinized epithelium hetero-
genous basal expression of K6 but not K16 has been
reported previously (26) but only in the rete-ridges,
using anti-K6 KA12 antibody. As no photograph of the
staining was published, it was diﬃcult to critically
evaluate the reactivity. None of our normal oral tissues
expressed K6 in the basal layer which is consistent with
the literature using LHK6B (27) but the pattern of K6
expression in other pre-cancerous oral dysplasias is not
known. Interestingly, staining observed with LP34 was
entirely suprabasal in both OSF and normal tissue and
this antibody is commercially marketed for the detection
of K6 and K18 (Cancer Research Technology, London,
UK) or K5, K6 and K18 (Acris, Hiddenhausen,
Germany), indicating its precise reactivity is yet to be
established. We have shown with multiple mAbs (LE61,
LE65 and CY-90) that K8⁄K18 complex or K18 alone
are not detectable in these samples, implying LP34
staining may be K6-speciﬁc. However, as K6 is present
in the basal layer of OSF epithelium (Fig. 1d), the lack
of LP34 reactivity suggests that this mAb may not
recognize K6 either. If LP34 was reacting with K5 then
staining would be observed in the basal layer, but this
was absent in normal samples indicating that LP34 may
not also detect K5. The LP34 staining in normal and
OSF epithelium could be from cross-reactivity with
another, as yet unidentiﬁed suprabasal keratin, in a
manner similar to anti-K14 LL001 antibody which
stains both basal and suprabasal keratinocytes in
normal buccal epithelium (Fig. 2g), when the K14
mRNA expression is restricted to the basal layer (10).
Alternatively, it is conceivable that the LP34-binding
site on K6 may undergo a conformational change in
K6⁄K16 complexes to unmask the epitope. This does not
occur in the basal layer of OSF epithelium as K16 is
absent, whereas in the suprabasal layers both K6 and
K16 are expressed, inducing LP34 binding. The confor-
mation-speciﬁc epitope phenomenon has been reported
for a number of keratin antibodies (28–32) and requires
further investigation as LP34 is widely used in diagnos-
tic pathology. Nevertheless, LHK6B staining in the
basal layer of oral epithelium appears to be a charac-
teristic feature of OSF in this study. Furthermore, as the
basal layer predominantly contains proliferating cells
and the suprabasal cells are derived from basal kerat-
inocytes, anomalous expression of K6 in the basal layer
is likely to inﬂuence subsequent diﬀerentiation-related
cellular features such as keratinization and epithelial
atrophy. Interestingly, this K6 expression pattern is also
exhibited by normal oral keratinocytes induced to
diﬀerentiate in an organotypical culture (27).
Reduced expression of K19 and K17 in basal keratino-
cytes of the OSF epithelium
The sporadic K19 expression in the basal layer of
normal non-keratinized oral epithelia is consistent with
that reported in the literature. Decreased K19 expres-
sion in OSF may be symptomatic of the keratinized state
of the tissue as K19 expression is known to be
incompatible with keratinization in normal oral epithe-
lia (33, 34).
K17 has been described as both an oral epithelial basal
cell marker (35) and a suprabasal hyperproliferation
Figure 6 Suprabasal expression of K17 in oral submucous ﬁbrosis
epithelium shown by image analysis of 3,3¢-diaminobenzidine immu-
nostaining and correlated with histological grading of disease severity.
No statistically signiﬁcant difference is measurable between early
lesions and normal epithelium but increased K17 is evident with
intermediate pathology and advanced lesions display highly signiﬁcant
K17 suprabasal increased expression.
Table 3 Loss of basal K17 expression in a subset of moderate-to-
severe oral submucous ﬁbrosis (OSF) cases
Sample
K17 staining OSF histological grading
Basal Suprabasal Early Intermediate Advanced
OSF 1 ) + +
OSF 11 ) + +
OSF 28 ) ++ +
OSF 33a ) ++ +
OSF 4 ++ ) +
OSF 21 +++ ) +
OSF 23 ++ ) +
OSF 35 ++ ) +
OSF 41 +++ ) +
aEvidence of dysplastic change in the epithelium.
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marker similar to K16 in epidermal wound healing (26,
36, 37). Our data are consistent with the former as
expression of K17 is predominantly in the basal layer of
normal epithelium with sparse suprabasal expression in
50% of samples. Table 3 shows four of 28 OSF samples
in which there was no basal expression of K17 and 3 of
these were amongst the most advanced OSF cases,
whilst the other was classiﬁed as intermediate with
evidence of dysplasia. Conversely, ﬁve of 28 samples
expressed basal but no suprabasal K17 and none was
advanced case. Loss of basal K17 appears to be a
feature of certain advanced OSF pathologies in a
particular cytokine environment such as the low level
of interferon-c found in some OSF lesions (38). This
premise is consistent with the fact that interferon-c is
known to induce K17 in keratinocytes (39, 40). Perhaps
K17 expression is more sensitive to interferon-c
than K15 because K15 is also induced by interferon-c
(41) but it remains uninﬂuenced by OSF pathology
(Fig. 2i,j). We also note that, despite the small number
of samples, four of 28 OSF tissues (14%) showing loss
of K17 in the basal layer, as well as being biopsied from
some of the most advanced lesions, is the same number
that would be projected to progress to oral squamous
cell carcinoma.
Induction of K17 in the suprabasal layers of OSF
epithelium correlates with disease severity
Although K17 expression in the basal layer was absent
in a subset of the most severe cases, overall there was no
correlation between the basal K17 expression and
disease severity. However, expression in the suprabasal
layers correlated with histological grading of OSF
severity whereby the most signiﬁcant K17 increase
occurred in the most advanced cases (Fig. 6). None of
the other keratins inﬂuenced in OSF showed any
signiﬁcant correlation with the disease severity. These
observations suggest that perturbation in K17 expres-
sion is perhaps a primary outcome of OSF pathology
and the expression of other keratins is inﬂuenced by
factors in addition to the disease pathology such as
keratinization or dysplasia.
Keratinization in OSF epithelium has a molecular signa-
ture distinct from that in pre-cancerous dysplasia
The commonest pre-cancerous dysplasias are kerati-
nized; however, hyperkeratinization does not always
lead to dysplasia. Virtually all of our OSF samples
showed evidence of keratinization but dysplastic
changes were present only in seven samples. There are
several lines of evidence to suggest that OSF keratini-
zation may be diﬀerent from that seen in hyperkeratotic
lesions or dysplasia. In pre-cancerous dysplasia K16 has
been reported to be induced (42) whilst we did not
observe any change in the expression of this protein in
OSF epithelium. The complete absence of K19 in OSF
epithelium observed in this study is in contrast to its
reported induction in pre-cancerous dysplasia (33).
Furthermore, in hyperkeratotic lesions and in pre-
cancerous dysplasia we have reported an upregulation
of keratin K2 (11) when in OSF epithelium we did not
observe K2 expression. Taking together these observa-
tions strongly suggest that keratinization in OSF may
have a molecular signature clearly distinct from that
observed in hyperkeratotic lesions and dysplasia. These
data provide a foundation for future molecular analysis
using expression microarrays.
In conclusion, we have provided deﬁnitive data to
show that OSF results in an altered keratinocyte
phenotype. We have shown an induction of keratiniza-
tion-speciﬁc keratins K1 and K10 in the suprabasal
layers of OSF epithelium. In the basal layer we found
increased K6 and decreased K19 expression. K17
expression in the basal layer was downregulated only
in a subset of the most severe cases, whereas in the
suprabasal layers K17 expression increased with disease
severity. This altered keratinocyte phenotype in OSF,
indicates a potential mechanism for the chronic con-
nective tissue pathology via perturbed epithelial mesen-
chymal interactions as well as the malignant conversion
to oral squamous cell carcinoma.
Supplementary material
The following supplementary material is available for
this article online:
Table S1: Keratin immunostaining of OSF and nor-
mal epithelial samples: correlation between visual
assessment and pixel analysis
This material is available as part of the online article
from http://www.blackwell-synergy.com
Please note: Blackwell Publishing are not responsible
for the content or functionality of any supplementary
materials supplied by the authors. Any queries (other
than missing material) should be directed to the
corresponding author for the article.
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Oral cancer screening in the Bangladeshi community of Tower
Hamlets: a social model
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BACKGROUND: UK oral cancer incidence has risen by 22% in the last 10 years. Oral cancer is often detected at a late stage when
treatment is debilitating and the chances of survival are poor. Certain black and minority ethnic groups are at elevated risk of oral
cancer due to the prevalence of risk factor behaviours. We describe the background to, the development of and outcomes of an oral
cancer screening activity appropriate to the needs of members of a disadvantaged community at high risk of oral cancer, carried out
between 2006 and 2008 in Tower Hamlets, East London.
METHODS: In all, 1320 people participated during 34 days of screening, divided into two phases (Phase I (2006/2007): n¼ 485, Phase II
(2008): n¼ 835). Modifications to the delivery process were implemented for Phase II in an attempt to recruit more high-risk
individuals and to improve screening specificity.
RESULTS: In total, 75 people were urgently referred for further investigation (Phase I: n¼ 20, Phase II: n¼ 55). Nine were diagnosed
with dysplastic lesions (Phase I: n¼ 3, Phase II: n¼ 6) and a further eight showed potentially malignant disorders without dysplasia
(Phase I: n¼ 1, Phase II: n¼ 7). Screening participants with low levels of completed education (OR: 6.94, 95% CI: 1.66, 28.98) and
who chewed paan with tobacco (OR: 8.01, 95% CI: 3.54, 18.08) were more likely to be referred for further investigation.
CONCLUSION: The project offers insights for the further development of oral cancer screening interventions for disadvantaged
communities.
British Journal of Cancer (2009) 101, S68 – S72. doi:10.1038/sj.bjc.6605394 www.bjcancer.com
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Oral cancer is defined as cancers of the lip, tongue, oral cavity,
oropharynx, hypopharynx and piriform sinus. The majority of
tumours are squamous cell carcinomas, with the most common
sites being the oral cavity (31%) and the tongue (29%). The least
common site for oral cancer is the lip, accounting for only 6% of
cases (Office for National Statistics, 1996–2005). UK oral cancer
incidence rates have increased by 22% in the last 10 years (Office
for National Statistics, 1996–2005). In 2005, 4900 people were
diagnosed with oral cancer in this country (Office for National
Statistics, 1996–2005). There are inequalities in oral cancer
incidence and survival, with rates varying according to level of
deprivation, geographical location and ethnicity (Office for
National Statistics, 1996–2005; NCIN, 2009). The available data
suggest that risk of oral cancer is higher among older Asian
females than in females from the general population, although this
is not the case for males (NCIN, 2009).
The average 5-year survival rate for cancer of the oral cavity
is around 50% (Office for National Statistics, 1996–2005). This
is because the majority of cases are diagnosed at a late stage,
when treatment is debilitating and the chances of survival are
poor (Murphy et al, 2007). Oral cancer survival varies considerably
by stage at diagnosis and by site (Office for National Statistics,
1996–2005). Treatment for early stage oral cancer or oral
dysplasia, tends to be considerably less invasive and debilitating
(Lodi et al, 2006; van der Waal, 2009).
The Bangladeshi community in Tower Hamlets
Oral cancer is undoubtedly an important public health issue, but as
it is a relatively rare disease in the United Kingdom, targeted
population strategies are likely to be most cost effective. From 2005
to 2008, Cancer Research UK ran an oral cancer project targeted at
the Bangladeshi community in Tower Hamlets, East London,
funded largely by the Chief Dental Officer, Department of Health.
Tower Hamlets is the third most deprived borough in England
(Office for National Statistics, 2001). One third of the borough’s
population is Bangladeshi, totalling nearly 66 000. This is the
largest Bangladeshi community outside of Bangladesh (Office for
National Statistics, 2001). Conducting the project in this borough
offered the opportunity to closely target a large community at high
risk of oral cancer residing in a relatively small geographical area
in a deprived part of London.
The Bangladeshi community exhibits a high prevalence of a
number of oral cancer risk factors, including smoking, chewing
tobacco and chewing areca nut but excluding alcohol consumption
when compared with the general adult population (Croucher et al,
2003; Health Survey for England, 2004). Forty per cent of
Bangladeshi men report being current smokers, compared to
24% of men from the general population. Although Bangladeshi*Correspondence: H Nunn; E-mail: hazel.nunn@cancer.org.uk
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women are much less likely to report being current smokers
compared to women from the general population (2% compared to
23%), national estimates of chewing tobacco or areca nut use range
from 16% of Bangladeshi women chewing paan with tobacco and
13% chewing paan without tobacco but with areca nut (Health
Survey for England, 2004) to 48.5% of a sample of Bangladeshi
women resident in Tower Hamlets chewing paan with tobacco
(Croucher et al, 2003). As the Bangladeshi community of Tower
Hamlets shows significantly different risk factor behaviours from
the general UK population, highly targeted oral cancer screening
is likely to be needed.
This paper aims to describe the development of an oral cancer
screening activity appropriate to the needs of a disadvantaged
community at high risk of oral cancer. Specifically, it will describe
the delivery structure of the screening activity, explain the process
followed and review and discuss some outcomes.
Oral screening and potentially malignant disorders
There is significant potential for early detection of oral cancer
because the oral cavity and oropharynx are relatively accessible
and amenable to examination without invasive procedures. The
existence of potentially malignant disorders of the oral mucosa
implies there should be significant potential for prevention of oral
cancer through oral visual screening (Scully and Porter, 2000).
Potentially malignant disorders are defined as ‘all clinical
presentations that carry a risk of cancer’ (Warnakulasuriya,
2007). They tend to be linked to tobacco use (Napier and Speight,
2008). The proportion of potentially malignant disorders that
transform into frank oral cancers varies greatly, based on
characteristics of the disorder and its site, the patient’s age and
gender (Napier and Speight, 2008), and the patient’s behaviour
(Warnakulasuriya et al, 2008; van der Waal, 2009). Overall
malignant transformation rate for white patches (leukoplakias) is
estimated at around 1% per year (van der Waal, 2009) while it is
thought that between 75% and 90% of red patches (erythroplakias)
will undergo malignant transformation (Scully and Porter, 2000).
Dysplastic change is reported to be the best predictor of future
malignancy, and the more severe the dysplasia, the greater the
likelihood of malignant transformation (Schepman et al, 1998).
Estimates suggest that around 50% of patients with dysplasia may
go on to develop oral squamous cell carcinoma (Napier and
Speight, 2008).
The transformation rate of other potentially malignant disorders
of the oral and oropharyngeal mucosa is harder to quantify,
ranging from 0.13% to 2.2% for all potentially malignant disorders
combined (Napier and Speight, 2008). Of specific relevance to an
Asian population, where areca nut (betel quid) usage is prevalent,
is oral sub-mucous fibrosis (OSF). This potentially malignant
disorder has a reported malignant transformation rate of 14%
(Tilakaratne et al, 2006).
A number of possible screening techniques have been proposed
for oral cancer. The simplest involves visual examination of the
oral mucosa (Kujan et al, 2006). A recent Cochrane review con-
cluded that there was not enough evidence to determine whether
oral screening by visual examination, or any other modality, in the
general population could reduce mortality from oral cancer (Kujan
et al, 2006), but an increasing number of studies suggest that oral
screening could feasibly be carried out cost effectively as part of
routine dental inspection in NHS general dental practice (Field
et al, 1995; Lim et al, 2003; Speight et al, 2006). This may be of
limited relevance to the Bangladeshi population of Tower Hamlets
who are known to have poor attendance rates at General Dental
Practitioners (Pearson et al, 1999).
Cuba is one of the only countries in the world to report a
national oral cancer screening programme. This programme uses
annual visual examination in dental practices (Fernandez Garrote
et al, 1995). While there is some evidence that repeated screenings led
to a reduced likelihood of advanced stage oral cancer (Sankaranarayanan
et al, 2002), overall there has been limited evidence of a shift from
advanced to earlier stage oral cancer following introduction of the
programme (Fernandez Garrote et al, 1995).
MATERIALS AND METHODS
Developing a delivery structure
The following steps were followed in developing a protocol for
screening activity:
1. Establishment of a community advisory group This comprised
local stakeholders from the Primary Care Trust Smoking
Cessation and Dental Access teams, Cancer Services, Oral
Medicine and Oral Maxillofacial Surgery teams, community
organisations, as well as practice nurses and patient and
community representatives. The group offered guidance on the
development and promotion of oral cancer screening activity
among the Bangladeshi community and the development of
accompanying oral cancer awareness literature.
2. Formal qualitative research was conducted with the target
population, by means of focus group discussions and key
informant interviews, to inform development of the oral cancer
screening activity and accompanying literature.
3. Identification of screening sites in the locality to undertake
screening activity where a mobile dental unit provided by the
Primary Care Trust could be used.
4. Screening criteria established Oral cancer screening involved
visual examination of the soft tissue of the oral cavity and
oropharynx, and palpation of the neck using standardised criteria.
The activity was conducted by two registered dental practitioners
after refresher training to ensure compliance with guidance
(National Institute for Health and Clinical Excellence, 2005).
5. Development of referral pathways Patients could be referred
directly from the mobile dental unit, either to the Department
of Oral Medicine, Barts and the London Dental Institute for
further investigation, and/or to local stop tobacco services for
cessation support.
6. Determination of inclusion criteria In addition to being
Bangladeshi or British Bangladeshi and a resident of Tower
Hamlets, inclusion criteria for screening included being aged at
least 30 years and practising one or more of the following health-
compromising behaviours: smoking tobacco, chewing tobacco,
chewing paan (betel quid) without tobacco. Potential partici-
pants falling outside these inclusion criteria were not actively
recruited, but if they persistently sought screening, whatever
their age, gender, ethnicity or behaviour, they were not excluded.
The delivery process
Delivery of oral cancer screening in Tower Hamlets as part of this
project was divided into two phases. Phase I involved 10 screening
sessions, which took place in 2006 and 2007, and Phase II consisted
of 24 screening sessions, which took place in 2008. Several
refinements were made to the delivery process for Phase II.
In both phases, all screening sessions were held in the six wards
within Tower Hamlets with the highest proportions of Bangladeshi
residents based on ethnicity data from the 2001 census (Office for
National Statistics, 2001). In Phase I, the 10 screening sessions
were fairly evenly divided between these six wards, with exact
locations of the mobile dental unit based on advice from the
community advisory group. In Phase II, locations for conducting
24 oral cancer screening sessions were purposefully selected using
ward ethnicity data from the 2001 census (Office for National
Statistics, 2001), with the number of sessions conducted in each
ward proportional to the size of the Bangladeshi population in that
ward, with a higher number of screening sessions held in wards
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with the highest proportions of Bangladeshi residents. The exact
location within each ward was again based on advice from our
community advisory group.
Screening was undertaken using a mobile dental unit – a
specifically adapted motor vehicle, housing a dental clinic with
conventional reclining dental chair and telescopic high-intensity
lighting. This provided a clean, safe and confidential environment
for examination of the illuminated oral mucosa in the supine
position with the availability of all the instruments and amenities
that would be present in a permanent dental clinic. Use of the
mobile dental unit addressed all as the issues arising from pre-trial
attempts at mucosal examination using hand-held portable
equipment, including inconsistent lighting intensity, confidenti-
ality and modesty concerns when examining in busy areas,
difficulty gaining adequate oral mucosal access without the patient
in the supine position, concerns about the examiners’ posture and
lack of appropriate cross-infection control.
Ensuring the cultural acceptability of oral cancer screening
activity was addressed by the use of bi-lingual (English/Sylheti)
advocates. Again, the procedure was modified between Phase I and
Phase II. In Phase I, the main roles of bilingual advocates were to
provide language support during and after screening and to
facilitate the referral process by following up referred patients
individually. In Phase II, the advocates had a more integral role in
the delivery process, continuing to provide language and other
support during and after screening, recruiting participants to
tobacco cessation, facilitating the referral process and collecting
evaluation data and promoting oral cancer screening activity. As
well as encouraging passing pedestrians to take part, this
promotion of oral cancer screening involved placing oral cancer
awareness and advertising health education material in areas
where, from their local knowledge, the advocates knew that older
Bangladeshis lived, or visited, such as community centres, shops
and sheltered accommodation. In addition, at the referral stage,
the advocates facilitated the distribution of referral letters,
followed up the letters with telephone calls to ensure the letters
had been received and understood, and offered to accompany
patients to their referral appointment if required. This process
ensured as many patients as possible complied with referral.
Final modifications to the delivery process for Phase II
concerned selection, training and calibration of the dentists
conducting screening. For Phase I, dentists with varying levels of
experience in the diagnosis and management of oral cancer were
recruited. They were standardised by attendance at a pre-screening
refresher session where images of oral mucosal lesions were
examined in relation to the NICE guidelines on the referral of
suspected cancer (National Institute for Health and Clinical
Excellence, 2005). A more robust standardisation and calibration
process was developed for Phase II based on an updated protocol
(Ikeda et al, 1995; Barnes et al, 2005). Just two dentists were
recruited for Phase II, both with extensive clinical experience in
diagnosing oral mucosal pathology at secondary referral centres.
Assessing outcomes
The following outcomes of the activity are reported:
 numbers (Phases I and II) and demographic details (Phase II
only) of screening participants and details of recruitment to
local tobacco cessation services (Phase II only)
 numbers referred to secondary care services (Phases I and II)
 compliance with referral (Phases I and II)
 clinical outcomes and diagnoses (Phases I and II)
 socio-demographic and behavioural predictors of referral
(Phase II only) using a retrospective case–control design,
whereby participants referred were matched with multiple
controls to increase study power
 financial considerations
During Phase II, a questionnaire was used to identify potential
screening participants. Those identified as meeting the inclusion
criteria were then asked to take part in a second interview.
Information about age, gender, years of completed education,
economic activity, self-reported health, oral cancer awareness and
tobacco consumption was collected. The core content of the
interview was provided by using validated questions taken from
existing inventories (Humphris et al, 1999; Health Survey for
England, 2004).
Data collection were approved by the local research ethics
committee and analysed using STATA version 10. Participants
gave their written consent to take part in the interview.
RESULTS
Characteristics of screened population and recruitment to
tobacco cessation
Between 2006 and 2008, a total of 34 screening sessions were
undertaken in Tower Hamlets with 1320 individuals screened (485
in Phase I and 835 in Phase II). On average, 39 people were
screened per session (range 19–82). Each session was B7 h in
duration, undertaken between 0930 and 1630 with flexible break
times dependent on the flow of patients.
The mean age of the screened population was 42.3 years (SD 15.9
years). As shown in Table 1, 45% of patients screened in Phase II
were female, 84% were from the Bangladeshi community and
58% were tobacco or areca nut users. In Phase II, a total of 202
screening participants were recruited to tobacco cessation (i.e. 42%
of participants who were tobacco users). Data collection in Phase I
were incomplete.
Referral, compliance and clinical outcomes
Of the 1320 individuals screened, 75 were referred for Oral
Medicine consultation at Barts and The London Dental Institute.
Table 2 shows the outcomes of these referrals. Despite attempts
to ensure as many patients as possible complied with referral,
20 (27%) failed to attend either their initial hospital appoin-
tment or subsequent follow-up appointments such that a
definitive diagnosis of their condition could not be made. Six
out of 14 patients failed to comply with referral in Phase I (30%),
while 14 out of 55 failed to comply in Phase II (25%). In all, 55
patients did attend after referral, and further investigations were
instigated as appropriate to generate the diagnoses shown in
Table 2.
None of those referred presented with frank oral cancer but 17
(31%) were diagnosed with potentially malignant disorders as
shown in Table 2. Of these, nine had evidence of dysplasia (two
moderate/severe) and five had OSF. The remaining 38 patients had
benign lesions, of which the most common was keratosis (n¼ 31).
Of the 55 patients attending the secondary referral service at
Barts and the London, 35 (64%) remain under regular review
including all those with potentially malignant disorders. These
individuals exhibit a number of risk factors for the development
Table 1 Details of screening participants in Phase II
Phase II (2008)
Number of screening sessions 24
Number of individuals screened 835
Number of females screened (%) 375 (45%)
Number of Bangladeshis screened (%) 762 (91%)
Number of tobacco/areca nut users screened (%) 485 (58%)
Number of recruits to tobacco cessation 202
A social model of oral cancer screening
H Nunn et al
S70
British Journal of Cancer (2009) 101(S2), S68 – S72 & 2009 Cancer Research UK
of oral cancer and their pre-existing mucosal lesions indicate a
significant risk of further lesions developing. Only 20 patients
presenting with confirmed benign lesions and minimal risk
factors, who had access to appropriate follow-up within primary
dental care services, were able to be discharged from further review
in the Department of Oral Medicine. In Phase I, 7 out of 14 (50%)
of compliant referred patients remain under review, whereas in
Phase II, 28 out of 41 compliant patients (68%) remain under
review.
Socio-demographic and behavioural predictors of referral
Data were available for 49 of the 55 patients referred in Phase II.
They were matched with 344 non-referred controls. Features
of the cases and controls are reported in Table 3. Screening
participants with low levels of completed education (OR: 6.94,
95% CI: 1.66, 28.98) and who chewed paan with tobacco (OR: 8.01,
95% CI: 3.54, 18.08) were more likely to be referred to the
secondary care service. For other characteristics – economic
activity, general health, smoking cigarettes, bidi and chewing
paan without tobacco – there were no statistically significant
differences in the screened population compared with the referred
population.
Financial considerations
The 34 screening sessions in Tower Hamlets cost Bd32 000
including all associated direct costs such as staff and hire of fully
equipped mobile dental units but not including consultant time
and hospital facilities for follow-up appointments. As 1320 people
were screened during this period, the cost per screen was Bd24,
which is approximately half the figure for the NHS breast-
screening programme that stands at d45.50 per screen.
DISCUSSION
This project has shown the feasibility of conducting oral cancer
screening in a deprived borough in East London, using a mobile
dental clinic with dental practitioners undertaking the screening,
supported by ethnically matched advocates from the local
community. In line with the aims of the project, over 90% of the
screening attendees in Phase II were from the local Bangladeshi
community. This project also confirms the importance of
providing oral health services in community settings (Croucher
and Sohanpal, 2006).
Of the 1320 people screened, 75 (5.7%) were referred to
secondary care for further investigation. This is in line with
previous UK oral cancer screening initiatives (Downer et al, 2006)
and is almost identical to that observed in a large screening trial in
Kerala, India (Sankaranarayanan et al, 2005). Those referred were
more likely to be paan with tobacco chewers, confirming previous
findings (Pearson et al, 1999; Jayalekshmi et al, 2009), and to have
limited years of completed education.
Only 55 (73%) of the 75 referred to secondary care attended
their appointment despite considerable efforts being made both
by the secondary referral centre and the local advocates. This
is clearly a concern. However, this attendance rate is compa-
rable with that in other studies (Downer et al, 2006) and is
somewhat higher than the 63% reported for the Kerala study
(Sankaranarayanan et al, 2005). It is also worthy of note that
in the national bowel cancer screening programme B20% of
those with a positive faecal occult blood test do not attend for
colonoscopy.
Reasons for non-attendance at secondary care were investigated
by telephoning patients who initially failed to attend, but
subsequently did so. Common reasons for initial non-attendance
included language barriers, non-receipt of referral letter and a
perceived difficulty in attending hospital. Among the 20 patients
who never attended secondary care, it has been established that
two had returned to Bangladesh but it was not possible to
Table 2 Definitive diagnosis by secondary referral centre
Clinical/histological
Number of patients (of those who
attended oral medicine clinic)
diagnosis Phase I Phase II Total
Potentially malignant disorders
Dysplasia 3 6 9
Oral sub-mucous fibrosis 1 4 5
Lichen planus 0 3 3
Total potentially malignant disorders 4 13 17
Benign lesions
Keratosis 9 22 31
Candidiasis 0 1 1
Fibro-epithelial polyp 0 1 1
Physiological pigmentation 1 2 3
Haemangioma 0 2 2
Total benign lesions 10 28 38
Total 14 41 55
Table 3 Predictors of referral
Variables Univariate analysis: OR (95% CI) P-value Multivariate analysis: OR (95% CI) P-value
Years in education
19+ 1.00 1.00
15–18 2.81 (0.97–8.13) 0.04 1.98 (0.61–6.41) 0.25
Under 14 1.64 (0.57–4.69) 0.34 2.02 (0.62–6.57) 0.24
None 3.6(10.20–41.30) 0.01 6.94 (1.66–28.98) 0.01
Economically active 0.70 (0.29–1.68) 0.42 0.32 (0.09–1.15) 0.08
Self-reported health
Good-excellent 1.11 (0.57–2.17) 0.73 1.60 (0.71–3.58) 0.25
Self-reported oral health
Good-excellent 0.87 (0.39–1.94) 0.74 0.77 (0.33–1.78) 0.55
Any oral pain 0.98 (0.51–1.91) 0.97 0.86 (0.61–1.23) 0.43
Smoke cigarettes 0.81 (0.32–2.00) 0.65 0.64 (0.22–1.88) 0.42
Smoke bidi 1.58 (0.14–18.06) 0.70 1.84 (0.14–23.04) 0.63
Chew paan with tobacco 5.69 (2.66–12.18) 0.00 8.01 (3.54–18.08) 0.00
Chew paan without tobacco 0.56 (0.26–1.17) 0.12 0.73 (0.29–1.81) 0.50
OC awareness: 5+ correct 1.02 (0.52–2.04) 0.93 1.02 (0.53–2.45) 0.73
Results of univariate and multivariate conditional logistic analysis.
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determine whether this was as a direct result of the screening
outcome and associated psychological burden.
Among the 55 patients who attended secondary care, 17 (31%)
were found to have potentially malignant disorders. Benign oral
mucosal hyperkeratosis was by far the most common lesion,
occurring in 31 (56%) of the 55 individuals. This is consistent with
a paan chewing habit, where the rough fibres of the betel quid
cause frictional damage to the epithelial surface of the mucosa
(Lalli et al, 2008). In total, 35 (64%) of the 55 attendees at
secondary care remain under follow-up because of their mucosal
condition and associated risk factors. These can be considered as
positive referrals.
One of the unique features of this project was the linkage
between oral cancer and the tobacco cessation programme. In
Phase II of the project, over 40% of tobacco users attending
screening (202 of 485) were recruited to tobacco cessation.
Future developments
This project has shown the feasibility and acceptability of
oral cancer screening using a mobile dental unit among the
Bangladeshi community of Tower Hamlets. It would now be
valuable to test this approach in other high-risk communities.
Further investigation into the reasons for non-compliance with
referral to secondary care is needed. Innovative use of the mobile
dental unit could eradicate delay in obtaining a definitive diagnosis
from initial screening if suspicious lesions were biopsied in the
field. A brush biopsy and immediate cytological analysis could
be an appropriately quick and minimally invasive procedure to
undertake on the mobile dental unit. There would, however, be
significant cost implications.
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